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Genetics of clear cell renal cell carcinoma: 
new tumor suppressor genes and aberrant chromatin regulation 
Gerben Duns 
Stellingen behorende bij het proefschrift Centrak U 
Mcdische M 
Genetics of clear cell renal cell carcinoma: Biblint!Jeek C 
new tumor suppressor genes and aberrant chromatin regulati Groniugcn G 
1. De 3p21 regio bevat met PBRM1, SETD2 en BAP1 meerdere ccRCC- geassocieerde 
tumorsuppressor- genen (dit proefschrift). 
2. Verschillende ccRCC tumoren hebben inactiverende mutaties in zowel VHL als PBRM1 
als SETD2, wat erop wijst dat inactivatie van deze genen individueel niet voldoende is 
voor de ontwikkeling van ccRCC tumoren (dit proefschrift). 
3. PBRM1 is in een meerderheid van ccRCC tumoren ge"inactiveerd en is daarmee een 
interessant aangrijpingspunt voor nieuw te ontwikkelen gerichte therapieen tegen 
ccRCC (dit proefschrift). 
4. Een verstoring van de regulering van chromatine is een essentiele gebeurtenis in de 
ontwikkeling van ccRCC tumoren (dit proefschrift) 
s. lnactivatie van VHL a Ileen leidt niet tot de ontwikkeling van ccRCC tumoren. Het is 
dan ook een logische stap om de (ccRCC) tumoren van patienten die leiden aan VHL­
syndroom te screenen op mutaties in de "nieuwe" ccRCC- geassocieerde 
tumorsuppressor-genen. 
6. Het doen van (een promotie-)onderzoek is te vergelijken met het maken van een 
wielertocht in de bergen: je vraagt je geregeld af waarom je er aan begonnen bent, 
maar het behalen van resultaat/ bereiken van de top geeft voldoening. 
7. "De weereld is een speeltooneel, elck speelt zyn rol en kryght zijn deel" (Joost van 
den Vandel). 
8. Voetballers die bij clubs spelen die overheidssubsidies ontvangen zouden niet meer 
moeten verdienen dan de Balkenende- norm. 
9. De doodstraf is een wrede en onmenselijke straf, net zoals de in Nederland 
bestaande levenslange gevangenisstraf zonder enig uitzicht op vervroegde vrijlating. 
Gerben Duns, 7 december 2011 
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Clear cell renal cell carcinoma 
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, and 
accounts for 3% of all new cancers diagnosed in the Western world (Jemal et al., 
2010). The incidence of RCC is the lowest in Asia and Africa (with the lowest recorded 
rates less than 1 new annual case per 100,000 population, age standardized) and the 
highest in Europe and North America (with the highest recorded rates in both men 
and women observed in the Czech Republic, with 20.2 and 9 .5 annual new cases per 
100,000, respectively). The incidence in the Netherlands is 7. 9 and 4.5 per 100,000 in 
men and women, respectively (Curado et al., 2007). 
There is evidence, supported by animal experiments and histological characterization 
of pre- and early stages of epithelial renal tumors that RCC derives from the mature 
nephron (Motzer et al., 1996). RCC is a clinicopathologically heterogeneous disease 
that consists of a number of histologically defined entities. The present classification of 
renal cell carcinoma was established by international consensus and led to the World 
Health Organization (WHO) 2004 classification. According to this classification, which 
is based on both morphological and genetic characteristics, RCC can be grouped 
into clear cell, papillary, chromophobe, collecting duct, medullary carcinoma, and 
unclassified categories (Eble et al., 2004). The WHO classification of RCC and the 
cytogenetic aberrations associated with the different RCC subtypes are summarized in 
Table 1. Clear cell renal cell carcinoma (ccRCC) is by far the most prevalent subtype, 
Table 1. Classification renal cell carcinoma (RCC) subtypes. 
Histologic subtype (WHO 
classification 2004) 
Clear cell RCC 
Papillary RCC 
Chromophobe 
Hereditary cancer syndromes -- --- --
Collecting duct carcinoma 
Medullary carcinoma ----






Prevalence (%) Cytogenetic findings 
70 
10 to 15 
4 to 6 
5 
� deletions, VHL mutatio..'2.:__ 
Trisomy of chromosomes 7 and 17, loss of 
Y chromosome 
Loss of multiple chromosomes: 
1,2,6,10,13,17,21 







Loss of multiple chromosomes: 
1,6, 14, 15,22; gain of chromosome 3 
Extracellular matrix gene loss 
Loss of multiple chromosomes: 
1,4,6,8, 13, 14 
Multiple gene loss (most often 20q13) 
Translocations involving Xp11.2 
Sources: Eble et al., 2004; Prasad et al., 2006 
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comprising more than 70% of adult malignant kidney tumors. ccRCC is a malignant 
tumor composed of cells with a clear cytoplasm due to an intensive intracytoplasmatic 
accumulation of glycogen and lipids. Electron-microscopic and immunohistochemical 
features resembling the proximal tubule are seen in ccRCC, suggesting that ccRCC 
tumors are derived from the epithelial cells of the proximal tubulus (Thoenes et al., 
1985). Figure 1 shows a schematic picture of the different parts of the nephron from 
which ccRCC and the other RCC subtypes are thought to be derived from (Prasad 
et al., 2006). 
Proximal tubulus 
Papil/aryRCC 
Clear cell RCC 
> Cortex 
Medulla 
Loop of Henle 
Mucinous tubular and 
spindle cell carcinoma 
.__ _____ __. ___________ _ ,,,,,· ,, 
Cortical collecting duct 
Chromaphobe RCC 
Medullary collecting duct 
Collecting duct carcinoma 
Renal medullary carcinomory 
Figure 1. Schematic overview of the nephron, showing the different parts from which the 
RCC subtypes are thought to be derived from. Figure is modified from http://www.beltina.org. 
In general ccRCC tumors occur sporadically. The average age of diagnosis is 60-64 
years. However, 7% of sporadic cases of ccRCC are diagnosed in patients who are 
younger than 40, and rare cases have been described in patients between 14 and 
18 years, without evidence of familial disorders (Bruder et al., 2004). The three most 
well-established risk factors associated with the development of ccRCC are smoking, 
obesity and hypertension (Chow et al., 2000; McGuire et al., 2011; Parkin et al., 1985). 
Hereditary clear cell renal cell carcinoma 
Approximately 2% of ccRCC tumors are familial (reviewed by Maher, 1996). The most 
frequent cause of familial RCC is a dominantly inherited cancer syndrome named VHL 
disease, which is estimated to occur at rates of 1 :45500 to 1: 100000 (Maddock et al., 
1996; Maher et al., 1990a). VHL disease is the result of germline mutations in the Von 
Hippe/ Lindau (VHL) gene, and is characterized by the development of benign and 
malignant tumors across several organs, mainly in parts of the body with a high density 
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of blood vessels (reviewed by Kaelin, 2002). The lifetime risk of developing one or 
more ccRCC tumors in VHL disease is over 70% by the age of 60 (Maher et al., 19906). 
In a majority of sporadic ccRCC tumors VHL is inactivated as well (Gnarra et al., 1994; 
Nickerson et al., 2008). 
An intriguing finding has been the frequent occurrence of translocations involving 
chromosome 3 in familial cases of ccRCC that are not linked to VHL. The best known 
case is undoubtedly the t(3,8)(p14;q24) translocation reported by Cohen et al. (1979) 
in a three-generation family in which all members with bilateral ccRCC carried this 
constitutive translocation. The chromosome 3 breakpoint appeared to map in intron 
3 of FHIT (Zimonjic et al., 1997). Subsequently, several other familial cases of ccRCC 
have been identified with a constitutive translocation involving chromosome 3 (Bonne 
et al., 2007; Foster et al., 2007; Rodriguez-Perales et al., 2004). The various cases, 
however, do not appear to share a breakpoint on chromosome 3. And, although 
detailed analysis of a number of these translocations has resulted in the identification 
of genes disrupted by the translocation, none of these genes appear to be mutated in 
a substantial number of sporadic cases of ccRCC. It has been suggested that in these 
cases susceptibility to ccRCC may result from chromosome 3 instability, predisposing 
to loss of 3p. Indeed, analysis of the tumors in these families often revealed loss of the 
translocation chromosome that contained the short arm of chromosome 3 (reviewed 
by Bodmer et al., 2002; Li et al., 1993). 
Therapy 
In most cases, ccRCC tumors are still localized at the moment they are found. Surgical 
removal is the standard of care for these tumors, and offers long-term recurrence­
free survival, although for patients who suffer from metastatic disease or develop 
distant relapse, the scenario is worse. Renal cell carcinomas are resistant to traditional 
cytotoxic chemotherapy. lmmunotherapy, which has been the most frequently used 
therapy until recently, has not been satisfactory in most cases either (reviewed by 
Bukowski et al., 201 1  ). 
Advances in the understanding of ccRCC biology have resulted in the development 
of targeted approaches, which include the use of humanized monoclonal antibodies 
against VEGF, small-molecule tyrosine-kinase inhibitors, and inhibitors of mTOR. 
These approaches, which target pathways that are characteristic and essential for 
ccRCC tumors, show superior response rates compared to conventional strategies 
(reviewed by Clark, 2009). 
Genetics of clear cell renal cell carcinoma 
At the genomic level, ccRCC is characterized by a range of copy number alterations, 
of which loss of the short arm of chromosome 3 is by far the most frequent (Van den 
Berg et al., 1993). Genomic regions with a high incidence of allelic loss are thought to 
harbor so-called tumor suppressor genes (TSGs), defined by Haber and Harlow ( 1997) 
as "genes that sustain loss-of-function mutations in the development of cancer". The 
allelic losses are regarded as one of the two genetic alterations that are necessary 
to bial lelically inactivate TSGs (Knudson, 1971 ). In ccRCC a tumor suppressor gene 
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has been identified in the recurrently lost 3p25 region, namely VHL. One allele of 
the VHL gene is thus deleted in most - if not all - ccRCCs. The remaining allele is 
inactivated by small mutations in 43-82% of ccRCC samples (Foster et al., 1994a; 
Gnarra et al., 1994; Nickerson et al., 2008; Shuin et al., 1994). In combination with the 
predisposition to multicentric ccRCC in patients with VHL germline mutations, these 
data have pinpointed VHL as a classic tumor suppressor gene. Further support came 
from the observation that reintroduction of wildtype VHL into VHL-null ccRCC cells 
suppresses tumorigenicity both in vitro and in vivo (Chen et al., 1995; Gnarra et al., 
1996; lliopoulos et al., 1995; Schoenfeld et al., 1998). 
As mentioned, in a subset of ccRCC tumors, VHL is not biallelically inactivated. 
Thus, at least for these tumors, VHL inactivation is probably not the driving force 
for the observed 3p loss. Moreover, VHL inactivation alone causes a senescence-like 
phenotype in vitro and in vivo (Young et al., 2008), and although kidneys from patients 
suffering from VHL disease contain VHL mutations in hundreds of pre-neoplastic 
lesions, only a few of these are thought to develop into ccRCC tumors (Mandriota 
et al., 2002). These observations strongly suggest that alternative and/or additional 
ccRCC cancer genes play a role in ccRCC development. The observed frequent loss 
of regions of 3p, other than 3p25, in ccRCC tumors strongly suggests that these 
regions might contain unidentified ccRCC tumor suppressor genes. Many studies have 
therefore attempted to precisely map the position and the boundaries of the deleted 
regions of 3p. 
Loss-of-heterozygosity (LOH) studies suggest that 3p21 loss is slightly more 
frequent than, and/or may occur separately from, loss of the 3p25 and 3p14 loci 
(Clifford et al., 1998; Van den Berg et al., 1997). Allelic loss of 3p25 or of 3p12-14, 
but not of 3p21, has been shown to occur in renal cell adenoma, suggesting that loss 
of the 3p21 region is a prerequisite for malignant development of ccRCC (Van den 
Berg et al., 1998). This suggests that loss of these 3p segments may independently 
contribute to ccRCC development, and indicates the presence of tumor suppressor 
genes at the 3p21 and 3p14 regions. A few genes located at these regions on 3p 
have been suggested to have a tumor suppressor role in ccRCC, most notably 
fragile histidine triad protein gene (FHIT), and ras association (RalGDS/AF-6) domain 
family member 1 (RASSF1A) (Figure 2). FHIT co-localizes with the fragile site FRA3B 
at 3p14.2. A multitude of studies in different types of tumors have shown various 
molecular alterations, including CpG-island hypermethylation, leading to inactivation 
of FHIT. FHIT participates in a number of important signal pathways in response to 
endogenously or exogenously applied stressful agents, particularly those that cause 
DNA damage (reviewed by Saldivar et al., 2010). There are still questions to pursue 
concerning the selective advantage conferred to cells by loss of expression of FHIT, 
and the involvement of FHIT in ccRCC is disputed (Bugert et al., 1997 Van den Berg 
et al., 1997). 
RASSF1, located at 3p21, was initially suggested to be a tumor suppressor 
gene in lung cancer, based on its location in a region of frequent LOH and the 
absence of expression as a result of promoter hypermethylation of the remaining 
allele (Agathanggelou et al., 2001). Dreijerink et al. (2001) showed promoter 






Figure 2. Schematic picture of the 
short arm of chromosome 3, showing 
the locations of the VHL ccRCC tumor 
suppressor gene, and the putative 
ccRCC tumor suppressor genes 
RASSF1 and FHIT. 
hypermethylation of RASSF1 in 39 out of 43 
primary ccRCC tumors. The RASSF1 gene 
has two GC-rich promoters that produce 
two isoforms, RASSF1 A and RASSF1 C. In 
ccRCC, both these transcripts suppress 
the tumorigenicity of the KRC/Y RCC cell 
line in SCID mice (Li et al. ,  2004). This 
can be regarded as a hallmark of a tumor 
suppressor gene. However, as RASSF1 a is 
not inactivated by mutation but by promoter 
methylation, this gene may not be seen as a 
tumor suppressor gene in the classic sense. 
The aberrant promoter hypermethylation 
is a secondary effect as another event has 
to precede this one in order to establish 
the aberrant hypermethylation. Moreover, 
the process of hypermethylation will 
simultaneously affect all alleles of a gene in 
a single event. This is in contrast with the 
situation for the classic tumor suppressor 
genes where inactivation requires two 
independent events (Knudson et al., 1971). 
Therefore, inactivation of FHIT and RASSF1 
is probably not the driving force for the 
frequently observed loss of 3p14 and 3p21, 
respectively. 
The proposed model, suggesting that 
loss of 3p segments occurs independently 
in ccRCC tumorigenesis, is challenged 
by recent studies that show that for the 
majority of ccRCCs the loss of 3p most likely encompasses the entire p-arm. In a 
study by Sukosd et al. (2003), based on microsatellite analyses, 95 out of 98 ccRCC 
tumors showed loss of a segment ranging from pter to 3p12. In a SNP-based study 
by Toma et al. (2008), 15 out of 20 tumors had lost the entire p-arm. Neither of these 
studies reported any cases with retention of heterozygosity at the VHL locus, while 
retention at the FHIT locus was observed in six cases in the combined studies. The 
data of Braga et al. (2002) and Chudek et al. (1997) underscore these conclusions. 
Their data on 55 and 100 ccRCCs, respectively, indicate large terminal deletions for 
42 and 94 cases, respectively, of which 28 and 89 most likely encompass almost the 
entire p-arm. Chudek et al. (1997) reported retention of the most telomeric part of 3p 
in 6 cases, but this segment did not include the VHL locus. Many studies that report 
interstitial 3p deletions in ccRCC tumors are based on the analysis of microsatellite 
markers. The interpretation of microsatellite data of primary tumors is complicated to 
say the least. Primary tumors have an admixture of normal tissue, and this will dampen 
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the effect of LOH on the observed ratios between the alleles. A study by Liu et al. 
(1999) suggested that up to 50% of the low molecular weight allele deletions in tumor 
samples may go undetected in this type of study. Thus, reported interstitial deletions, 
or interruptions of regions of deletion, based on only one marker should be regarded 
with caution. Alimov et al. (2000) used an analysis protocol that took the findings of 
Liu et al into account, and did report interstitial deletions in six primary RCCs. Wilhelm 
et al. (1995) avoided the influence of contaminating normal cells by using short-term 
cultures of primary ccRCC. All 41 tumors that they analyzed appeared to have strictly 
terminal deletions of the major part of 3p, including the FHIT locus. Thus, it ca nnot 
be excluded that interstitial deletions do occur, but they are presumably very scarce. 
The combined genomic studies strongly suggest that the short arm of chromosome 
3 may harbor several, as yet unidentified, tumor suppressor genes that contribute 
to ccRCC development. Identifying ccRCC tumor suppressor genes by positional 
cloning strategies alone has proven extremely difficult. Decades of research on the 
identification of the tumor suppressor genes other tha n VHL that underlie the high 
frequency of 3p deletions in ccRCC has not led to the identification of a clea r-cut 
tumor suppressor gene. The identification of tumor suppressor genes was hampered 
by the omission of methods to screen large numbers of genes in parallel for small 
(point) mutations. This situation has changed in the last decade. New methods like 
Gene Identification by Nonsense-mediated mRNA decay Inhibition (GINI), and, more 
recently, next-generation sequencing-based approaches, have given us new and 
powerful tools to identify tumor suppressor genes. 
AIM 
The aim of this thesis was to identify new tumor suppressor genes that are involved 
in the development of clear cell renal cell carcinoma (ccRCC). Subsequent detailed 
functional analysis of these genes should help us to understa nd the initial processes 
that underlie the development of ccRCC. 
OUTLINE 
In Chapter 2, we applied Gene Identification by Nonsense mediated mRNA decay 
Inhibition (GIN/) in the search for novel ccRCC tumor suppressor genes. This led to the 
identification of SETD2 as a new candidate ccRCC tumor suppressor gene. Using the 
current knowledge on ccRCC genetics, we evaluated the use of GIN/ in the search for 
tumor suppressor genes in Chapter 3. 
SETD2 codes for a histone methyltransferase that is nonredundantly responsible 
for trimethylation of lysine 36 of histone H3 (H3K36me3). This modification has been 
suggested to have a function in alternative splice site choice. In Chapter 4, we describe 
the initial steps that should result in the elucidation of the mechanisms through which 
SETD2 inactivation could contribute to ccRCC development. We investigated the 
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effect of siRNA-mediated SETD2 knockdown in proximal tubular epithelial cells on 
transcript levels and alternative splice site choice. 
The recently developed next-generation sequencing (NGS) technologies make it 
possible to sequence large numbers of genes in parallel. In Chapter 5, we continued 
our search for ccRCC tumor suppressor genes by sequencing all coding regions and 
exon-i ntron boundaries from the short arm of chromosome 3 in ten primary ccRCC 
tumors, using exome capturing followed by NGS. This led to the identification of 
PBRM 1 as a candidate ccRCC tumor suppressor gene. 
Besides protein coding genes, non-coding transcripts, inc luding microRNAs, have 
been shown to have a function in the development of several tumor types. Therefore, 
we compared miRNA transcript levels in ccRCC-derived cell lines with the miRNA 
levels in normal proximal epithelium, and correlated these transcript levels with copy 
numbers and transcript levels of predicted targets, as described in Chapter 6. 
In Chapter 7, the work described in this thesis is discussed. 
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ABSTRACT 
Sporadic clear cell renal cel l carcinoma (cRCC) is genetically characterized by the 
recurrent loss of the short arm of chromosome 3, with a hotspot for copy number loss 
in the 3p21 region. We applied a method called "gene identification by nonsense­
mediated mRNA decay inhibition"  to a panel of 10 cRCC cell lines with 3p21 copy 
number loss to identify biallelic inactivated genes located at 3p21. This revealed 
inactivation of the histone methyltransferase gene SETD2, located on 3p21.31, as 
a common event in cRCC cel l s. SETD2 is nonredundantly responsible for trimethylation 
of the histone mark H3K36. Consistent with this function, we observed loss or a decrease 
of H3K36me3 in 7 out of the 10 cRCC cell lines. Identification of missense mutations 
in 2 out of 10 primary cRCC tumor samples added support to the involvement of loss 
of SETD2 function in the development of cRCC tumors. 
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INTRODUCTION 
Clear cell  renal cell carcinoma (cRCC) is the most prevalent subtype of renal cell 
carcinoma and accounts for 3% of all human malignancies (1 ). Originating from the 
epithelium of the proximal tubulus, it is genetically characterized by recurrent loss 
of 3p regions. These losses are thought to represent one of the two hits required to 
functionally inactivate tumor suppressor genes (TSG) located in these regions (2) . The 
Von Hippel-Lindau gene, located at 3p25, has been identified as a TSG involved in 
the pathology of cRCC, and is inactivated in the majority (57-80%) of cRCCs (3, 4). 
Although the frequent copy number loss of 3p21 (5) also suggests the presence of one 
or more additional TSGs in this segment of 3p, decades of research have not led to 
the identification of a TSG located in this genomic segment. In an attempt to identify 
a putative 3p21 TSG, we applied a modified version of the "gene identification by 
nonsense-mediated mRNA decay inhibition" (GINI) method (6) to a panel of 10 cRCC 
cell lines showing copy number loss of 3p21. The GINI method allows for genome-wide 
identification of transcripts harboring premature termination codons (PTC). Inhibition 
of the nonsense-mediated mRNA decay pathway in vitro results in the accumulation 
of PTC transcripts, which can be detected using gene expression microarrays. Several 
groups have successfully applied modified versions of the GINI method in their search 
for TSGs (7-9). Using GINI, we identified the histone methyltransferase gene SETD2/ 
HYPB, located on 3p21.31, as a new TSG involved in the development of cRCC. 
MATERIALS AND METHODS 
Cell lines 
cRCC cell lines RCC-AB, RCC-ER, RCC-FG2, RCC-HS, RCC-JF, RCC-JW, RCC-MF, 
and RCC-WK were obtained from Cell Line Services, Eppenheim, Germany. The 
cells, which tested negatively for Mycop/asrna, bacteria, and fungi, had been passed 
10 to 13 times upon arrival (as stated by Cell Line Services). Experiments were 
performed on cells that had undergone six to eight additional passages. cRCC cell 
lines RCC-1, RCC-4, and RCC-5 were established by Dr. C.D. Gerharz (Institute of 
Pathology, University Hospital, Dusseldorf, Germany) and karyotyped. To ensure their 
authenticity, they were recently re-karyotyped. All cRCC cell lines were maintained in 
RPMI 1640 (Sigma). Embryonal kidney cell line HEK293T was obtained from American 
Type Culture Collection (CRL-1573) and maintained in DMEM (Sigma). MN160 and 
PTEC are primary cultures derived from proximal tubular epithelial cells. DNA was 
purified using a phenol/chloroform extraction method. 
Primary tumor samples 
Primary cRCC tumor samples (for details, see Supplementary Table S1) were snap­
frozen in liquid nitrogen, sections were cut and the histology was reviewed by a 
pathologist (H. Hollema). Tissue biopsies containing at least 70% tumor cel ls were 
selected for analysis. DNA was isolated using the OIAamp DNA Micro Kit (Oiagen). 
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DNA samples from formalin-fixed matching normal kidney samples were obtained 
using a paraffin material DNA isolation protocol. 
ArrayCGH 
ArrayCGH was carried out using Agilent Human Genome CGH Microarray 244a sl ides 
(pin G4411 B) following the protocols of the manufacturer. Slides were scanned using 
the G25052C DNA m icroarray scanner (Agilent Technologies). Array images were 
analyzed using Agilent feature extraction software (v10.5.1.1) and DNA analytics 
(Agilent). 
G I N I  
Cells were grown to 70% confluence and treated with emetine dihydrochloride hydrate 
(100 µg/m l medium) or caffeine (10 m mol/L in medium), or not treated. Following 8 
hours of incubation at 37 °C, cells were harvested. Experiments were performed in 
duplicate. RNA was isolated using the RNeasy Mini Kit (Oiagen). Transcript abundance 
in treated and untreated cells was measured using Human HT-12_ V3_Beadchips 
(48K; lllumina). The Lumi package implemented in R (10, 11) was used for variance 
stabil izing transformation fol lowed by robust spline normalization of the microarray 
data (GEO accession no. GSE20491 ). GeneSpring GX 10.0 (Agilent) was used to 
calculate treatment-induced fold changes. Putative PTC-containing transcripts were 
selected according to the following criteria: 
1. Transcripts should show emetine- as well as caffeine-induced accumulation in one 
or more cell lines. Transcripts were considered to be accumulated when present in 
the list of 1,000 transcripts with the highest treatment-induced fold changes. 
2. Transcripts showing accumulation in the majority of cell l ines were considered to be 
so-called stress-response genes and were discarded from further analyses. 
3. In untreated cells, PTC transcripts should show a significantly lower abundance 
than their non-PTC harboring counterparts. 
4. Emetine- and caffeine-induced accumulation pushes the abundance towards a 
level sim i lar to the abundance in PTEC and MN 160. 
Mutation analysis 
Thirty-seven PCR primer sets were designed to amplify and sequence all coding 
sequences and exon-intron boundaries of SETD2 annotated in the human genome 
(National Center for Biotechnology Information). Amplified PCR products were 
purified using EXOSAP IT (GE Healthcare) and sequenced using BigDye Terminator 
chemistry (Applied Biosystems). 
Reaction products were run on the ABl3130XL Genetic Analyzer (Applied 
Biosystems). Sequences wereevaluated using Mutation Surveyor (SoftGenetics LCC). 
Cancer samples showing putative mutations were re-sequenced to eliminate any 
potential sequencing artifacts. To check for aberrant transcripts, cDNA fragments, 
obtained by reverse transcription of RNA from the cell l ines, were amplified using 
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stepdown PCR (60°C-55°C} and visualized on a 2% agarose gel. Primer sequences are 
available upon request. 
Western blot analysis 
Cells were lysed in Triton extraction buffer [0.5% Triton X-100 (v/v), 2 mmol/L 
phenylmethylsulfonyl fluoride, and 0.02% NaN3 (m/v)]. Histones were isolated by 
acid extraction O/N in 0.2 N HCI, separated using SOS-PAGE (15%) and transferred 
to a nitrocellulose membrane. The following primary and secondary antibodies were 
used for Western analysis: rabbit anti-histone 3 (ab1791, 1 :4,000; Abeam}, rabbit 
antitrimethyl histone H3 (Lys36; ab9050, 1 :750; Abeam), rabbit anti-dimethyl-histone 
H3 (Lys 36; 07-369, 1 :2,000; Millipore) and horseradish peroxidase->conjugated 
secondary antibody (goat anti-rabbit; Bio-Rad). Positive staining was visualized 
using ECL solution mixture from Roche. Attached antibodies were stripped from the 
membrane using Re-Blot Plus Strong Solution (Chemicon/Millipore) to allow reuse of 
the membrane. 
RESULTS AND DISCUSSION 
ArrayCGH analysis 
In our search for candidate TSGs located at 3p21, we decided to include only c RCC­
derived cell lines and primary tumor samples that showed copy number loss for 3p21. 
This selection was based on our arrayCGH data. Seven out of 11 cRCC cell lines and 6 
out of 11 cRCC primary tumor samples lost the entire short arm of chromosome 3 (3p). 
Three cell lines and three primary tumor samples had copy number loss of a part of 
3p, with a segment of overlap from 21.4 to 69.6 Mb from pter, including 3p21 but not 
the VHL gene, located at 3p26-p25 (Supplementary Fig. S1). One cell line (RCC-WK) 
did not show copy number loss of 3p21 and was not considered in the subsequent 
GINI analysis. 
GIN I  analysis 
To identify transcripts harboring PTCs, we performed GINI on 10 cRCC cell lines 
with copy number loss of 3p21. Gene expression microarrays were used to identify 
transcripts that were accumulated as a result of nonsense-mediated mRNA decay 
inhibition. Transcripts were selected for further analysis based on criteria outlined in 
Materials and Methods. In this study, we restricted the search for biallelic inactivated 
transcripts to the 3p21 region. One gene fitting all our criteria was the histone 
methyltransferase gene SETD2, located at 3p21.31. Based on the observed "transcript 
level profiles",  we expected SETD2 to harbor PTCs in RCC-AB and RCC-ER (Fig. 1 ). 
SETD2 mutation analysis 
The presence of PTC-introducing mutations in these two cell lines was confirmed by 
sequence analysis of all exons and exon-intron boundaries of SETD2. A 1-bp deletion 
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Figure 1 .  Effect of nonsense-mediated mRNA decay inhibition on SETD2 transcript 
levels in cRCC cell lines. For each cell line, SETD2 transcript levels are shown in untreated 
(black columns), caffeine-treated (striped columns), and emetine-treated (gray columns) cells, 
respectively. Normalized intensity values are shown on a log 2 scale. Levels below a value 
of 7 are close to the detection limit. The SETD2 probe binds to the 3' part of the transcript. 
The SETD2 transcript in RCC-FG2 lacks this part (Supplementary Fig. S2.g) ,  explaining the low 
transcript levels. SETD2 transcript a bundance is low in untreated RCC-AB and RCC-ER cells 
compared with the other cell lines and shows caffeine- and emetine-induced accumulation 
in RCC-AB and RCC-ER. Based on these transcript level profiles, we expected RCC-AB and 
RCC-ER to harbor PTCs in the SETD2 gene. 
resulting in a PTC 42 nucleotides downstream was detected in RCC-AB. In RCC-ER, a 
nonsense mutation was identified (Fig. 2; Supplementary Fig. S2; Supplementary Table 
S2). The other cel l  lines were sequenced for mutations other than those causing PTCs. 
We identified an in-frame 9-bp deletion in exon 1 in RCC-MF, a missense mutation in 
exon 3 in RCC-JW not corresponding to a known single-nucleotide polymorphism (not 
present in dbSNP}, and a silent mutation in exon 3 in RCC-J F. In addition, the SETD2 
transcript of RCC-FG2 seemed to lack the terminal three exons (Supplementary Fig. 
S2). To further assess the clinical relevance of these findings, we sequenced SETD2 
in 10 cRCC primary tumors with 3p21 copy number loss (Supplementary Fig. S2), and 
in two of them, we identified missense mutations that did not correspond to known 
single-nucleotide polymorphisms (dbSNP). The mutations identified in RCC-AB, 
RCC-ER, and RCC-MF as well as the aberrant splicing observed in RCC-FG2 will all 
have a severe effect on the function of the protein. The three missense mutations 
identified affect amino acids that are conserved across SETD2 orthologues in several 
species (Supplementary Fig. S3). The missense mutation in T-3 affects the SET domain, 
which is responsible for the methyltransferase activity of the protein. The missense 
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Figure 2. SETD2 mutations in cRCC samples. Schematic representation of SETD2 with a rrows 
showing the locations of the mutations and the corresponding amino acid changes. AWS, AWS 
domain ;  SET, SET domain ;  PS, post-SET domain ;  LCR, low-charge reg ion; WW, WW domain ;  
I P, interaction with RNAPOL2A; Del, deletion .  Nationa l  Center for Biotechnology Information 
Reference Sequence: NP _054878.5. 
mutation in T-4 affects the low charge region, which is thought to have transcriptional 
activation activity, whereas the missense mutation in RCC-JW affects an amino acid 
which is not located in a known functional domain (Fig. 2). The missense mutation 
in T-3 was shown to be somatic (Supplementary Fig. S2). The matching normal 
renal sample of T-4 was heterozygous for the missense mutation, indicating that 
SETD2 mutations might contribute to genetic susceptibility for cRCC. The missense 
mutations in T-4 and RCC-JW were not seen in 100 healthy control samples. AGVGD, 
SIFT, and Polyphen gave ambiguous results in their predictions of the pathogenicity 
of the mutations (Supplementary Table S3). However, the ratio between observed 
nonsynonymous and synonymous mutations (6:1) was higher than the 2:1 predicted 
for nonselected passenger mutations (12), indicating that the observed mutations are 
functional rather than coincidental. The observed mutation frequency in the cRCC 
primary tumor samples might be an underestimation of the actual frequency, as the 
samples were not checked for aberrant splicing caused by intronic mutations. 
Our findings were confirmed by a massive sequencing project on cRCC performed 
recently that found somatic truncating mutations in SETD2 in 12 out of 407 (3%) cRCC 
clinical specimens (13). Sequencing of a panel of nine small cell lung carcinoma­
derived cell lines, a type of carcinoma also characterized by loss of 3p21 (14), did not 
reveal any hemizygous mutations (data not shown). This implies that the inactivating 
mutations of SETD2 could be specific for cRCC, as is also suggested by Dalgliesh and 
colleagues (13). 
Trimethylation of H3K36 i n  cRCC 
SETD2 was discovered in 1998 and initially characterized as Huntingtin-interacting 
protein (HYPB; refs. 15, 16). In 2005, HYPB was shown to function as a histone 
methyltransferase via a conserved SET domain and was renamed SETD2 ([Su(var)3-9, 
enhancer of zeste [E(z)] and trithorax (trx)] domain-containing protein 2). A number 
of recent articles correlate loss- or gain-of-function of histone-modifying enzymes, 
including histone lysine methyltransferases, with the pathology of several types 
of cancer. Aberrant activity of h istone-modifying enzymes could result in altered 
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chromatin configuration and disruption of normal transcriptional programs, pushing 
the cell towards cancerous development (17) .  Recently, a trend for lower SETD2 
transcript levels in breast cancer tissue was shown, linking the reduction of SETD2 
mRNA levels with tumor development (18). SETD2 is nonredundantly responsible 
for all trimethylation of lysine 36 of histone H3 (19, 20). This mark may be involved 
in transcriptional elongation and splicing (21). To assess the effect of the mutations 
identified in SETD2 on the global level of trimethylated H3K36, we performed Western 
blot analysis on our panel of cRCC cell lines. There was a strong decrease of global 
H3K36me3 levels in 7 out of 10 tested cRCC cell lines, whereas H3K36me2 levels were 
consistent across the panel of cell lines (Fig. 3). In RCC-ER and RCC-AB, which harbor 
hemizygous mutations introducing PTCs in SETD2, H3K36me3 was lost. The observed 
faint residual staining was probably an effect of nonspecific binding of the antibody. 
RCC-MF and RCC-FG2 have trimethylated H3K36 levels similar to those observed in 
RCC-AB and RCC-ER, indicating that the mutations in these cell lines totally disrupt 
the H3K36me3 methyltransferase activity of the SETD2 protein as well. The missense 
mutation identified in RCC-JW seems to have no effect on the H3K36me3 activity 
of the SETD2 protein, as the level of global trimethylated H3K36 was not decreased 
in this cel l  line. Given the decrease of global trimethylated H3K36 levels in a large 
subset of our cRCC cell line panel ,  global H3K36me3 might play a tumorsuppressive 
role in proximal epithelial tubu lar cells. The observed decrease of global trimethylated 
H3K36 in cRCC cel l  lines in which no mutations in SETD2 were identified implies that, 
besides the loss of methyltransferase activity of SETD2, other mechanisms might also 
result in the loss of H3K36me3. Altogether, our resu lts provide a strong basis for the 
involvement of loss of SETD2 function in the development of cRCC. 




Figure 3. Global histone methylation levels in cRCC cell lines. Global H3K36me3 and 
H3K36me2 levels in cRCC-derived cell lines as detected by Western blot analysis. H E K293T 
samples were included as positive controls. Histone 3 (H3) levels were used as a loading control. 
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Supplementary Figure 1. Schematic overview copy number loss of the short arm of 
chromosome 3 for the individual clear cell renal cel l  carcinoma samples. Red lines correspond 
to regions with copy number loss. Black lines correspond to regions which do not show copy 
number loss. Blue horizontal line: smallest region of overlap of copy number loss, which ranges 
from 2 1 .4 Mb to 69.6 Mb from Pter. 
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Supplementary Figure 2. 
Mutation analysis SETD2 
gene: sequencing (a-f) and 
PCR amplification of cDNA 
(g) to check for mutations 
and aberrant transcripts. 
a. Sequence ana lysis of part of 
exon 3 of SETD2. ( 1 )  Wi ld type.  (2) 
RCC-JW, showing the hemizygous 
c.3829G> T mutation (*). 
b. Sequence ana lysis of part of 
exon 1 1  of SETD2. ( 1 )  Wild type .  (2) 
RCC-MF, showing the hemizygous 
c. 5330_5338de lAA CA CA CA C  
mutation (*). c. Sequence ana lysis 
of part of exon 1 5  of SETD2. ( 1 )  
Wi ld type. (2) RCC-AB, showing 
the hemizygous c.6447de/C 
mutation (*). d. Sequence ana lysis 
of part of exon 3 of SETD2. ( 1 ) Wi ld 
type. (2) RCC-ER, showing the 
hemizygous c.20 1 lT>A mutation 
(*). e.  Sequence ana lysis of part 
of exon 7 of SETD2. ( 1 ) Wi ld type. 
(2) Primary clea r cel l  rena l  ce l l  
carcinoma tumour T-3, showing 
the hemizygous c.4899G>A 
mutation (*). (3) Corresponding  
norma l  kidney tissue does not 
show the mutation, indicating 
that the mutation is somatic. 
f. Sequence ana lysis of part of 
exon 1 6  of SETD2. (1) Wi ld type. 
(2) Primary clear cel l  rena l  cel l 
carcinoma tumour T-4, showing 
the hemizygous c.7 1 1 3A>G 
mutation (*). (3) The same mutation 
was found in  the correspond ing 
norma l kidney tissue, indicati ng  a 
germl ine orig in .  g. PCR ampl ified 
cDNA fragments of exons 1 5-2 1 
of the SETD2 transcript. Cel l l i ne  
1 :  RCC-FG2, 2:  RCC-5, 3 :  HK-2 
(immortalized PTEC cell line) . 
RCC-FG2 shows a PCR product 
of norm a I length for exons 1 5- 1 7  
and exons 1 7-1 8 ,  but n o  product 
if the reversed primer is situated 
downstream of exon 1 8 . This 
indicates aberrant spl ic ing leading 
to loss of exons 1 9-2 1 . 3 
(G) 
G C A G T G A C T A /i C A A T A G T T 
15-17 17-18 
1 2 3  1 2 3  
- - -
17-19 
1 2 3 
- -
17-20 
1 2 3 
- -
17-21 Exons 
1 2 3 Cell line --
---
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NP 054878 . 5  
XP 516423 . 2  
XP 864 158 . l  
XP 5898 8 6 .  3 
NP 00107480 9 . l 
XP 23 6648 . 4  
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cRCC primary tumour: T-8. Amino acid change: D1616N 
NP 054878 . 5  2345  VVQPAMVT
I
VAPGQPQPLQPSBMVVTNNLLDLPPPSPPKPKTXVLPPN 
XP 516423 . 2  2330 VVOPAAAVT VAPGQPOPLOPSEMVVTNNLLDLPPPSPPKPKTIVLPPN 
XP 864 158 . l 2343  VVQPATAVT VAPGQPOPLOPPEMVVTNNLLDLPPPSPPKPKTIVLPPN 
XP 589886 .  3 2 328 VVQPTAAVT VAPGQPOPLOPPEMVVTNNLLDLPPPSPPKPKTIVLPPN 
NP 00107480 9 . 1 1815 VVQPTAAVT VAPGQPOSLQPPEMVVTNNLLDLPPPSPPKPKTIVLPPN 
XP 23 6648 . 4 2205 VVQPAAAVT VAPGQPQPLOPPEMVVTNNLLDLPPPSPPKPKTIVLPPN 
XP 418 510 . 2  2135 IVQPPPAVT VAAGQPOPIQQPELVVTNNLLDLPPPSPPKPKTIVLPPN 
cRCC primary tumour: T-4. Amino acid change: T2354A 
NP 054878 . 5  
XP 516423 . 2  
XP 864 158 . l  
XP 58988 6 .  3 
NP 00107480 9 . l  
XP 23 6648 . 4  
XP 4 18 510 . 2  
1253 
1238 














cRCC cell line: RCC-JW. Amino acid change: G1259V 
P1otelnAcc. Gent 019anlsm 
IIP -°'""71 5 SETD2 Homo sapiens 
XP _,1o-i:) Z SETD2 Pan lroglodytes 
"-�1� 1 SETD2 Canis lupus fam,t,ans 
XP_!580380.3 SETD2 Bos taurus 
IIP_001074:)()II 1 Seld2 Mus musculus 
XP_� 4 Setd2 Rattus nol\'tgocus 






















Supplementary Figure 3. Conservation SETD2 protein across species. Amino acids for which 
missense mutations were identified ( in red squares) a re shown together with their  su rrounding 
amino acids .  Conservation is shown across 7 different species (according to Homo/ogene) . 
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Supplementary Table 1. Characteristics primary ccRCC tumor samples. 
Tumour Age at diagnosis Sex 
T- 1 70 F 
T-2 60 M 
T-3 67 M 
--
T-4 66 F 
T-5 66 M 
T-6 46 F 
T-7 52 M 
T-8 84 F 
T-9 68 M 
T- 1 0  82 F 




pT3bG 1 NxM0 
T2G 1 N0M0 
pT1 aG2NxMx 
pT1 G 1  NxMx 




T3G3N 1 M0 
Stage 
? 
I l l  - -
I l l  
I l l  
? 
? 




I l l  
Diagnosis (WHO) 
Clear ce l l  rena l  ce l l  ca rcinoma 
Clear ce l l  rena l  ce l l  carcinoma 
Clear cel l  rena l  cel l  ca rc inoma 
- --
Renal cel l  ca rc inoma 
Clear ce l l  rena l  cel l  carc inoma 
C lear  cel l rena l  ce l l  carcinoma 
Clear ce l l  rena l  ce l l  carcinoma 
Clear ce l l  rena l  cel l ca rc inoma 
Clear ce l l  rena l  ce l l  carcinoma 
Clear ce l l  rena l  cel l  ca rc inoma 
Clear cel l  rena l  ce l l  carcinoma 
Supplementary Table 2 .  Overview of SETD2 mutations identified in ccRCC samples 
Sample DNA mutation 
ccRCC cel l  lines 
RCC-AB Hem c.6447delC 
--
RCC-ER Hem c.20 1 ?T>A 
RCC-FG2 unknown 
RCC-J F Hem.c41 89T>C 
RCC-JW Hem c.3829G > T 
----- -
-- - - -
RCC-MF Hem c.5330_5228delAACACACAC 




c.7 1 1 3A>G 
Effect on mRNA Effect on protein 
del exons 1 9-2 1 




G 1 259V 
1 7  60-1 7 62del NTH 
D 1 6 1 6N 
T2354A 
Hem:  hemizygous, de l :  deletion. NCB I  Reference Sequence: N M_01 4 1 59.6,  NP _054878 .5  
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S u p p l e m e n t a r y  Ta b l e  3 .  P r e d i c t i o n  p r o g r a m  s c o r e s  f o r  i d e n t i f i e d  m i s s e n s e  m u t a t i o n s  
m u t a t i o n  C o n s e r v a t i o n  
S a m p l e  c D N A  l e v e l  p r o t e i n  l e v e l  n u c l e o t i d e  ( 0 . 0 - 1 . 0 )  A m i n o  a c i d  
R C C - J W  H e m  c . 3 8 2 9 G >  T  G 1 2 5 9 V  0 . 8  
h i g h l y  
- -
-
T- 3  c . 4 8 9 9 G > A  D 1 6 1 6 N  1 . 0  
h i g h l y  
T- 4  c . 7 1 1 3 A > G  T 2 3 5 4 A  1 . 0  
h i g h l y  
S I F T  P o l y P h e n  
m e d i a n  s e q u e n c e  
S a m p l e  p r e d i c t e d  t o  s c o r e  
c o n s e r v a t i o n  p r e d i c t i o n  
R C C - J W  a f f e c t  p r o t e i n  0 . 0 2  4 . 3 2  
p o s s i b l y  
f u n c t i o n  d a m a g i n g  
T - 3  a ff e c t  p r o t e i n  0 . 0 0  4 . 3 2  
b e n i g n  
f u n c t i o n  
- -
T- 4  a ff e c t  p r o t e i n  0 . 0 0  
4 . 3 2  
b e n i g n  
f u n c t i o n  
u p  t o  
O p o s s u m  
C h i c k e n  
C h i c k e n  
- -
P S I C  s c o r e  
d i ff e r e n c e  
1 . 9 9 4  
1 . 4 3 6  
1 . 3 4 4  
p h y s i o c h e m i c a l  
d i ff e r e n c e  
m o d e r a t e  
s m a l l  
s m a l l  
G r a n t h a m  
A G V G D  
d i s t a n c e  ( 0 - 2 1 5 )  
p r e d i c t i o n  
1 0 9  
C 1 5  
2 3  
C 1 5  
5 8  
C 5 5  
*  B a s e d  o n  t h e  G r a n t h a m  s c o r e s ,  t h e  a m i n o  a c i d  s u b s t i t u t i o n  i n  R C C - J W  i s  e x p e c t e d  t o  h a v e  a  s i g n i f i c a n t  b i o c h e m i c a l  e f f e c t . ( G r a n t h a m  s c o r e :  1 0 9) .  T h e  
a m i n o  a c i d  s u b s t i t u t i o n s  i n  T- 3  a n d  T - 4  a r e  n o t  e x p e c t e d  t o  h a v e  a  s i g n i f i c a n t  b i o c h e m i c a l  e ff e c t  ( G r a n t h a m  s c o r e s :  5 8  a n d  2 3 ) .  
*  A c c o r d i n g  t o  t h e  A G V G D  p r e d i c t i o n  p r o g r a m ,  t h e  i d e n t i f i e d  v a r i a n t  i n  T- 4  i s  l i k e l y  t o  i n t e r f e r e  w i t h  p r o t e i n  f u n c t i o n  ( s c o r e :  C 5 5 )  ,  w h i l e  t h e  v a r i a n t s  
i d e n t i f i e d  i n  T - 3  a n d  R C C - J W  a r e  l e s s  l i k e l y  t o  i n t e rf e r e  w i t h  p r o t e i n  f u n c t i o n  ( s c o r e  C 1 5 ) .  ( C O :  n o t  l i k e l y  t o  i n t e r f e r e  w i t h  f u n c t i o n ,  C 6 5 :  m o s t  l i k e l y  t o  
i n t e rf e r e  w i t h  f u n c t i o n )  
*  A c c o r d i n g  t o  t h e  S I F T  p r e d i c t i o n  p r o g r a m ,  a l l  t h r e e  i d e n t i f i e d  v a r i a n t s  a ff e c t  t h e  f u n c t i o n  o f  t h e  p r o t e i n . ( m e d i a n  s e q u e n c e  c o n s e r v a t i o n
=
4 . 3 2 ,  l o w  
c o n f i d e n c e )  
*  A c c o r d i n g  t o  t h e  P o l y p h e n  p r e d i c t i o n  p r o g r a m ,  t h e  v a r i a n t  i d e n t i f i e d  i n  R C C - J W  h a s  a  " p o s s i b l y  d a m a g i n g " e ff e c t  ( P S / C  s c o r e :  1 .  9 9 4 ) .  T h e  v a r i a n t e s  
i d e n t i f i e d  i n  T - 3  a n d  T- 4  a r e  n o t  p r e d i c t e d  t o  h a v e  a  p a t h o g e n i c  e ff e c t  ( P S I C  s c o r e s :  1 . 3 4 4  a n d  1 . 4 3 6 ) .  
H e m :  h e m i z y g o u s ,  d e l :  d e l e t i o n .  N C B I  R e f e r e n c e  S e q u e n c e :  N M _ 0 1 4 1 5 9 . 6 ,  N P  _ 0 5 4 8 7 8 . 5  
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ABSTRACT 
Gene Identification by Nonsense mediated mRNA decay Inhibition (GINI) provides 
a promising possibility to identify putative tumor suppressor genes (TSGs). We 
applied a GINI strategy to a panel of ccRCC-derived cell lines and identified SETD2 as 
a novel ccRCC tumor suppressor gene, as described in Chapter 2. Here, we describe 
the appl ied GINI strategy in more detail. Moreover, we evaluate the use of GINI in 
the search for TSGs by using the current knowledge on ccRCC genetics. We show 
that GINI has some intrinsic limitations. TSGs that code for relatively small proteins 
and/ or have only a limited number of exons appear to have a l imited chance on being 
identified by GINI. Moreover, the succes of the method is dependent on the quality of 
the used gene expression platform. 
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INTRODUCTION 
Tumor suppressor genes are in general inactivated by large deletions, mutations that 
alter the amino acid sequence of the protein, or mutations that introduce a premature 
termination codon (PTC), which include nonsense mutations, out-of-frame indels or a 
splice site mutation. In the majority of cases, the presence of a PTC does not result 
in the production of truncated proteins, but rather induces accelerated decay by 
nonsense mediated mRNA decay (NMD) (Anczukow et al., 2008; Karam et al. ,  2008; 
Mort et al., 2008; Perrin-Vidoz et al., 2002). 
In 2001 Noensie and Dietz described a method for the genome-wide identification 
of transcripts that harbor a PTC in cell lines. They pharmacologically inhibited nonsense 
mediated mRNA decay (NMD) by the translational inhibitor emetine dihydrochlorate. 
This results in the accumulation of a subset of transcripts harboring PTCs and the 
increased transcript levels can be measured using gene expression microarrays. The 
presence of the PTC in the transcript can be confirmed by Sanger sequencing (Noensie 
and Dietz, 2001). 
Gene Identification by Nonsense-mediated mRNA decay Inhibition (GINI) provides 
a promising possibility to identify putative tumor suppressor genes (Huusko et al., 2004; 
Ivanov et al., 2007). We applied a GINI strategy in our search for tumor suppressor 
genes involved in the development of clear cell renal cell carcinoma (ccRCC). We 
combined several methods and criteria to maximize the chances of finding ccRCC 
tumor suppressor genes and, at the same time, minimize the number of false-positive 
candidates that hampered the analysis of GINI strategies described earlier. Here, we 
describe the GINI strategy that led to our identification of histone methyltransferase 
SETD2 as a new ccRCC tumor suppressor (Duns et al., 2010). Moreover, using the 
known ccRCC tumor suppressor gene VHL (Gnarra et al., 1994; Nickerson et al., 2008) 
and the recently identified ccRCC tumor suppressor gene PBRM1 (Chapter 5 of this 
thesis; Varela et al., 2011) as examples, we describe the intrinsic limitations of using 
GINI in the search for tumor suppressor genes. 
MATERIAL AND METHODS 
Cel l  l ines 
Prostate cancer cell line Du145 was obtained from the American Type Culture 
Collection, Manasses, Virginia, USA, and maintained in DMEM (Sigma-Aldrich, St.Louis, 
MO, USA). The previously described splice site acceptor mutation introducing a PTC 
in MLH1 and the hemizygous nonsense mutation in EPHB2 in DU145 (Huusko et al., 
2004) were confirmed in this cell line using capillary Sanger sequencing. 
The ccRCC-derived cell lines RCC-AB, RCC-ER, RCC-FG2, RCC-HS, RCC-J F, 
RCC-JW, RCC-MF, and RCC-WK were obtained from Cell Line Services, Eppenheim, 
Germany. The cells, which tested negatively for Mycoplasma, bacteria, and fungi, had 
been passed 10 to 13 times upon arrival (as stated by Cell Line Services). Experiments 
were performed on cells that had undergone six to eight additional passages. cRCC 
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cell l ines RCC-1 , RCC-4, and RCC-5 were established by Dr. C.D. Gerharz (Institute of 
Pathology, University Hospital,  Dusseldorf, Germany) and karyotyped. To ensure their 
authenticity, they were recently re-karyotyped. All ccRCC cell lines were maintained 
in RPMI 1640 (Sigma). MN160 and PTEC are primary cu ltures derived from proximal 
tubular epithelial cells. DNA was purified using a phenol/chloroform extraction 
method. 
ArrayCG H 
ArrayCGH was carried out using Agi lent Human Genome CGH Microarray 244a slides 
(pin G4411 B) following the manufacturer's protocols. Slides were scan ned using the 
G25052C DNA microarray scanner (Agilent Technologies, Santa Clara, CA, USA). 
Array images were analyzed using Agilent feature extraction software (v10.5.1.1 ) and 
DNA analytics (Agilent). 
GIN I  
Cells were grown to 70% conf luence and either treated with emetine dihydrochloride 
hydrate (100 µg/ml medium) or caffeine (10 mmol/L in medium), or not treated. 
Following 8 hours of incubation at 37 °C, cel ls were harvested. Experiments were 
performed in du plicate. RNA was isolated using the RNeasy Mini Kit (Oiagen, Ven lo, 
the Netherlands). 
Transcript abundance in treated and u ntreated cells was measured using Human 
HT-1 2_V3_Beadchips (48K; lllumina, San Diego, CA, USA). The Lumi package 
implemented in R (Du et al., 2008; Lin et al. ,  2008) was used for variance stabilizing 
transformation followed by robust spline normalization of the microarray data (GEO 
accession no. GSE20491 ). GeneSpring GX 10.0 (Agilent) was used to calcu late 
treatment-induced fold changes. 
Mutation analysis 
Mutational analysis of SETD2 in the panel of ccRCC-derived cell lines is described 
in Chapter 2. Mutational analysis of PBRM 1 and VHL in the panel of ccRCC-derived 
cell lines and primary tumors is described in Chapter 5. Nine and ten PCR primer 
sets were designed to amplify and sequence exons and exon-intron boundaries of 
AR/D3A, and AR/D5B, respectively, an notated in the human genome (National Center 
for Biotechnology Information). Amplified PCR products were purified using EXOSAP 
IT (GE Healthcare, Little Chalfont, Buckinghamshire, UK) and sequenced using BigDye 
Terminator chemistry (Applied Biosystems, Foster City, CA, USA). Reaction products 
were run  on the ABl3130XL Genetic Analyzer (Applied Biosystems). Sequences were 
evaluated using Mutation Surveyor (SoftGenetics LCC, State College, PA, USA). The 
following primers were used: ARID3A: exon 1_F: CGGCCAGGTATTTGCATCCG, 
exon 1_R: CACCAACATCTCCGCCCAAC, exon 2a_F: CTGCATCCTGCATGAGATGG, 
exon 2a_R: CCATCACGGCCTGTAGTTTC, exon 2b_F:CAGGGCCATGAAACTACAG, 
exon 2b_R: CACTCAGAGCCAGTAACAG, exon 3_F: GCCGGCTCTTCCTATTTC­
CAGAGA, exon 3_R: GCAACGTGGGCCTTCAAAGGG, exon 4_F: CTCCAGT­
GCAGGAGGGACATGGT, exon 4_R: CTCACCACCGCCCCGACATACC, exon S_F: 
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GGTGGATAAACCGAGGCAGAGCTG, exon S_R: CCTCGCACCCCTACTTGACGC, 
exon 6_F: G GTGGTGCCACAGTGG GGTTTAC, exon 6_R: ACCCAGAGAGG GGAA­
GAGGTATCC, exon 7 _F: TCGCACCATTGCACTCCAG ,  exon 7 _R :  ATGTAGG CTC­
CAAGGCCCTCAC, exon 8_F: CAGAGCTTGCAGTGAGCTG , exon 8_R : taccg­
ggtgaacgatggtat. AR I DS B :  exon 1 a_F: ACATGG CAGTGAGGAAGC, exon 1 a_R :  
AGAGAAAGGCGCCATACG, exon 1 b_F: TGCCTTGATCCATCCTCTTC, exon 1 b_R :  
ATACAGACGACCCAACAG, exon 2_F :  CCCAGCGTTATATCTGTTGGGTCGT, exon 
2_R :  GGAGTCGATCCTGCTTGCCTGC, exon 3_F: TGGGCCTTGTGGAGAGTGGATCA, 
exon 3_R :  ACCCATCCAGTCATCTCTCCATCC, exon 4_F :  GCTGGCATCCCCCA­
GACTGTAA, exon 4_R :  CCCGTTCCCCATCACCGCTCTT, exon S_F: TGTAATAAT­
GAGGGCTGCCTGCCAC, exon S_R :  TGCCTCCAAGACACAGGCACAGA, exon 6_F :  
TACCGGTTCACCCTTAGCAC, exon 6_R: TCCAATTCAAAGAATCTGAGCA, exon 
7 _F: CTTTGGGCAAATTGTTTCCT, exon 7 _R: CCCAATAAACCCCAAAAGT, exon 8_F :  
TTCTCTGTTTCTGG GTTTCCAG, exon 8_R: TTTCAGTTTCCCAAAAGGTCA, exon 
9_F: CCATAGCATTGATGCTACTGGA, exon 9_R: CATCAAGCCATCCAACTGTG . 
Quantitative RT-PCR 
RT-PCR was performed on G I N I  samples to assess PBRM 1 transcript l eve ls .  RNA 
was reverse transcribed us ing  the Fermentas RevertAid H minus first strand cDNA 
kit (Thermo Fisher Scientific, Wa ltham,  Massachusetts, U SA) . SybrGreen RT-PCR 
was performed i n  a tota l vo lume of 10 u l  us ing a 384-we l l  m icrowel l  p lates and the 
AB l7900HT Fast RT-PCR system (Appl ied B iosystems, Foster City, CA, U SA) The 
fo l lowing primers were used for PBRM 1 :  Forward :  TGCAGAGGCCAACCTACAAC, 
Reversed : TCGTGTAGCCAGGTGGAATG . The housekeeping gene TBP was used 
as a reference (forward primer: GCCCGAAACGCCGAATAT, reversed primer: 
CCGTGGTTCGTGGCTCTCT) . Al l PCR experiments were performed in trip l i cate. 
RESULTS AND DISCUSSION 
NMD inhibition by emetine and caffeine treatment 
Pharmacologica l  i nh ibition of N M D  induces a cel l u l a r  stress response (Noensie and  
Dietz, 2001 ) .  Therefore, t he  l i st o f  transcripts that show an  i ncrease in abundance 
as a result of N M D  inh ib ition not on ly inc ludes transcripts that harbor premature 
term ination codons ( "PTC transcripts") ,  but a l so transcripts encoded by upregu lated 
" stress response genes " .  Severa l approaches have been used in earl ier G I N I  surveys 
to reduce the number of these fa lse-positives and to obta in a l im ited l i st of cand idate 
PTC transcripts .  These approaches inc lude a combination of N M D  inh ibition with 
transcriptiona l  i n h ibition by actinomycin D (Huusko et a l . ,  2004; Ivanov et a l . ,  2007), 
and the use of s i RNA-med iated knockdown of proteins  essentia l  for N M D  (Huusko et 
a l . ,  2004) . 
We anticipated that treatment of cel l s  by compounds that block N M D  via d ifferent 
mechan isms wou ld  excite different stress responses. A combination of treatments with 
d ifferent compounds cou ld therefore be used to exc l ude treatment-specific stress 
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response genes. In an attempt to obtain a selective list of candidate PTC transcripts in 
ccRCC-derived cel l  lines, we combined two different methods of inhibiting the NMD 
that were used in earlier GINI screens: 
( 1 )  t reating the cells with emetine dihydrochlorate (we will refer to this inhibition as 
emetine treatment) (Noensie et al . , 2001 ). This inhibits the movement of the ribosome 
along the nascent transcripts. As a result, the so-cal led " pioneer round of translation" ,  
which is  essential for N MD, cannot take place ( lshigaki et  al., 2001 ). 
(2) treating the cells with caffeine (Ivanov et al . ,  2007). This inhibits the 
phosphorylation of Rent1 (hUpf1) by SMG-1, a process which is essential for NMD­
induced mRNA degradation (Brumbaugh et al., 2004; Ohnishi et al., 2003). 
GIN I  val idation 
To validate these methods, we first app lied them to the human prostate cancer cel l  
line DU145, which harbors truncating mutations in MLH1 and EPHB2 (Huusko et al., 
2004). Emetine- and caffeine-treatment of DU 145 resulted on average in 2.6- and 2.8-
fold accumulation for MLH1 and 2.1- and 2.1-fold accumulation for EPHB2 transcripts, 
respectively, as assessed by RT-PCR (Figure 1). 
We then checked if gene expression microarrays could be used to identify these 
treatment-induced increases in transcript levels. MLH1 showed emetine- and caffeine­
induced fold changes of 3.9 and 2.3, respectively, for EPHB2, this was 1.6 and 1.4, 
respectively (data not shown). Thus, gene expression microarrays can be used to 
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Figure 1 .  I ncreased transcript levels of MLH1 and EPHB2 as a result of NMD inhibition in the 
prostate cancer- derived cell line DU1 45 .  
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GIN I  i n  ccRCC 
We subsequently applied GINI in the search for tumor suppressor genes involved in 
ccRCC development. We used a combination of methods and criteria to increase our 
chances of identifying tumor suppressor genes, while at the same time limiting the 
number of false-positive candidate PTC transcripts. 
Loss of the short arm of chromosome 3 (3p) is frequently observed in ccRCC 
tumors, which suggests the presence of tumor suppressor(s) in this region (Knudson et 
al., 1 97 1 ). To increase the chance of identifying these genes, we selected ten ccRCC­
derived cell lines showing copy number loss of 3p, as assessed by arrayCGH (This thesis: 
Chapter 2). We anticipated that a gene which is inactivated in a majority of tumors has 
a considerable chance of being inactivated by a mutation introducing a PTC that elicits 
NMD in at least one of the cell lines, although most likely not in all of them. In addition, 
we used two proximal tubular epithelial cell (PTEC) samples as reference. The transcript 
levels in these samples should reflect the "normal" situation. We inhibited NMD in the 
ccRCC-derived cell lines by treating them with emetine or caffeine. 
Filtering steps 
Transcript levels in treated and untreated cells were assessed using gene expression 
microarrays. For each ccRCC-derived cell line, lists of probes were generated that 
showed emetine- or caffeine-induced increase of transcript levels. We arbitrarily 
selected the top 1 000 probes with the highest treatment-induced fold changes. To 
limit the lists of candidate PTC transcripts, we applied the following three criteria 
(summarized in Figure 2): 
(1 ) To eliminate treatment-specific stress response genes, transcripts that showed 
increased transcript levels after only one of the two treatments were eliminated. This 
resulted in a list of 203 (range 1 21 -321 ) probes on average per cell line. 
(2) Genes were then selected based on their genomic location. 1 4  probes 
(representing 1 4  genes) that passed filtering step #1 in one or more of the cell lines 
were located on the short arm of chromosome 3, including the RASSF1 gene, an 
isoform of which is a known physiological NMD transcript (Mendell et al., 2004). 
(3) The "GINI profiles",  i.e., the transcript levels in the wild-type (WT) and treated 
samples, of the 1 3  other genes were visually inspected for a so-called "PTC profile" :  
due to NMD, PTC transcripts should be significantly less abundant than their non-PTC 
harboring counterparts (in PTECs as well as in the other ccRCC-derived cell lines). 
Emetine- and caffeine-treatment should restore the abundance of PTC transcripts to a 
level that resembles the wild-type transcript levels. The expected transcript levels for 
a hypothetical gene harboring a premature termination codon in two of the cell lines 
are shown in Figure 2. 
This last filtering step, comparing transcript levels in other untreated cell lines of 
comparable nature as a selection criterion, has been described previously (Rossi et al. ,  
2005). This is  however clearly not without risks, as transcript levels of several genes will 
likely vary, even between cells of the same origin. So for genes that show fluctuating 
transcript levels between the different untreated samples, the criteria should be 
applied less stringently. 
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1. & 2. 3. PTC profile 
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Figure 2. Overview of our G IN I  strategy. The graph shows the expected transcript levels for a 
hypothetical gene that harbors mutations introducing a premature termination codon in tumor­
derived cell lines T-3 and T-6. LOH: loss of heterozygosity, PTC: transcript harboring premature 
termination codons, N: "normal"  cells, T: tumor-derived cell line. 
SETD2 is the only gene out of the 1 3  candidates on 3p that fitted all 
these cr iteria. 
The GINI patterns of SETD2 in RCC-AB and RCC-ER were indicative for the presence 
of a premature termination codon : in untreated RCC-AB and RCC-ER cel ls the SETD2 
transcript abundance was low compared to the other cell l ines. Emetine- and caffeine 
treatment resulted in the accumulation of SETD2 transcripts in RCC-AB and RCC-ER 
(Figure 3). 
We indeed identified a 1-bp deletion introducing a frameshift and a nonsense 
mutation in RCC-AB and RCC-ER, respectively (Duns  et al . ,  2010). A screen for 
mutations other than those causing premature termination codons in the other 
ccRCC-derived cell l ines revealed inactivating mutations in three of them. A h uge 
sequencing project on ccRCC tumors by Dalgl iesh et al. (2010) identified truncating 
mutations in SETD2 i n  12 out of 407 (3%) clinical ccRCC specimens, providing in vivo 
evidence for SETD2 being a candidate ccRCC tumor suppressor gene (Dalgliesh et 
al., 2010). SETD2 is located at 3p21 and encodes a histone methyltransferase that is 
nonredundantly responsible for trimethylation of lysine 36 of histone 3 (H3K36me3) 
(Edmunds et al. , 2008). 
False-positives 
Given the emerging role for deregulated chromatin regulation in ccRCC pathogenesis, 
we re-analyzed our data, and focused on PTC profiles for genes with a function 
in chromatin regulation. We saw possible PTC profiles for the genes coding for 
the chromatin remodeling proteins ARID3A and AR/05B i n  five and two cell lines, 
respectively (Figure 4). 
However, we did not identify any tru ncating mutations by capillary Sanger 
sequencing in these genes. 
44 CHAPTER 3 













13 8 .0 . 
ro 
§ 1 .0 . 0 z 
■ Untreated ■ Caffeine 
□ Emetine 
Figure 3. Effect of nonsense-mediated mRNA decay inhibition on SETD2 transcript levels 
in ccRCC-derived cell lines. For each cel l  l ine,  SETD2 transcript levels a re shown in untreated, 
caffeine-treated and emetine-treated cel ls ,  respectively. Normal ized intensity values are shown 
on a log2 sca le. Levels below a va lue of 7 a re close to the detection l im it .  The dotted horizonta l 
l ines represent the average transcript levels measured in untreated proximal tubu lar  epithe l ia l  
ce l ls .  
False-negatives 
With the current knowledge on ccRCC genetics and the known mutational status of 
PBRM1 and VHL in our panel of ccRCC-derived cell lines (Chapter 5 of this thesis), 
we retrospectively evaluated our GINI strategy and showed that the use of GINI in 
searching for tumor suppressor genes has some intrinsic limitations. 
The VHL gene, located at 3p25 and coding for the Von Hippe! Lindau protein, is a 
major tumor suppressor gene in clear cel l renal cel l carcinoma. VHL has been shown 
to be inactivated in a majority of ccRCC tumors (Gnarra et al., 1994; Nickerson et 
al. , 2008). PBRM1, located at 3p21, and coding for BAP180, the chromatin targeting 
subunit of the SWI/SNF complex, was recently identified as the second major tumor 
suppressor gene in ccRCC (Chapter 5 of this thesis; Varela et al., 2011 ). Capillary 
Sanger sequencing of VHL and PBRM1 in our panel of ten ccRCC-derived cell l ines 
revealed inactivating mutations in six and five of them, respectively. Three and four 
of the mutations identified in VHL and PBRM 1 ,  respectively, introduce premature 
termination codons. (This thesis: Chapter 5, table 1). However, the GINI profiles for 
VHL and PBRM1 among the panel of ccRCC-derived cell l ines do not indicate the 
presence of premature termination codons in any of the ccRCC-derived cell lines 
(Figure 5). Thus, VHL and PBRM1 exemplify intrinsic drawbacks of using GINI in the 
search for tumor suppressor genes; this is explained below. 
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Figure 4. Effect of nonsense-mediated mRNA decay inhibition on ARID3A and ARIDSB 
transcript levels in ccRCC-derived cell l ines. For each ce l l  l ine ,  ARID3A (A) and AR/05B (B) 
transcript levels are shown in  untreated , caffeine-treated and emetine-treated cel ls, respectively. 
Norma l ized intensity val ues a re shown on a log 2 sca le .  Levels  below a va lue of 7 a re close to the 
detection l im it. The dotted horizonta l l ines represent the average transcript levels measured i n  
untreated proxima l  tubu lar  epithe l ia l  ce l ls. 
Size of the encoded protein a nd number  of exons 
The success of  the method,  i .e . ,  the identification of  a given tumor suppressor gene, 
depends crucially on the presence of an N M D-eliciting mutation in that gene in at least 
one of the tested samples. Premature termination codons that are located in the last 
exon, or within the last 55 nucleotides of the penultimate exon are not recognized by 
an NM D machinery (Nagy et al. ,  1 998). Therefore, tumor suppressor genes that code 
for small proteins and/or have only a limited number of exons have a smaller chance of 
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Figure 5. Effect of nonsense-mediated mRNA decay inhibition on VHL and PBRM1 transcript 
levels in ccRCC-derived cell lines. For each cel l  l ine, VHL (A) and PBRM 1 (B) transcript l evels 
are shown i n  untreated, caffeine-treated, and emetine-treated cel ls, respectively. Norm a l ized 
intensity va l ues a re shown on a log2 sca le .  Levels  below a va lue  of 7 a re close to the detection 
l im it. The dotted horizonta l l ines represent the average transcript levels measured i n  untreated 
proxima l  tubular  epithe l ia l  cel ls .  
being inactivated by a N MD-eliciting mutation compa red to genes that code for larger 
proteins and/or contain more exons. Even more, a PTC in a gene containing only one 
exon will never elicit N MD. 
The full VHL gene contains three exons and encodes a protein (VHL30) containing 
213 amino acids (lliopoulos et al., 1995). As a result, a relatively large fraction of 
premature termination codons in VHL in ccRCC tumors is expected to be in a location 
in which they cannot be detected by the N MD machinery (Figure 6.a). We identified 
mutations in VHL that introduce a premature termination codon in three out of ten 
ccRCC-derived cell lines. None of these a re at a position where they could elicit N MD 







Figure 6. VHL and PBRM1 mutations in ccRCC samples. Schematic overview of pVHL  (A) and 
BAF180, encoded by PBRM 1 (8). Colors highlight the protein parts encoded by the different 
exons. Arrows show the location of the mutations and the corresponding amino acid changes. 
Underlined: mutations in ccRCC-derived cell lines that introduce a premature termination codon 
(PTC). PTCs located downstream of * are not recognized by the NMD machinery. For VHL, the 
region in which a PTC is not recognized by NM D includes 234 nucleotides (fu l l  VHL transcript: 
642 nucleotides). For PBRM 1 ,  this region includes 228 nucleotides (full PBRM 1 transcript: 4806 
nucleotides). NMD: mutation results in a PTC that is recognized by the NMD machinery. National 
Center for Biotechnology Information Reference Sequence: NM_00055 1 .3, NP_00054 1 .2 (VHL) 
and NM_0 1 8 1 65.4, NP_060635.2 (PBRM 1). 
out of ten primary ccRCC tumors, we identified mutations in VHL that introduce a 
PTC. In only one primary tumor (T-e), could the PTC transcript have been potentially 
recognized by the NMD machinery (Figure 6.a). So, the chance of identifying a given 
tumor suppressor gene by GINI depends on the size of the encoded protein and the 
number of exons. 
Expression platform 
PBRM1 il lustrates how GINI depends on the expression platform used. Screening of 
PBRM 1 (28 exons, 1602 amino acids) for mutations in our cel l  lines revealed four 
mutations introducing premature termination codons that are all supposed to be 
detected by the NMD pathway (Figure 6. b) .  However, the observed signals for PBRM1 
expression were very low in all samples, and none of the probes showed increased 
HAPTER 3 
transcript levels as a result of NMD inhibition in any of these four cell lines (Figure 
5.b) .  Using RT-PCR on the GINI samples from RCC-4, we clearly show an increase 
in PBRM1 transcript abundance as a result of both emetine- and caffeine treatment 
(Figure 7). Thus, we must conclude that the expression profiling platform we used was 
not sensitive enough to reliably identify the changes in transcript abundance. 
Cell l ines 
A further limitation of the GINI strategy is its dependence on dividing cells. Therefore, 
tumor-derived cell lines have to be available. In order to enlarge the chance of 
identifying tumor suppressor genes that are mutated in only a small fraction of samples, 
the GINI strategy should preferably be applied to a large number of cell lines. 
CONCLUSION 
In conclusion, the GINI strategy has proven to  be  a very helpful tool in identifying 
putative tumor suppressor genes. However, as described above, the method has 
some limitations. The recent development of next-generation sequencing (NGS) 
technologies makes it possible to sequence large numbers of genes in parallel, making 
the use of GINI redundant. The method might, however, still be useful in specific cases. 
For example, Sumitsuji et al. (2003) showed that NMD inhibition fol lowed by cDNA 
sequencing can be used to rapidly identify mutations in the MLH1 gene, which is large 
and difficult to sequence, in patients suspected of having hereditary nonpolyposis 
colon cancer. 
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Figure 7. Effect of nonsense-mediated mRNA decay inhibition on PBRM1 transcript levels in 
ccRCC-derived cell line RCC-4 as assessed by RT-PCR. 
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ABSTRACT 
SETD2 was recently identified as a new candidate ccRCC tumor suppressor gene. 
SETD2 codes for a histone methyltransferase that is responsible for trimethylation of 
lysine 36 of histone H3 (H3K36me3). The specific role of SETD 2  in ccRCC development 
is la rgely unknown. H3K36me3 is involved in a lternative splice site choice, while 
misregulation of splicing is common in cancer and plays a role in tumor development 
and maintenance. One could therefore speculate that SETD2 inactivation contributes 
to ccRCC development by the deregulated splicing of target genes. Here, we describe 
the initia l steps to determine the effects of functional loss of SETD2 in proxima l tubular 
epithelial cells and its contribution to ccRCC development. We show significantly 
altered transcript levels for a subset of genes as a result of siRNA-mediated knockdown: 
this subset is enriched for genes that function in angiogenesis-related processes. This 
is in concordance with the observation that SETD2 is required for embryonic vascular 
remodeling in mice, and might indicate a role for SETD2 in tumor angiogenesis. 
Moreover, several genes show an appa rent change in alternative splice site choice as 
a result of SETD2-knockdown, which corroborates earlier findings. Further functional 
studies are needed to determine the exact mechanisms and proteins that underlie the 
observed changes in transcript levels and a lternative splice site choice, and the effect 
of these changes on the function of the encoded proteins, as well as their potentia l  
role in ccRCC tumorigenesis. 
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INTRODUCTION 
SET domain-containing protein 2 
SET domain-containing protein 2 (SETD2) was recently identified as a candidate tumor 
suppressor gene in clear cell renal cell carcinoma (ccRCC) (Dalgliesh et a l . ,  201 0; Duns 
et al . ,  2010). SETD2 codes for a histone methyltransferase which is nonredundantly 
responsible for trimethylation of lysine 36 of histone H3 (H3K36me3) (Edmunds et al. ,  
2008; Yoh et al., 2008). We showed inactivating mutations in SETD2 in five out of ten 
ccRCC-derived cell lines. These five cell lines, and two additional ccRCC-derived cell 
lines, all showed loss or a significant decrease of global H3K36me3. Our data support 
the findings of Dalgliesh et al. (2010) who identified inactivating mutations in SETD2 
in 12 out of 407 (3%) primary ccRCC tumors. Inactivating mutations in SETD2 appear 
to be specific for ccRCC (Dalgliesh et al.,  2010). However, decreased SETD2 transcript 
levels have been observed in malignant breast cancer (Al Sarakbi et a l . ,  2009), and a 
transposon-based genetic screen in mice suggested a role for SETD2 inactivation in 
the development of pancreatic cancer (Starr et al.,  2009). 
The precise role of SETD2 inactivation in ccRCC development is unknown, 
although it is known that SETD2 is required for embryonic vascular remodeling in mice 
(Hu et al., 2010), which might point to a role in tumor angiogenesis. Xie et al. (2008) 
showed that SETD2 can directly interact with P53, and selectively regulates a subset 
of P53 target genes. This might suggest a tumorigenic role for SETD2 inactivation 
through deregulation of the P53 pathway. The identification of inactivating mutations 
in additional histone modifying enzymes in a subset of ccRCC tumors (Dalgliesh et 
al.,2010) however strongly suggests that the tumorigenic effect of SETD2 inactivation 
is probably the result of the loss of its histone methyltransferase activity. 
Histone modifications and cancer 
Post-translational modification of histone tails can affect chromatin structure and/or 
result in the recruitment or rejection of specific protein complexes, affecting gene 
regulation. A number of recent papers correlate loss- or gain-of-function of histone­
modifying enzymes, including histone lysine methyltransferases, with the pathology 
of several types of cancers (reviewed by Fullgrabe et al., 201 0; Morin et al., 2011 ). 
Aberrant activity of histone- modifying enzymes could result in altered chromatin 
configuration and disruption of normal transcriptional programs, pushing the cell 
towards cancerous development. 
Trimethylation of histone 3 at position K36 
The H3K36me3 mark is mainly located on the gene body of active genes and is 
therefore associated with actively transcribed genes (Barski et al., 2007). Several 
observations suggest the involvement of H3K36me3 and other histone modifications 
in the regulation of splicing. H3K36me3 is specifically enriched in exons relative 
to intronic regions (Andersson et al., 2009; Huff et al., 201 0; Kolasinska-Zwierz et 
al., 2009; Spies et al., 2009). Furthermore, H3K36me3 is less prominently enriched 
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in alternatively spliced exons than in constitutive exons (Andersson et al., 2009; 
Kolasinska-Zwierz et al. ,  2009). Moreover, H3K36me3 peaks at bona fide exons, 
but not at intronic exon-like sequence composition regions ( ECRs), which have high 
nucleosome occupancy like that of bona fide exons, but are not spliced (Huff et al., 
201 0). Recent reports provide more direct evidence for the involvement of H3K36me3 
in alternative splicing. Depolarization of human neuronal cells increases H3K36me3 
methylation locally around the alternatively spliced exon 18 of NCAM and induces 
exon skipping (Schor et al.,  2009) . It has been suggested that histone modifications 
are able to modulate the outcome of alternative splicing by influencing the elongation 
rate of RNAPOLII (Schor et al.,  2009). Slowing of the elongation rate could result in 
recognition of " weak" splice sites, resulting in inclusion of alternative exons (De la 
Mata et al., 2003) . Recently, Luco et al. (2010) showed that H3K36me3 can directly 
affect splicing by the recruitment of polypyrimidine tract-binding protein (PTB) via 
chromatin-binding protein MRG 15, which specifically recognizes trimethylated 
H3K36 . PTB binds to exon-specific silencing elements, resulting in the repression 
of these exons (Luco et al.,  2010). They suggest the existence of several of these 
"adaptor complexes", which consist of a combination of: (1) a modified histone tail, 
(2) a chromatin-binding protein that recognizes this specific histone modification, and 
(3) a splice regulator that is recruited to the histone mark via the chromatin-binding 
protein (reviewed by Luco et al., 2011 ) .  
Alternative splicing and cancer 
About 90% of human pre-m RNAs can be alternatively spliced, which results in the 
production of protein isoforms. Expression of these isoforms is in many cases tissue­
specific, dependent on the balance of splicing enhancer and repressor activities 
that are present. Alternative splicing plays an important role in differentiation and 
development-al programs and contributes to cell lineage and tissue identity (Allemand 
et al., 2008; Wang et al . ,  2008). The importance of alternative splicing is apparent from 
the numerous diseases that have been shown to be caused by mutations in either 
cis-acting or trans-acting protein splicing factors (Caceres & Kornblihtt, 2002; Cooper 
et al., 2009). Misregulation of splicing is com mon in cancer and plays a role in tumor 
development and maintenance (Venables et al . ,  2004; 2009) . Recently, it was shown 
that disturbed expression of splicing factors in ccRCC may lead to impaired alternative 
splicing of genes regulating tumor growth and may contribute to the process of 
carcinogenesis (Piekielko-Witkowska et al., 201 0) .  
Aim 
This chapter describes the initial steps to determine the effects of functional loss of 
SETD2 in proximal tubular epithelial cells (PTECs) that are thought to be the progenitor 
cells of ccRCCs, and its contribution to ccRCC development. Here, we aim to identify 
the genes that carry a H3K36me3 mark in proximal tubular epithelial cells, and assess 
the effect of H3K36me3 knockdown on expression and alternative exon usage of 
target genes in these cells. 
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MATERIALS AND METHODS 
Proximal tubular epithel ial cel ls and cel l  l ines 
PTEC-2A09 and PTEC-060123 are primary cultures derived from proximal tubular 
epithelia l cells (Pathology Department, University Medical Centre, Groningen, the 
Netherlands). PTECs were grown in renal epithelial cell basal medium supplied with 
rena l epithelia l  cell growth kit (ATCC, PCS-400-030, PCS-400-040). ccRCC-derived cell 
line RCC-AB was obtained from Cell Line Services, Eppenheim, Germany. The cell 
line, which tested negatively for Mycop/asma,  bacteria, and fungi, had been passed 
10 to 13 times upon arrival (as stated by Cell Line Services). RCC-AB was maintained 
in RPMl1640 (Sigma, St. Louis, MO, USA). Embryonal kidney cell line HEK293T was 
obtained from American Type Culture Collection (CRL-1573) and maintained in 
DMEM (Sigma). Experiments were performed on cells that had undergone six to eight 
additional passages. 
siRNA experiments 
Proximal epithelial cells were grown to a confluence of near 100% in 25 or 75 cm2 
flasks (37 °C, 5% CO2). The cells were transfected with SETD2 on-target plus siRNA or 
Non Targeting siRNA (Dharmacon, Lafayette, CO, USA ) at 100 nM final concentration 
using l ipofectamine 2000 reagent ( lnvitrogen, Carlsbad, CA, USA), Mock transfected, 
or not treated. Following 72 h incubation, cells were harvested. Pellets were split 
in two fractions, and RNA was isolated from one fraction using the Fermentas 
Genejet RNA purification kit according to the manufacturer's instructions (Thermo 
Fisher Scientific, Waltham, MA, USA). Decreases in SETD2 transcript levels were 
assessed by quantitative RT-PCR with a Taqman gene expression assay for SETD2 
(Hs01015881_m 1) (Applied Biosystems, Foster City, CA, USA), and normalized against 
housekeeping gene TBP (forward primer: GCCCGAAACGCCGAATAT, reverse primer: 
CCGTGGTTCGTGGCTCTCT), using the ABl9700 HT Sequence detector system 
(Applied Biosystems). The other part of the cell pellet was used for histone modification 
analysis. Cells were lysed in Triton extraction buffer [0.5% Triton X-100 (v/v), 2 mmol/L 
phenylmethylsulfonyl fluoride, and 0.02% NaN3 (m/v)]. Histones were isolated by acid 
extraction O/N in 0.2 N HCL, separated using SDS-PAGE (15%) and transferred to 
a nitrocellulose membrane. The following primary and secondary antibodies were 
used for Western analysis: rabbit anti- histone 3 (Ab1791, 1 :4,000;Abcam, Cambridge, 
UK), rabbit anti-trimethyl histone H3 (Lys36; ab9050, 1 :750; Abeam) and horseradish 
peroxidase-conjugated secondary antibody (goat anti-rabbit: Bio-RAD, Hercules, CA, 
USA). Positive staining was visualized using ECL solution mixture from Roche, Basel, 
Switzerland. Attached antibodies were stripped from the membrane using Re-Bl ot 
Plus Strong Solution (Chemicon/Millipore) to al low reuse of the membrane. 
RNA-seq sample preparation 
RNA was converted into a library of template molecules suitable for subsequent 
cluster generation using the lllumina TruSeq™ RNA Sample preparation kit ( l llumina , 
San Diego, CA, USA). In brief, 400 ng of tota l RNA was ethanol precipitated, and 
EFFECT OF SETD2 KNOCKDOWN ON TRANSCRIPT LEVELS AND ALTERNATIVE SPLICING 57 
the pellet was resuspended in a fragmentation mix. The RNA was subsequently 
fragmented on a thermal cycler (94°C for 8 minutes). Fragmented RNA was reversibly 
transcribed into cDNA using SuperScript II reverse transcriptase and random primers 
on a thermal cycler (25°C for 10 minutes, 42°C for 50 minutes, 70°C for 15 minutes), 
following the manufacturer's instructions. Second strand cDNA was subsequently 
synthesized by adding a Second strand master mix and incubating at 16°C for a hour. 
Double stranded cDNA was separated from the second strand master mix using 
Ampure XP beads (Beckman Coulter Genomics, Danvers, MA, USA), following the 
manufacturer's instructions. 3' and 5' overhangs that result from fragmentation were 
subsequently removed by adding End repair mix to the purified double stranded 
cDNA, and incubating at 30°C for 30 minutes using thermal cycler. To prevent the 
blunt-end fragments from forming concatamers during the adapter ligation reaction, 
a single 'N nucleotide was added to the 3' ends by adding A-Tailing mix to the blunt­
end fragments, and incubating at 37 °C for 30 minutes using a thermal cycler. Multiple 
indexing adapter were added to the ds cDNA by adding DNA ligase mix and RNA 
adapter index, and subsequently incubating at 30°C for 10 minutes in a thermal 
cycler. Adapter-ligated ds cDNA was purified using Ampure XP beads (Beckman 
Coulter Genomics), fol lowing the manufacturer's instructions. DNA fragments that had 
adapter molecules on both ends were subsequently en riched and amplified using 
PCR. PCR Master mix and a PCR Primer cocktai l ,  which an neals to the ends of the 
adapters, were added to the adapter-ligated ds cDNA. The adapter-ligated ds cDNA 
was subsequently amplified in a PCR-reaction (98°C for 30 seconds, 15 cycles of (98°C 
for 10 seconds, 60°C for 30 seconds, 72°C for 30 seconds), 72°C for 5 minutes) using a 
thermal cycler. The amplified adapter-ligated cDNA library was subsequently purified 
using Ampure XP beads (Beckman Coulter Genomics), following the manufacturer's 
instructions. Quality and quantity of the obtained adapter-ligated cDNA library was 
assessed using the Experian™ DNA 12K analysis kit (Bio-RAD, Hercules, CA, USA). 
DSN (Duplex-specific thermostable nuclease) normalization was subsequently used 
to deplete abundant sequences such as those derived from rRNA and tRNA following 
the DSN Normalization Sample Preparation Guide (lllumina, San Diego, USA). This 
obviates the use of Poly-A selection, which has a bias towards the 3' end of transcripts, 
which could be problematic when analyzing alternative splicing. In short, a reaction 
mix containing 100 ng of the cDNA sample prep and hybridization buffer (50 mM 
Hepes, pH 7 .5, 0 .5 M NaCL) was prepared in a PCR tube. Double stranded cDNA 
molecules were denatured to single stranded DNA molecules, and subsequently 
renaturated by incubating the tube on a thermal cycler at 98°C for 2 minutes followed 
by 68°C for 5 hours. Double stranded DNA, which represent the highly abundant 
transcripts, were subsequently removed from the reaction mixture by treatment 
with Specific thermostable nuclease (DSN) enzyme (Evrogen, Moscow, Russia) at 
68°C, for 25 minutes. DSN treated DNA was subsequently en riched using Phusion 
polymerase (Fin nzymes Oy, Espoo, Finland), and purified with SPRI beads (Agencourt, 
Beverly, MA, USA) as described in the DSN Normalization Sample Preparation Guide 
(lllumina). Quality and quantity of the DSN treated cDNA library was assessed using 
the Experian TM DNA 12 K analysis kit (Bio-Rad). 
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Chromatin immunoprecipitation 
Chromatin immunoprecipitation was performed us ing the S imp le Ch l P® Enzymatic 
Chromatin IP Kit (Magnetic Beads) # 9003 (Ce l l  S igna l i ng Technology, Beverly, 
Massachusetts, USA), accord ing to the manufactu rer's instructions. B riefly, 
approximately 2 x 1 07 (proxima l  tubu lar  epithe l ia l  cel l s) to 4 x 1 07 (H EK293T) ce l ls were 
used for each experiment. DNA was cross- l i nked to h istones by treati ng cel l s  with 37% 
formaldehyde (1 0 m ins, RT) . Cross- l i nking was stopped by adding g lycine to a fina l  
concentration of  0. 1 25M (5  m ins, RT) . Ce l ls were subsequently washed with PBS  and 
harvested by scrap ing .  Cel l pel lets were resuspended in cel l  lysis buffer with p rotease 
inh ibitor and incubated for 1 0  m ins on ice. Nucle i  were subsequently pe l leted by 
centrifugation .  Chromatin was subsequently fragmented so that the majority of 
fragments consisted of one nucleosome, us ing m icrococca l n uclease digestion at 
37°C for 20 m inutes. Nuclease d igestion was stopped by adding EDTA to a fina l  
concentration of  5 mM.  Nucle i  were pel leted and resuspended in a Ch l P  buffer. N uc le i  
were lysed using a Sandel in son icator (3 sets of 20 second pu lses at 35% amp l itude) 
(Sande l i n ,  Berl in ,  Germany). Breakdown of the nuc lear membrane was determ ined by 
observing n uclei under a l ight m icroscope. A fraction of the cross- l i nked preparation 
was used for ana lysis of DNA d igestion and determination of chromatin concentration .  
DNA was isolated from this fraction us i ng  spin col umns, and DNA fragment s ize was 
determ ined by e lectrophoresis on a 1 % agarose ge l .  DNA concentration was assessed 
using a Nanodrop 8000 spectrophotometer (Thermo Scientific, Wi lm ington ,  DE ,  
USA) . Chromatin immunoprecipitation was  performed on the cross- l i nked chromatin 
preparation (O/N,  4°C), accord ing to the manufactu rer's instructions . The fo l lowing  
antibodies (a l l  from Cel l S igna l ing Technology), wh ich were kind ly made ava i lab le to  us 
by B ioke, Le iden, the Netherlands, were used : Tri -Methyl -H istone H3 (Lys 36) (D5A7) 
XP™ Rabbit mAb (1 :50), Tri-Methyl-H istone H3 (Lys4) (C42D8) Rabbit mAb (1 : 50), Tri­
Methyl-H istone H3 (Lys27) (C36B 1 1 ) Rabbit mAb (1 : 1 00), Hi stone 3 (D2B  1 2) XP® Rabbit 
mAb (Ch IP Formu l ated) #4620 ( 1  : 50), Normal Rabbit lgG #2729 ( 1 : 1 00) . RT-PCR was 
used to assess the specific enrichment as a resu lt of IP with the h istone modification­
specific antibod ies. The fo l lowing primer sets (a l l  from Cel l  S igna l i ng Techno logy) were 
used: H3K36me3: S imp leCh l P™ H uman GAPDH intron 2 (#4478) vs S impleCh l P™ 
Human GAPDH promoter (#447 1 ) . H3K4me3: S impleCh l P™ Human GAPDH pro moter 
(#447 1 )  vs SimpleCh l P™ Human MyoD1 Exon 1 (#4490), H3K27me3: H uman M yoD1  
Exon 1 (#4490) vs  S impleCh l P™ H uman GAPDH promoter (#447 1 ) . I P  samples were 
incubated overn ight at 4°C with rotation .  CH I P  Grade Prote in G Magnetic Beads # 
9600 were used to col lect the immunocomplexes (2h ,  4°C) . The Protein  G Magnetic 
beads were subsequently pel leted by placing the tubes in a Magnetic Separation 
Rack. After salt-wash ing the beads, chromatin was e l uted from the antibody/Protein  G 
beads by gently vortexing in Ch l P  El ution Buffer (30 m ins, 65°C). Protein  G Magnetic 
beads were pel l eted by placing the tubes i n  a magnetic separation rack, and the e l uted 
chromatin supernatant was transferred to new tube. 6 µI SM NaCl and 2 µI Proteinase 
K was added , and incubated for 2 hours at 65°C. DNA was subsequently pu rified us ing 
spin co l umns, and quantified usi ng  a rea l-time quantitative PCR method. 
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Chl P-seq sample preparation 
Chromatin immunoprecipitated DNA was prepared for next-generation sequencing 
(NGS) analysis following the "Preparing Samples for Ch IP sequencing of DNA" manual 
( lllumina). 3' and 5' overhangs were converted into phosphorylated blunt ends, by 
incubating a reaction mix containing 30 µ I  Ch IP enriched D NA ( ~ 10 ng), 10 µ I  Hp, 
4 µ I  T4 DNA ligase buffer with 10 mM ATP, 2 µ I  d NTP mix, 1 µ I  T4 DNA polymerase, 
1 µ I  Kienow DNA polymerase and 1 µI T4 PNK) for 30 minutes at 20°C. End-repaired 
D NA was purified using the OIAquick PCR purification kit, and eluted in 34 µ I  Elution 
buffer, according to the manufacturer's instructions (Oiagen, Venlo, the Netherlands). 
'A' bases were added to the 3'end , by incubating a reaction mix containing 34 µI DNA 
sample, 5 µ I  Kienow buffer, 10 µ I  dATP, and 1 µ I  K ienow exo (3' to 5' exo minus) for 
30 minutes at 37°C. A-tailed D NA fragments were purified using the minElute PCR 
purification kit, and eluted in 10 µ I  Elution buffer, according to the manufacturer's 
instructions (Oiagen). Adapters (that have a single 'T' base overhang at their 3' end) 
were subsequently ligated to the A-tai led D NA fragments by incubating a reaction 
mix containing 10 µ I  DNA sample, 15 µ I  DNA ligase buffer, 1 µI diluted adapter oligo 
mix and 4 µ I  DNA ligase for 15 minutes at RT. The adapter- ligated D NA fragments 
were purified using the minElute PCR purification kit, and eluted in 10 µI Elution buffer 
(Oiagen). The adapter- l igated library was subsequently size-selected (range 200-300 
bp) by running the D NA sample on a 2.5% agarose gel in TAE buffer. The region of the 
gel containing the appropriate sized DNA fragments was excised using a scalpel. DNA 
was purified from the agarose slices using the Oiagen Gel extraction kit, and eluted 
in 36 µ I  E lution Buffer, according to the manufacturer's instructions (Oiagen). Adapter­
modified DNA fragments were subsequently amplified in a reaction mix containing 
36 µ I  DNA, 10 µ I  5x Phusion* buffer, 1 .5 µ I  d NTP mix, 1 . 1 µ I  PCR primer 1. 1,  1 µ I  PCR 
primer 2. 1 and 0.5 µ I  Phusion polymerase using the following PCR protocol :  98°C for 30 
seconds, 18 cycles of (98°C for 10 seconds, 65 °C for 30 seconds, 72°C for 30 seconds), 
72°C for 5 minutes. The adapter-modified D NA fragments were subsequently purified 
using the minElute PCR purification kit (Oiagen). 
Seq uencing 
Enriched bar-coded libraries were sequenced with 100 bp paired-end reads (RNA-seq) 
or single-end reads (Ch lP-seq) across one lane of an lllumina HiSEO 2000 f low cel l  
( l llumina). 
RNA-Seq ana lysis 
The resulting 1 00 bp sequence reads were a l igned to the human reference genome 
(hg19) and resource containing sequences spanning annotated exon-exon junctions. 
The Burrows-Wheeler aligner (BWA) (v0.5 .7) (Li & Durbin, 2009) was used with default 
setting except that the Smith-Waterman alignment for the unmapped mate was 
disabled. Exon-exon junctions were compiled using transcript models from Ensembl 
v61 (Flicek et al. ,  2010), RefSeq (Pruitt and Maglott, 2001) and UCSC 'known genes' 
(Rhead et a l . ,  2010) gene annotation sources (downloaded from http:/ /genome.ucsc . 
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edu on March 17 , 2009), as described (Morin et al. ,  2010). Sequence reads that were 
uniquely aligned to junction sequences were computationally repositioned to assign 
the genomic hg 19 coordinates and an alignment file in the barn format (Li et al., 
2009), swith duplicated reads marked with Picard tools (v.1.11) was generated for the 
downstream analyses. We used custom JAVA programs to generate coverage profiles 
from the alignment barn file. We accepted reads with a BWA read quality of at least 
5 and allowed reads that represented duplicated DNA fragments. Resulting files in 
'bigWig' format (Kent et al . ,  2010) were used for visualization in the UCSC browser. 
RPKM, data normalization and 2-score 
To quantify expression levels using generated genome wide read-profiles we calculated 
Reads Per Kilobase per Million mapped reads (RPKM) (Mortazavi et al. , 2008; Pepke et 
al. , 2009) for all exons annotated in Ensembl v61 (253,750 in total) using the following 
expression: 
RPKM = nl(L *N) 
Where n is a fractional number of reads aligned to the region, L is the length of 
the region in Kb, and N is the number reads aligned into all annotated exons, in 
millions. We excl uded reads aligned to the mitochondrial genome in calculating the 
normalization constant, N. For pair-wise sample comparisons, an empirical Z-score 
was calculated assuming the mean coverage of exon followed a Poisson distribution: 
where CA and C8 are mean coverages of a given exon for samples A and B, respectively, 
and xA8 is a ratio of total number of aligned exonic reads for two samples, xA8 = NAIN8. 
We also calculated an asymmetry as 
and a fold-change 
FC = (1 + A) /(1 - A) 
We first calculated the Z-score, asymmetry and fold-change for every individual exon. 
Exons that had Z � 2 and FC � 1.5 were considered as upregulated, while exons that 
had Z � 2 and FC � 0.66 were considered downregulated between samples. 
Alternatively we also calcu lated all above observables for the whole gene. In this 
case, the mean coverage was calculated as the sum of total coverage for all exons in 
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the gene divided by tota l exonic length. The same thresholds for the z-score and fold­
change were a pplied to determine lists of up- and downregulated genes. 
CHIP-Seq analysis 
Single-end 100 bp sequence reads were ma pped to hg19 (NCBI 37) using Burrows­
Wheeler a l igner (BWA) (v0.5.9) (Li et al. , 2009) and default parameters. Reads having 
identical coordinates were collapsed into a single read and reads with BWA alignment 
quality � 5 (in this way, we also filtered reads aligned into multiple locations) were 
directionally extended 150 basepairs. By applying custom JAVA software to extended 
ChlP-seq reads we generated genome-wide profiles in the Wig and bigWig formats 
(Kent et al,. 2010) to be visualized in the UCSC genome browser (Karolchik et al. , 
2007) and for downstream ana lysis. 
Different a pproaches were a pplied to the ana lysis of various epigenetic 
modifications. To determine genes that were marked with H3K36me3, we calculated 
read coverage and RPKM over the annotated gene models (Ensembl v61 ). By 
considering genome-wide distribution of H3K36me3, and comparing RPKM ca lculated 
for the random genomic regions, we selected a threshold to separate the signa l from 
the background, and by doing so, determined the genes that are marked by this 
histone modification. To determine genes that were marked with a H3K4me3 mark, 
we calculated RPKM for the regions flanking transcription start sites (TSS) ( +/- 1000 bp) 
and used FindPeaks2 software (Fejes et al., 2008) to identify enriched locations at FDR 
~0.01. To determine genes that were marked with a H3K27me3 mark, we calculated 
RPKM for the regions flanking transcription start sites (TSS) ( +/- 1000 bp) and used the 
genome-wide H3K27me3 distribution to determine a threshold discriminating marked 
promoters from unmarked promoters. 
RESULTS 
Histone modifications in proximal tubular ep ithelial cells 
Chromatin immunoprecipitation fol lowed by next-generation sequencing (ChlP­
seq) can be used genome-wide to identify genomic segments that are bound by 
chromatin-binding proteins or carry a specific histone modification. Here, we aimed 
to identify genes that have a H3K36me3 mark in proxima l  tubular epithelia l cells. 
We validated the ChlP-seq method on chromatin from HEK293T cells. Chromatin 
immuno-precipitation using an antibody specific for H3K36me3 resulted in an 
a pproximately 6.0-fold enrichment of genomic segments that have a H3K36me3 mark, 
as compared to immunoprecipitation using an antibody against the core of histone 3 
(H3). Subsequent next-generation sequencing of the DNA-content of the precipitated 
chromatin revea led H3K36me3 profiles that showed similarity to previously published 
H3K36me3 profiles (Barski et al., 2007; Mikkelsen et a l . ,  2007)  (data not shown) . Having 
validated the method, we then performed ChlP-seq experiments on two proxima l  
tubular epithelial cell samples to identify the set of genes that have a H3K36me3 
mark in this cell type. In para l lel, we assessed the H3K4me3 and H3K27me3 profiles 
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in one of the proximal tubular epithelial cell samples. The enrichment for the ChlP­
seq experiments on chromatin from the proximal tubular epithelial cells was 4.8, 7.0, 
and 12.3 for H3K36me3, H3K27me3, and H3K4me3, respectively. Subsequent next­
generation sequencing (for ChlP-seq alignment statistics, see Supplementary Table 
5 7 )  revealed a distribution of the histone modifications across the genome that was 
expected from literature:  H3K36me3 is mainly present on the "body" of active genes. 
H3K27me3, which is associated with inactive genes, shows a reciprocal pattern with 
H3K36me3. H3K4me3 is enriched around transcription start sites of active or poised 
genes (Figure 1). The differences in distribution of the histone modifications explain the 
differences in enrichment following chromatin immunoprecipitation; in contrast with 
H3K36me3 and H3K27me3, which are located at broad genomic regions, H3K4me3 
is located at much more restricted regions, and therefore shows a higher enrichment. 
We compared the distribution of H3K36me3, H3K27me3, and H3K4me3 in proximal 
tubular epithelial cells with previously published ChlP-seq data from adult kidney and 
fetal kidney samples (GEO database GSM621634 and GSM621634, respectively). 
Overall, the patterns show a striking resemblance. However, for several genes that 
are known to be specifically expressed in endothelial cells we see H3K4me3 and 
H3K36me3 marks in the "total kidney" samples, which contain endothelial cells, while 
these marks are absent in proximal tubular epithelial cells (Figure 2), showing that a 
subset of genes has tissue-specific histone marks. 
We correlated the level of histone modifications present on genes with the 
transcript levels of these genes in the proximal tubular epithelial sample, as assessed 
by RNA-seq (For RNAseq alignment statistics, see Supplementary Table 2). For 
H3K4me3 and H3K36me3, we clearly see a positive correlation with transcript levels. 
For H3K27me3, we clearly see a negative correlation (Figure 3). 
siRNA-mediated knockdown of SETD2 
SETD2 transcript levels were decreased approximately 60% in siRNA-treated PTECs 
compared to wildtype PTECs (Figure 4.a). This resulted in a decrease of the level 
of global H3K36me3 of approximately 70%, as depicted in Figure 4b. We included 
clear cell renal cell carcinoma cell line RCC-AB in this experiment. RCC-AB harbors an 
inactivating mutation in SETD2, which results in loss of H3K36me3 (Duns et al., 2010). 
The observed faint residual staining is probably an effect of nonspecific binding of 
the antibody (Figure 4b). The effect of the decreased H3K36me3 levels in proximal 
tubular epithelial cells on expression and alternative splice site choice of target genes 
was assessed by RNA-seq. 
Effect of SETD2 knockdown on transcript levels 
We observed a significant decrease (fold-change (FC) <2/3, z-score<-2.0) in expression 
for 55 protein coding genes, and a significant increase in expression for 33 protein 
coding genes as a result of SETD2 knockdown (FC>1.5, z-score>2.0) (Table 1 ) .  As 
expected, SETD2 is in the list of genes that show a significant decrease in transcript 
level. The differentially regulated genes were analyzed for fur:,ctional enrichment using 
DAVID (Dennis et al., 2003). The Functional Annotation Chart Tool was used to obtain 
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Table 1 .  Genes showing s ign ificantly a ltered transcript levels as a resu lt  of SETD2 knockdown in  
proximal  tubu lar  epithe l i a l  ce l l  sample PTEC-2A09. 
Name 
E I F4EBP1  







I N S IG2 
PRDX3 










NDRG 1  
P4HA1 






I M PAD1 
CCN D 1  






B N I P3 L  








TH BS1  
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Ensembl_lD RPKM (WT) 
ENSG000001 87840 2649 
ENSG000001 7  6 1 7 1  9552 
ENSG000001 67772 5 1 24 
ENSG000001 1 1 674 7480 
EN SG00000 1 54736 1 435 
ENSG000001 05825 1 4229 
ENSG000001 04368 85 1 2  
ENSG000001 67779 1 907 
ENSG000001 25629 1 920 
ENSG000001 65672 9333 
ENSG00000 1 00 1 38 3003 
ENSG00000 1 02 1 44 36735 
ENSG00000 1 8 1 555 21 72 
ENSG000001 43 1 83 29 1 4  
ENSG000001 68209 3589 
EN SG00000 1 3 1 0 1 6  26489 
EN SG00000 1 3247 1 3956 
ENSG00000099942 2490 
ENSG000001 59399 3392 
ENSG000001 64096 441 0  
ENSG000001 0441 9 3933 
ENSG000001 22884 4546 
ENSG00000 1 1 4023 4358 
ENSG000001 22861  41 6 1 5  
ENSG000001 67644 7727 
ENSG000001 34333 666 1 7 
ENSG00000070669 341 3 
ENSG000001 86468 1 02 1 2  
ENSG000001 04331  347 1 
EN SG00000 1 1 0092 32953 
ENSG00000 1 1 1 669 1 1 1 27 
ENSG000001 54734 1 67 1 1 
ENSG000001 79820 3876 
ENSG000001 55 1 30 31 98 
ENSG000001 1 1 678  336 1 
ENSG000001 97930 5763 
ENSG000001 04765 7439 
EN SG000001 06366 39433 
ENSG000001 00097 1 5285 
ENSG00000 1 1 8523 1 8976 
ENSG000001 1 7394 1 0726 
ENSG00000222047 55 1 5  
ENSG000001 7042 1 1 57 1 1 
EN SG00000 1 7 1 867 4746 
ENSG00000058085 42671  
ENSG000001 37801  22046 
RPKM (SETD2 KD) Fold change 
1 020 -2.6 
3886 -2.5 
2 1 66 -2.4 
3235 -2.3 
62 1 -2.3 
6379 -2.2 
388 1 -2.2 
903 -2. 1 
9 1 0  -2. 1 
4578 -2.0 
1 483 -2.0 
1 8305 -2.0 
1 084 -2.0 
1 460 -2.0 
1 8 1 7  -2.0 
1 3873 - 1 .9  
2072 - 1 .9 
1 3 1 1 - 1 . 9 
1 788 - 1 .9 
2341 - 1 . 9 
2 1 28 - 1 .8  
2575 - 1 .8 
2483 - 1 .8 
23798 - 1 .7 
4459 - 1 .7 
38508 - 1 .  7 
1 982 - 1 .  7 
5937 - 1 .7  
2048 - 1 .7 
1 9560 - 1 .7  
6644 - 1 .7 
1 0 1 29 - 1 .6 
2367 - 1 .6  
1 959 - 1 . 6  
2067 - 1 .6  
3557 - 1 .6 
4597 - 1 .6 
246 1 8  - 1 .6  
9543 - 1 .6 
1 1 958 - 1 . 6  
6863 - 1 .6  
3546 - 1 .6 
1 0 1 38 - 1 .5  
3064 - 1 . 5 
27688 - 1 .5  
1 4346 - 1 . 5  
Table 1 continued. 
Name Ensembl_lD 
PSAT1 ENSG000001 35069 
RPS29 ENSG000002 1 37 41 
TN FRSF1 2A ENSG00000006327 
H MGA1 ENSG000001 37309 
TGFA ENSG000001 63235 -- --- ---
GPX8 ENSG000001 64294 
RNF1 87 ENSG000001 68 1 59 
GTF2H5 ENSG000001 85068 
K IF1 C ENSG000001 29250 
DEFB1  ENSG000001 64825 
C2CD4A ENSG000001 98535 
SAA2 ENSG000001 34339 
G PX3 ENSG000002 1 1 445 --- --
VG F ENSG000001 28564 
C3 ENSG000001 25730 
SAA1 ENSG000001 73432 
C1 R ENSG000001 59403 
SST ENSG000001 57005 
CDC25B ENSG000001 0 1 224 
I Fl6  ENSG000001 26709 
DEPDC6 ENSG000001 55792 
G B P2 ENSG000001 62645 
MORC4 ENSG000001 33 1 3 1  
MAOA ENSG000001 8922 1 
M M P7 ENSG000001 37673 
ABCA1 ENSG000001 65029 
CEBPD ENSG00000221 869 
WDR74 ENSG000001 333 1 6  
CPD ENSG000001 08582 
NRBP2 ENSG000001 851 89 
CRYM ENSG000001 033 1 6  
ABCC3 ENSG000001 08846 
TMEM2 ENSG000001 35048 
SOD2 ENSG000001 1 2096 
PRO M 1  ENSG00000007062 
NAM PT ENSG000001 05835 
SLC34A2 ENSG000001 57765 
SYN E2 ENSG00000054654 
SAT1 ENSG000001 30066 
TNFSF1 0 ENSG00000 1 2 1 858 
G LS ENSG000001 1 541 9 
TN FRSF1 1 B ENSG000001 6476 1  
RPKM (WT) 
6079 
9 1 36 
77 1 6  
1 93 1 0  








87 1 -- --
645 
842 








2 1 42 
2738 















1 001 3 
7953 



















2 1 38 
38 1 3  





35 1 6  
3069 
1 0 1 306 










1 1 4 1 2  
8669 
1 5094 
1 1 676 
- -- --
Fold change 
- 1 .5 
-1 .5 
- 1 . 5  
- 1 . 5  
- 1 . 5  
- 1 .5 
-1 .5  
-1 . 5  


















1 . 8 
1 .8 
1 . 7 
1 . 7 
1 .7 






1 . 5 
1 . 5 
1 . 5 
1 . 5 
1 . 5 
- ----� 
--
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F i g u r e  1 .  H i s t o n e  m o d i f i c a t i o n  p r o f i l e s  i n  p r o x i m a l  t u b u l a r  c e l l  s a m p l e  P T E C - 2 A 0 9 .  C o v e r a g e  p r o f i l e s  f o r  H 3 K 3 6 m e 3  ( t o p ) ,  H 3 K 3 7 m e 3  ( m i d d l e )  
a n d  H 3 K 4 m e 3  ( b o t t o m )  g e n e r a t e d  f r o m  t h e  b a rn  a l i g n m e n t  f i l e  ( s e e  M a t e r i a l s  a n d  M e t h o d s ) ,  a n d  d i s p l a y e d  a s  c u s t o m  t r a c k s  o n  t h e  U C S C  g e n o m e  
b r o w s e r .  T h e  p r o f i l e s  r e p r e s e n t  t h e  n u m b e r  o f  s e q u e n c e  r e a d s  u n i q u e l y  a l i g n i n g  t o  ( A )  s e g m e n t s  o f  c h r o m o s o m e  3  ( 1 2 2 . 3 8 - 1 2 4 . 9 0  M b  f r o m  p t e r ) ,  a n d  
( B )  c h r o m o s o m e  6  ( 3 3 . 4 3 - 3 5 . 1 7  M b  f r o m  p t e r ) .  T h e  b o t t o m  p a r t  o f  t h e  f i g u r e s  s h o w s  t h e  l o c a t i o n s  o f  t h e  R e f S e q  g e n e s ,  w i t h  b o x e d  r e g i o n s  a n d  t h i n  
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Figure 2. H3K36me3 and H3K4me3 profiles on endothelium•specific genes. Coverage profi l es 
for H3K36me3 and H3K4me3 in proximal tubu lar  epithe l i a l  cel l  sample PTEC-2A09 (PTEC) a nd 
an adu lt kidney sample (G EO database GSM621 634), generated from the barn a l ignment fi le 
(see Materia ls  and Methods), and disp layed as custom tracks on the UCSC genome browser. 
The profi les represent the number of sequence reads un iquely a l ign ing to segments of (A) 
chromosome 9 (1 30.55-1 30.66 Mb from pter), and (B) chromosome 4 (1 00.6- 1 01 .6  M b  from 
pter). The bottom parts of the figu res show the location of the RefSeq genes in these genomic 
segments, with boxed regions and th in l ines representing exons and intrans, respectively. The 
ENG and EMCN genes, which code for the endothel ia l  markers Endog l in  and Endomucin ,  
respectively, are h igh l ighted by dotted squares in  A and B. These genes show H3K36me3 and 
H3K4me3 marks in  the total kidney sample, which are largely absent in  the proximal tubu la r  
epithe l ia l  ce l l s  (PTECs). 
the p-values that describe the probability that a functional term will be enriched among 
the up- or down regulated genes. Gene set enrichment analysis for KEGG pathways for 
the set of downregulated genes reveals enrichment for, amongst others, the glucolysis/ 
gluconeogenesis pathway, the p53 signaling pathway, renal cell carcinoma, and the 
ErbB signaling pathway, amongst others (Table 2). Gene set enrichment analysis for 
GO terms for the set of downregulated genes reveals enrichment for angiogenesis 
related processes, amongst others (Table 2). Gene set enrichment analysis for KEGG 
pathways for the set of upregulated genes reveals enrichment for arginine and praline 
metabolism. Gene set enrichment analysis for GO terms for the set of upregulated 
genes reveals enrichment for homeostatic processes (Table 2). 
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T a b l e  2 .  E n r i c h e d  K E G G  p a t h w a y s  a n d  t o p  1 0  e n r i c h e d  G O  t e r m s  f o r  g e n e s  s h o w i n g  s i g n i f i c a n t l y  a l t e r e d  t r a n s c r i p t  l e v e l s  a s  a  r e s u l t  o f  S E T D 2  k n o c k d o w n .  
D o w n r e g u l a t e d  g e n e s  U p r e g u l a t e d  g e n e s  
B e n j a m i n i -
#  B e n j a m i n i -
T e r m  #  g e n e s  
%  
P - v a l u e  H o c h b e r g  Te r m  g e n e s  %  
P - v a l u e  H o c h b e r g  
E n r i c h e d  K E G G  G l y c o l y s i s / G l u c o n e o g e n e s i s  5  8 . 5  3 . 8 0 E - 0 4  2 . 2 0 E - 0 2  A r g i n i n e  a n d  
3  8 . 8  
7 . 7 0 E - 0 3  1 . 8 0 E - 0 1  
p a t h w a y s  
p r a l i n e  m e t a b o l i s m  
P 5 3  s i g n a l i n g  p a t h w a y  3  5 . 1  6 . 0 0 E - 0 2  8 . 4 0 E - 0 1  
C o m p l e m e n t  a n d  3  5 . 1  6 . 2 0 E - 0 2  7 . 1 0 E - 0 1  
c o a g u l a t i o n  c a s c a d e s  
R e n a l  c e l l  c a r c i n o m a  3  5 . 1  6 . 3 0 E - 0 2  6 . 1 0 E - 0 1  
E r b B  s i g n a l i n g  p a t h w a y  3  5 . 1  
9 . 2 0 E - 0 2  6 . 8 0 E - 0 1  
R i b o s o m e  3  5 . 1  9 . 2 0 E - 0 2  6 . 8 0 E - 0 1  
- - - - -
P r o s t a t e  c a n c e r  3  5 . 1  9 . 6 0 E - 0 2  6 . 2 0 E - 0 1  
G O  t e r m s  ( B P  _ F A T )  B l o o d  v e s s e l  d e v e l o p m e n t  
8  1 3 . 6  2 . 0 0 E - 0 5  1 . 5 0 E - 0 2  c h e m i c a l  h o m e o s t a s i s  
7  2 0 . 6  3 . 4 0 E - 0 4  2 . 0 0 E - 0 1  
G l y c o l y s i s  5  
8 . 5  2 . 0 0 E - 0 5  7 . 9 0 E - 0 3  h o m e o s t a t i c  p r o c e s s  
7  2 0 . 6  2 . 5 0 E - 0 3  
5 . 5 0 E - 0 1  
- - -
V a s c u l a t u r e  d e v e l o p m e n t  8  1 3 . 6  
2 . 3 0 E - 0 5  6 . 0 0 E - 0 3  c e l l u l a r  i o n  h o m e o s t a s i s  5  1 4 . 7  
5 . 3 0 E - 0 3  6 . 8 0 E - 0 1  
g l u c o s e  c a t a b o l i c  p r o c e s s  5  8 . 5  4 . 7 0 E - 0 5  
9 . 1 0 E - 0 3  c e l l u l a r  i o n  h o m e o s t a s i s  5  
1 4 . 7  5 . 6 0 E - 0 3  
5 . 9 0 E - 0 1  
b l o o d  v e s s e l  m o r p h o g e n e s i s  7  
1 1 . 9  8 . 4 0 E - 0 5  1 . 3 0 E - 0 2  
i o n  h o m e o s t a s i s  5  1 4 . 7  7 . 3 0 E - 0 3  
6 . 0 0 E - 0 1  
h e x o s e  c a t a b o l i c  p r o c e s s  5  8 . 5  9 . 4 0 E - 0 5  1 . 2 0 E - 0 2  r e s p o n s e  t o  d r u g  4  
1 1 . 8  8 . 0 0 E - 0 3  
5 . 7 0 E - 0 1  
r e s p o n s e  t o  h y p o x i a  6  1 0 . 2  9 . 7 0 E - 0 5  1 . 1 0 E - 0 2  r e g u l a t i o n  o f  
3  8 . 8  9 . 3 0 E - 0 3  5 . 7 0 E - 0 1  
i n f l a m m a t o r y  r e s p o n s e  
m o n o s a c c h a r i d e  5  8 . 5  
1 . 0 0 E - 0 4  1 . 0 0 E - 0 2  c e l l u l a r  h o m e o s t a s i s  
5  1 4 . 7  1 . 1  0 E - 0 2  6 . 0 0 E - 0 1  
c a t a b o l i c  p r o c e s s  
- -
r e s p o n s e  t o  o x y g e n  l e v e l s  6  1 0 . 2  1 . 2 0 E - 0 4  
1 . 1  0 E - 0 2  b e h a v i o r  
5  1 4 . 7  1 . 2 0 E - 0 2  
5 . 6 0 E - 0 1  
A r g i n i n e  a n d  p r a l i n e  3  8 . 8  7 . 7 0 E - 0 3  1 . 8 0 E - 0 1  l y m p h o c y t e  c h e m o t a x i s  
2  
5 .9 1 . 3 0 E - 0 2  5 . 8 0 E - 0 1  
m e t a b o l i s m  








AXI N 1  -
RCC1 
Alternatively # reads 
Ensemble ID skipped exon retained 
ENSG000000083 1 1  1 9  4 
ENSG0000000041 9  7 0 ---
ENSG000001 68056 24 5 
-
ENSG0000005591 7  2 1 -- --- --- --
ENSG000001 1 3456 3 
ENSG000001 03 1 26 9 
- -
ENSG000001 801 98 6' 
2 
1 1  �-- - ---
9 
Wild type SETD2 knock down 
fraction # reads fraction 
skipped retained skipped retained skipped retained skipped 
9 0.3 0.7 4 2 0.7 0.3 
1 1  0.0 1 .0 7 1 7  0.3 0.7 ---
3 0.6 0.4 34 8 0.8 0.2 -- -- - --
9 0. 1 0.9 25 37 0.4 0.6 -- - -- ---
1 1  0.2 0.8 5 
3 0.8 0.2 1 
- - -
9 0.5 0. 5 2 
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Figure 3. Correlation between the 
presence of histone modifications and 
transcript levels in proximal tubular 
sample PTEC-2A09. Box plots showing 
the distribution of transcript levels 
( log 1 0RPKM) for al l Ensembl v61 human 
transcripts in  untreated PTEC-2A09 
cel ls ,  as assessed by RNA-seq. (A) 
H3K36me3.  The H3K36me3 coverage 
was measu red as the total number of 
reads fa l l i ng  with in  gene boundaries 
normal ized by the length of the gene. 
Using the cumu lative distributive 
function (CDF), an empirical threshold 
was selected to spl it genes into subsets 
having H3 K36me3 or no H3K36me3. 
(B) H3K4me3. The H3K4me3 coverage 
was measured as the total n umber 
of reads fa l l ing with in  1 Kb up- and 
downstream of the transcription start 
site (TSS), normal ized by 2 Kb. Using 
the cumu lative distributive function 
(CDF), an empirical threshold was 
selected to spl it genes into subsets 
having H3 K4me3 or no H3K4me3 . (C) 
H3K27me3. The H3K27me3 coverage 
was measu red as the total number 
of reads fa l l ing with in  1 Kb up and 
downstream of the transcription start 
site (TSS), norma l ized by 2 Kb. Using 
the cumu lative distributive function 
(CDF), an empirical threshold was 
selected to spl it genes into subsets 
having H3 K27me3 or no H3K27me3. 
Effect of SETD2 knockdown on alternative splice site choice 
Numerous individual exons show a significant decrease (FC � -1.5, z-score :::;: -2.0) or 
increase (FC � 1 .5, z-score � 2.0) of transcript levels as a result of SETD2 knockdown, 
whereas the transcript level for the whole gene is not significantly changed. This might 
be the result of a change in alternative splice site choice. We performed a preliminary 
data analysis, and focused on genes that showed significantly altered levels for one 










Figure 4. siRNA-mediated knockdown of SETD2 in proximal tubular epithelial cells. (A) SETD2 
transcripts levels relative to the level in untreated cel ls, as assessed by RT-PCR. (B) H3K36me3 
levels as assessed by Western blot ana lysis. B lotting with anti-h istone 3 (H3) served as a loading 
contro l .  
exon. Individual reads mapping at, and around, the alternatively spliced exons were 
visualized using the Integrative Genomics Viewer (IGV) (http://www.broadinstitute. 
org/igv/). Subsequently, the ratios between the number of reads that skip the exon of 
interest and the number of reads that retain the exon of interest were assessed, and 
compared between the wildtype (WT) sample and the SETD2 knockdown (SETD2 KD) 
sample. Our preliminary data analysis revealed possible changes in alternative splice 
site choice as a result of SETD2 knockdown for AASS, Axin 1, DPM1, LTBP3, PUM2, 
RAD1, and RCC1 (Table 3). In Figure 5, the transcript levels for the different isoforms of 
RAD1 are shown. SETD2 knockdown appears to result in a shift from isoform 2 (which 
lacks exon 3) towards isoform 1 (which retains exon 3) of RAD1. All the genes that 
show differential exon usage as a result of SETD2 knockdown have a H3K36me3 mark 
in the wildtype PTEC sample, as is shown for RAD1 in Figure 5d. 
Besides the apparent change in splice site choice for some genes, we observed an 
apparent change in transcriptional start site usage as a result of decreased H3K36me3 
levels for several genes, including STK19. Knockdown of SETD2 appears to result in 
usage of a downstream alternative start site of STK19 (Figure 6). 
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Figure 5. Differential alternative 
splice site choice as a result of 
SETD2 knockdown in proximal 
tubular epithelial cell sample 
PTEC-A09. (A) Coverage profiles 
of transcript levels, generated 
from the barn alignment file (see 
Materials and Methods), and 
displayed as custom tracks on 
the UCSC genome browser. The 
profiles represent the number of 
sequence reads uniquely aligning 
to the RAD 1  gene, as assessed 
by RNA-seq. The exon-intron 
structure of RAD 1  (RefSeq) is 
shown at the bottom, with boxed 
regions and thin lines representing 
exons and intrans, respectively. 
WT: untreated PTEC sample, 
SETD2 KD: PTEC sample treated 
with SETD2 siRNA. (B) Individual  C. 
sequence reads mapping to RAD 1 ,  
- -- ti --- • --- 1111 --- .. 







Exon 4 Exon 3 Exon 2 
, 2 -- - - - --- -- - - -- - --- - -- - - - -- -- - - - - - - - - - - - - - - - - -- -- -- ----- --- --
D isoform 1 as visualized by the Integrative 
Genomics Viewer. Boxes 
represent the aligned sequence 
reads. Total coverage is shown 
on top. Reads that span d ifferent 
exons are represented by two or 
more separate boxes connected 
by thin lines . In this  example, 
several sequence reads skip exon 
3 of RAD 1  in the WT sample, 
10 - - - - - - - - - - - - - ---- -
while most of the sequence reads 
in the SETD2 knockdown sample 
show retainment of this exon. (C) 
Graph representing the number 
of seq uence reads that show 
exclusion ( isoform 2) or retainment 
(isoform 1 )  of exon 3 of RAD 1 .  (D) 
Coverage profiles for H3K36me3 
(top) and H3K4me3 (bottom) 
generated from the barn alignment 
file (see M aterials and Methods), 
and displayed as custom tracks on 
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profiles represent the number of sequence reads uniq uely aligning to the RAD 1  gene. The exon-intron 
structure of RAD 1  (RefSeq) is shown at the bottom, with boxed regions and thin lines representing exons 
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Figure 6. Differential a lternative start site usage STK1 9 as a result of SETD2 knockdown in 
proximal tubular epithelial cel l  sample PTEC-2A09. (A) Coverage profi les of transcript l evels, 
generated from the barn a l ignment fi le (see Materia ls and Methods), and disp layed as custom 
tracks on the UCSC genome browser. The profi les represent the number of sequen ce reads 
un iquely al igning to the first part of the STK1 9 gene, as assessed by RNA-seq. The exon- intron 
structure of the first part of STK1 9 (RefSeq) is shown at the bottom, with boxed regions  and 
thin l ines representing exons (numbered) and intrans, respectively. TSS:  transcription start s ite, 
TSS*: a lternative transcription start site. WT: untreated PTEC sample, SETD2 KD: PTEC sample 
treated with SETD2 s iRNA. (B) Graph representing the number of sequence reads that map 
to exon 1 or exon 2 of  STK1 9 in the untreated and SETD2 knockdown samples. (C) Coverage 
profi les for H3K36me3 (top) and H3K4me3 (bottom) generated from the barn a l ignment fi l e  
(see Materia ls and Methods), and disp layed as custom tracks on the  UCSC genome browser. 
The profi les represent the number of sequence reads un iquely a l ign ing to the STK1 9 gene.  The 
exon-i ntron structure of STK1 9 (RefSeq) is shown at the bottom, with boxed regions and th in  l i nes 
representing exons (numbered) and intrans, respectively. 
H3K36me3 in different tissue types 
We used severa l pub l ica l ly ava i lab le  data sets from Ch l P-seq experiments (inc lud ing  
G EO databases G S M 537699 (adu lt l iver) ,  GSM61 3873 (breast myoepithe l i a l  ce l ls ,  and 
GS M669597 ( left l u m ina l  epithe l ium) to  assess whether H3K36me3 modification  of  the 
investigated genes was specific for proxima l  tu bu lar  epithe l i um .  None of the a bove 
genes appeared to have a H3K36me3 mark specifica l ly  in  proximal  tu bu la r  epithe l i a l 
ce l ls (data not shown). 
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DISCUSSION 
Inactivation of SETD2 has been suggested to be specific for clear cell renal cel l  
carcinoma (Dalgliesh et al., 2010). This might indicate the presence of H3K36me3 o n  a 
subset of genes specifically in proximal tubular epithelial cells. A change in transcription 
or transcription-related processes for these genes as a result of H3K36me3 loss might 
contribute to ccRCC development. As expected, the H3K36me3 profiles in PTECs are 
largely similar to those in other tissues. However, adult kidney and proximal tubular 
epithelial cells did show differences in their H3K36me3 profiles for a small subset of 
genes. Some of these genes are specifically expressed in endothelium cells, that are 
present in adult kidney, showing that a subset of genes has tissue-specific histone 
marks. Comparison of the H3K36me3 profiles of PTECs with other epithelial cells may 
identify a set of genes that specifically carry a H3K36me3 mark in PTECs. As an initial 
step, the analysis of bronchial epithelial cells will be carried out. 
Transient siRNA-mediated knockdown of SETD2 in proximal tubular cells, which 
resulted in a significant decrease in global H3K36me3 levels (Figure 4), results in 
significantly increased transcript levels of 33 genes and significantly decreased 
transcript levels of 55 genes. The set of downregulated genes showed a significant 
enrichment for genes that function in angiogenesis-related processes (Table 2). This 
is in concordance with the observation that SETD2 is required for embryonic vascular 
remodeling (Hu et al., 2009). The enrichment of genes that are involved in the p53 
signaling pathway might imply that SETD2 does indeed function in regulating a subset 
of P53 target genes (Xie et al., 2009). For most of the genes, it remains unclear if the 
observed changes in transcript levels are a direct result of SETD2 knockdown.  The 
observation that H3K36me3 is virtual ly absent on DEFB1 and C2CD4A in the PTEC 
sample implies that the observed increased transcript levels for these genes are not 
the result of loss of H3K36me3. 
Several individual exons show a significant decrease of transcript levels as a 
result of SETD2 knockdown, whereas the transcript level for the whole gene is not 
significantly changed. This might be the result of a change of an alternative splice 
site choice. Our preliminary data analysis revealed an apparent change in alternative 
splice site choice as a result of SETD2 knockdown for seven genes (Table 3). This 
indeed suggests the involvement of H3K36me3 in alternative splice site choice for 
at least a subset of genes. However, we did not confirm the changes in alternative 
splicing as a result of the modulation of H3K36me3 levels for FGFR2, TPM1, TPM2, 
and PKM2 that were observed by Luco et al. (2010) in this study. TPM1 and PKM2 are 
in our list of genes that show significant changes in the expression of an individual 
exon, while not showing differential transcript levels for the whole gene. This might 
indicate that alternative splice site choice for these genes has indeed changed as a 
result of SETD2 knockdown. However, due to numerous reads mapping to the intronic 
regions of these genes, we could not rel iably assess the numbers of reads skipping or 
retaining the exons concerned. FGFR2 did not show detectable transcript levels, and 
TPM2 did not show any detectable change in alternative exon usage (data not shown). 
Our preliminary data analysis also revealed a set of genes for which H3K36me3 
downregulation appears to result in change of their transcriptional start site. The 
observed changes should be treated with caution, as most of the transcripts show a 
lower coverage towards the 5' end, probably as a result of mRNA degradation, which 
in most cases starts in the 5' region of an mRNA molecule. The apparent changes 
in transcriptional start site usage could therefore be false-positives, due to low 
coverage. Either way, a possible link between H3K36me3 and intragenic transcription 
in mammals was recently provided by Xie et al. (2011). They showed that recruitment 
of histone demethylase KDM5B to H3K36me3 via interaction with chromodomain 
protein MRG15 decreased intragenic H3K4me3, resulting in suppression of cryptic 
intragenic transcription (Xie et al., 2011 ). 
Several of the genes that show changes in alternative exon usage are interesting 
with respect to tumorigenic development. LTBP3 plays a critical role in TGF-13 signaling 
(Hyytiainen et al. , 2004) lsoform 1 and 2 of LTBP3 are predominantly expressed in 
different tissue types, suggesting different functions in cellular regulation for these 
different isoforms. Axin 1 is a negative regulator of WNT-signaling. The observed 
shift from isoform 1 towards isoform 2 of Axin 1 has been previously observed in 
ovarian tumors (Klinck et al. , 2008). PUM2 and RAD1 code for proteins that control 
cell cycle entry (Kedde et al., 2010) and play a role in DNA repair (Zhang et al., 2011 ),  
respectively. So, given their function, deregulation of several of these genes could 
potentially contribute to ccRCC development. At the moment, knockdown experiments 
in additional PTEC samples are ongoing to confirm the role of SETD2/H3K36me3 in the 
choice of alternative splice site or start site for these genes. Additional studies will be 
needed to assess the relevance of these altered splicing events with respect to ccRCC 
development. Comparing the abundance of different isoforms between large numbers 
of ccRCC tumor samples and normal renal epithelial samples could provide clues about 
the fraction of ccRCC tumors in which these altered splicing events play a role. The 
genes for which we observed a change of alternative splice site selection or a change 
in alternative transcription start site all have a H3K36me3 mark in proximal tubular 
epithelial cells. However, the mark appeared not to be specific for proximal tubular 
epithelial cells, as H3K36me3 is also present on these genes in several other tissue 
types, including breast epithelium. There might, however, be more subtle differences in 
the local amount of H3K36me3 levels between proximal tubular epithelial cells and the 
other tissue types. The resolution of our H3K36me3 ChlP-seq data is not sufficient to 
detect these subtle differences. Another possibility is that, although the gene carries a 
H3K36me3 mark in several tissues, the change in exon usage has a tumorigenic effect in 
proximal tubular epithelial cells, but not in other cell types. Either way, additional data 
are being collected to further analyze H3K36me3 positions in PTEC samples and to 
compare them with those in other tissue types, such as bronchus epithelial cells. 
H3K36me3 is present on the "body" of genes that are transcribed by RNA 
Polymerase II ,  i.e . ,  a majority of actively transcribed protein coding genes (Edmunds 
et al., 2008). However, SETD2 knockdown in proximal tubular cells appears to affect 
the processing of only a limited number of target genes. One reason might be that 
the RNAi-mediated knockdown of SETD2 was not sufficient. Although the global 
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H3K36me3 level appears to be strongly decreased (Figure 4), the residual H3K36me3 
levels might be sufficient to result in the "normal" processing of most of the target 
genes. The ongoing experiments should reveal whether a stronger and/or prolonged 
knockdown of SETD2 and H3K36me3 levels indeed has a stronger effect on transcript 
levels, alternative splice site choice, or choice of transcr iptional start site for numerous 
additional target genes. 
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SUPPLEMENTARY TABLES 
Supplementary Table S1. Ch l Pseq statistics 
Percent Percent 
Sample mark total reads a l igned used al igned used 
PTEC-2A09 H3K27me3 1 33525 1 8  948 1 829 8735566 7 1 .0 65.4 
PTEC-2A09 H3 K36me3 1 1 988678 8805572 7421 825 73.4 6 1 .9 - -- --
PTEC-2A09 H3K4me3 1 2041 542 7904654 7044424 65.6 58.5 
HEK293 H3K36me3 46 1 1 6644 3 1 1 5081 6 28206308 67.5 6 1 .2 
Used: reads that passed qua l ity treshhold (QC=S), and dupl icated reads are col lapsed 
Supplementary Table S2. RNAseq statistics 
Tota l  number 
Sample of reads 
PTEC-2A09 (WT) 1 59681 542 
PTEC-2A09 (SETD2 KD) 1 8362241 6 
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Mapped to 
hg1 9  
1 36292574 
1 56 1 92275 
Number Mapped into Mapped i nto 
of reads Ensembl v61 Ensembl v61 
passing QC exons genes 
44977 1 20 1 1 1 1 8028 20976657 
56099498 1 1 95641 8 27 1 9253 1 
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ABSTRACT 
Clear cel l  renal cell carcinomas are characterized by loss of 3p. VHL, located at 
3p25, is a major ccRCC tumor suppressor gene and is inactivated in the majority of 
cases. However, inactivation of VHL alone is not sufficient for ccRCC development, 
but rather induces senescence. Recently, SETD2, located at 3p21, was identified as a 
new candidate tumor suppressor gene in ccRCC. Its observed mutational frequency 
in ccRCC tumors suggests however there are still undiscovered tumor suppressor 
genes on 3p. We therefore screened all genes on 3p for mutations in ten primary 
ccRCC tumors using targeted capturing followed by high-througput sequencing. We 
identified inactivating mutations in VHL and PBRM 1 in six and seven out of ten cases, 
respectively, pinpointing PBRM 1 as a candidate ccRCC tumor suppressor gene. In one 
primary tumor, we identified a truncating mutation in BAP1 .  Sequencing of PBRM 1 
in ccRCC-derived cell lines confirmed its frequent inactivation in ccRCC. PBRM 1 and 
BAP1 ,  which are both located at 3p21, code for BAF1 80, the chromatin targeting 
subunit  of the SWI/SNF complex, and BRCA 1 associated protein-1, which is involved 
in histone deubiquitination, respectively. 
Taken together, these data suggest an important role for aberrant chromatin 
regulation in ccRCC development. 
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INTRODUCTION 
Clear cell renal cell carcinoma (ccRCC) tumors show a different mutational spectrum 
compared to most other tumor types. In the majority of cases, the tumor suppressor 
gene Von Hippe/ Lindau (VHL) is inactivated, while classical tumor genes like P53, 
PTEN, KRAS, BRAF, RB and EGFR2 make only a small contribution [Dalgliesh et al. , 
2010]. Although VHL is a major tumor suppressor gene in ccRCC, its inactivation alone 
does not result in ccRCC development, but rather induces senescence [ Mandriota et 
al., 2002; Young et al., 2003]. This suggests that there are other genes involved in the 
development of ccRCC. 
The main focus in the search for these genes has been on segments of the short 
arm of chromosome 3 (3p) that show recurrent loss in ccRCC tumors, suggesting 
the presence of tumor suppressors in these regions. These regions include 3p25, in 
which VHL is located, and 3p21, which is the site of, until recently, unidentified tumor 
suppressor genes [Van den Berg et al. , 1997]. 
Recently, the histone methyltransferase gene SETD2, located at 3p21.31, was 
identified as a new candidate tumor suppressor gene involved in ccRCC development 
[Dalgliesh et al, 201 O; Duns et al. , 2010]. The identification of inactivating mutations 
in additional genes coding for histone modifying enzymes (JAR/D1C, UTX, MLL2) in a 
subset of ccRCC tumors points to a role of aberrant histone modulation in at least a 
fraction of ccRCC samples [Dalgliesh et al. , 201 0] . The observed mutational frequency 
of SETD2 in ccRCC tumors suggests however that this gene may not be the sole tumor 
suppressor gene in the 3p21 region. Here we describe the screening of all exons, 
exon-intron boundaries, and untranslated regions from 3p for mutations in a panel 
of ten primary ccRCC tumors, using targeted capturing followed by a high-troughput 
sequencing approach. 
MATERIAL AND METHODS 
Tumor samples and cel l  l ines 
Primary ccRCC tumor samples were snap-frozen in liquid nitrogen , section s  were 
cut and the histology was reviewed by one pathologist (H. Hollema). Tissue biopsies 
containing at least 70% tumor cells were selected for analysis. The characteristics of 
these ccRCC-derived cell lines were described earlier [Duns et al. , 201 0].  
S N P  analysis 
We used the Human CytoSNP-12 BeadChip ( l llumina, San Diego, CA, USA) to assess 
3p copy number loss in a panel of 13 primary clear cell renal cell carcinoma tumors 
following the manufacturer's instructions. Data were analysed using NEXUS v6.0 
(Biodiscovery, El Segundo, CA, USA). 
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Exome capture desig n and l ibrary preparation 
We developed a custom-designed SureSel ect kit (Agilent, Santa Clara, CA, USA) 
containing, at a 2x coverage, baits for 541 3p genes, UTX, JARID 1 C, TP53 and ISW 
(approximately 6000 exons) inc luding their 3' UTRs and 5 ' UTRs, and for all miRNAs 
from 3p. The set in total covered 2 Mb of sequences. 
Genomic l ibrary preparation targeted exome capture 
Genomic DNA was isolated from primary ccRCC tumor tissue using the Oiamp DNA 
Mini Kit (Oiagen, Venlo, The Netherlands) and size-fragmented by Adaptive Focused 
acoustics on a Covaris E120 (Covaris Inc, Woburn, Massachusetts, USA) (duty cycle: 
10%, intensity: 5, cycles per burst: 20, time: 180 s) to a median size of 200 bp. 
Fragmented DNA was purified using Oiaquick PCR purificaton columns. Genomic 
libraries were prepared using the NEBNext sample preparation kit following the 
manufacturer's instructions (NEB, Ipswich, UK). Adaptors were ligated to the end­
repaired and dA-tailed D NA fragments using an ll lumina Index PE adaptor oligo mix 
( l l lumina). Adapter- l igated D NA fragments were subsequently size- selected (300-350 
bp) using E-gel® Clonewell system ( lnvitrogen, Carlsbad, CA, USA). Size selected 
adapter-ligated libraries were amplified following the Phusion-high-fidelity-MM 
protocol (NEB). 500 ng of each amplified adapter-ligated library was hybridized to baits 
using the SureSelect Target Enrichment System for paired-end multiplex sequencing 
( l llumina). Hybridized D NA fragments were purified using AM Pure beads (Agencourt 
BioSciences Corporation, Beverley, MA, USA). lndex-barcode tags were added by 
post-hybridization amplification ( 12-14 cycles) following the Phusion-high-fidelity-MM 
protocol (NEB). Quality and quantity of fragmented DNA samples and libraries were 
assessed using Experian DNA 12K analysis kit (Bio-Rad, Hercules, CA, USA). 
Sequencing 
Enriched barcoded libraries were sequenced with 1 00 bp paired- end reads across one 
lane of an ll lumina HiSEQ 2000 flowcell ( l llumina). The sequence reads were analyzed 
using the CLC BIO Genomic Work Bench Suite 4.5 (CLC BIO, Arhus, Denmark). After 
trimming low quality sequences, reads were aligned against c hromosome 3 (GRCh37. 
p2 primary reference assembly). 
Variant ca l l i ng 
We used DIP and SNP analysis tools in CLC bio to identify putative inde ls and single  
nucleotide changes (quality central base = 20, average quality of  surrounding bases = 
15, maximum number of gaps and mismatches = 2). 
The list of putative variations was shortened by discarding those present in: (1) the 
dbSNP and/or 1000 Genome Project databases, (2) more than one sample, (3) 100 % 
of reads, or those that were (4) intergenic, i.e. not in an annotated gene. Furthermore, 
only putative variants present in paired reads were selected, as these reads have a 
high probability of being match ed correctly. The functional impact of mutations was 
predicted using Alamut (Interactive Biosoftware, Rouen, France), NetGene (http:// 
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www.cbs.dtu .dk/services/NetGene2/) and the Berke ley Drosoph i la Genome Project 
(http://www.fruitfly.org/seq_too ls/spl ice. htm l ) .  
Mutation screening 
PCR primer sets were designed to confi rm putative mutations found in VHL, PBRM1, 
BAP1 and ZNF197. I n  addition, 36 primer sets were designed to screen our pane l  
of ccRCC-derived ce l l  l i nes for mutations in the cod ing exons and exon- intron 
boundaries of VHL and PBRM1. Ampl ified PCR products were purified usi ng EXOSAP 
IT (G E Hea lthcare,  Litt le Cha lfont, Buckinghamsh ire ,  U K) and sequenced using B igDye 
Term inator chem istry (Appl ied Biosystems, Foster City, CA, USA) . Reaction products 
were run on the AB l 3 1 30XL Genetic Ana lyzer (Appl ied Biosystems). Sequences were 
eva luated using Mutation Surveyor (SoftGenetics LCC, State co l l ege, PA, USA) . Primer 
sequences a re ava i l able u pon request. 
RESULTS AND DISCUSSION 
S N P  analysis 
SNP  array ana lysis on 1 3  ccRCC tumors revea led an a l le l l i c  i mba lance of 3p, most l i ke ly  
indicating copy number loss, in ten tumors .  Seven primary ccRCC tumors appeared to 
have lost the entire short a rm of chromosome 3 (3p). Tumor samples T-b, T-c and T-d 
had copy number loss of part of chromosome 3, with a segment of overlap from pter 
to 64.0 Mb  re lative to pter, which inc l udes the 3p2 1 and 3p25 regions (Supp. F ig .  5 1  ) .  
3p  exome sequencing 
We conducted partia l  resequencing of the DNA from the ten primary ccRCC tumors 
that showed loss of 3p.  We enriched for a l l  m icroRNAs and a l l  exons, exon- intron 
boundaries, 5 'UTRs and 3'UTRs of 542 genes located on the short arm of chromosome 
3 and  fou r  additiona l  genes (UTX, JAR/D1C, TP53 and  /S\1\/), representing a tota l of 
2 . 1  Mb bases. Sequencing resu lted in an average of 8.7 m i l l ion pa ired-end reads per 
sample that cou ld  be a l igned aga inst chromosome 3 (G RCh 37 .p2) and to the genomic 
segments of UTX, JAR/D1C, TP53 and /SW. Variant ca l l i ng and qua l ity fi ltering ,  which 
is described in the Materia ls  and Methods section ,  resu lted in a l i st of 203 un ique  
putative variations in 1 36 genes (Supp.Tab le 5 1 ) . These i nc l ude  1 1  inde ls introduc ing 
a framesh ift, 3 inframe inde ls, 46 m issense mutations, 2 mutations that were pred icted 
to affect spl icing ,  7 va riations affecting a 5 'UTR, 59 mutations affecting a 3 'UTR, 52 
i ntron ic m utations with unknown effect and 23 synonymous m utations. (Supp .Tab le  
5 1 ) . The mutations i n  VHL, PBRM1, BAP1 and ZNF197 were confi rmed us ing  cap i l l a ry 
Sanger sequencing (Supp. Fig .52). 
VHL and PBRM1 are the only genes that show truncating m utations i n  more than 
one primary ccRCC tumor sample .  Notab ly, because a l l  the tumor samples showed 
loss of one copy of 3p, these hem izygous mutations resu lt in complete loss of the 
functiona l  protei ns. We identified five pathogen ic mutations in VHL. Fra mesh ift 
introducing mutations in VHL were identified in th ree out of ten primary tumors .  
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Tumor T-a shows a missense mutation in VHL that affects the P- domain and which 
is predicted to affect protein function and tumor T-j shows an exonic mutation which 
results in loss of a donor splice site (Supp.Table S1 ). 
Seven out of the ten primary ccRCC tumors proved to have mutations in PBRM1. 
Five of them are truncating mutations. In addition, we identified a missense mutation 
in PBRM1 affecting a bromodomain and predicted to be pathogenic in tumor T-h and 
a splice site mutation resulting in loss of an acceptor site in tumor T-a (Fig. 1, Supp. 
Table S1). 
' 
NH2� I 8D1 
1 1  
1 
Figure 1 .  PBRM1 mutations in ccRCC samples. Schematic representation of PBRM 1 with 
arrows showing the locations of the mutations and the corresponding amino acid changes. 
Red: truncating mutations. Black: missense mutations. Underscored: mutations in primary tumor 
samples. BD: Bromo domain ,  BAH: bromo-adjacent  homology domain, HMG: high mobility 
group. Fs: frameshift. National Center for Biotechnology Reference Sequence: NP _060635.2 
We did not identify mutations in SETD2 (3p21 ), JAR/01 C or UTX in this screen, nor 
did we detect mutations in the tumor suppressors TP53, MLH1, or other candidate 
tumor suppressors from 3p including FHIT, TUSC2, and FOXP1. 
We previously identified four inactivating mutations in SETD2 in our panel of ten 
ccRCC-derived cell lines [Duns et al. ,  201 0]. Capillary Sanger sequencing now revealed 
inactivating mutations in PBRM1 and VHL in five and six ccRCC cell lines, respectively 
(Fig. 1, Supp. Fig. S3, Supp.Table S2). Four primary tumor samples and four cell l ines 
had inactivating mutations in both VHL and PBRM1 (Table 1) . Three cell lines showed 
inactivation of SETD2, PBRM1 and VHL (Table 1). This suggests that inactivation of 
these genes affects separate pathways that all contribute to ccRCC tumorigenesis. 
VH L regulates the cellular response to oxygen availability in the local 
microenvironment. Under normoxic circumstances, VHL targets the transcription 
factor Hypoxia inducible factor a (HI Fa) for proteosomal degradation. Inactivation 
of VHL results in consistently high HIFa levels, resulting in upregulation of HIF 
targets, which include Vascular endothelial growth factor (VEGF) and Platelet derived 
growth factor (PDGF). Binding of these ligands to their cognate receptors activates 
a series of kinase-dependent signaling pathways including the RAF-MEK-ERK and 
Phosphatidylinositol-3 kinase-AKT-mTOR pathways, triggering angiogenesis and 
proliferation [Clark, 2009]. 
The functions of SETD2 and PBRM1 in tumorigenesis are less well understood. 
The histone methyltransferase SETD2 is responsib le for trimethylation of lysine 36 
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Table 1 .  Overview mutations in VHL, PBRM1 , SETD2, BAP1 and ZNF1 97 in ccRCC-derived cel l  l ines and primary ccRCC tumors. 
Primary ccRCC tumors 
Gene Refseq ID a 
PBRM1  N M_0 1 8 1 65.4 Spl ice site 
VH L N M_00055 1 .2 m issense 
S ETD2 N M_01 41 59.6 
BAP1 N M_004656.2 --- --
ZN F1 97 N M_006991 .3 
ccRCC derived cell l ines 
b c d e f g h 
_ _ __ ins 1 bp del 1 bp ins 1 bp del  1 bp missense del 1 bp 
del  2 bp 
--'-------
ins 1 bp del 4 bp Sp l ice site 
del 1 bp  ----
del 4 bp 
Gene Refseq ID  1 4 5 AB ER FG2 HS JF  JW M F  
PBRM 1 N M_0 1 8 1 65.4 ins 1 bp del 4 bp Nonsense m isse_n_se ___ ____ _ del  1 bp -- --
VH L N M_0005 5 1 . 2  ins 37 bp m issense _____ del 1 bp del 1 bp ins  6 bp missense 
S ETD2 N M_01 41 59.6 
ins : insertion ,  del : deletion, bp:  basepai r(s) 
del 1 bp Nonsense Loss 3 
exons 
m issense del 9 bp 
on histone 3 (H3K36me3), a modification which is associated with transcriptionally 
active genes and which has been suggested to play a role in transcriptional elongation 
and the regulation of alternative splicing of target genes [Luco et al . ,  2010]. SETD2 
inactivation appears to be unique for ccRCC tumors, suggesting a tumor suppressive 
function of SETD2 specifically in proximal tubular epithelial cel ls  [Dalg liesh et al., 201 0; 
Duns et al . ,  201 0]. In this screen, we did not identify inactivating mutations in SETD2. 
PBRM1 is located at 3p21 and encodes the Polybromo 1 (BAF180) protein, which 
is the chromatin targeting subunit of the Polybromo complex SWI/SNF [Thompson, 
2009]. SWI/SNF complexes are large ATP-dependent chromatin-remodeling machines 
that change the accessibility of DNA by controlling the dynamics of nucleosome 
occupancy [Reisman et al. ,  2009]. Several SWI/SNF components have previously been 
shown to be involved in cancer development: inactivating mutations in SMARCB 1 and 
AR/D 1A have been identified in rhabdoid tumors and ovarian carcinomas respectively 
[Reisman et al., 2009; J ones et al., 2010]. Inactivating mutations in BRG 1 have been 
identified in several tumor types [Rodrig uez-Nieto et al., 2011; Schneppenheim et al. ,  
2010], while truncating m utations in PBRM 1 have been described previously in breast 
cancer samples [Xia et a l . ,  2008]. 
The role  of SWI/SNF complexes in tumor suppression is poorly understood. SWI/ 
SNF components target several genes and signaling pathways that are involved in cell 
proliferation and cancer, incl uding the Wnt, ErbB, p53, MAPK and insulin signaling 
pathways, and in processes such as DNA repair, cell cycle regu lation and apoptosis 
[Euskirchen et al., 2011 ]. PBRM 1 plays a role in coordinating senescence by reg u lating 
the transcriptional activity of a subset of p53 target genes [Burrows et al . ,  201 0], and 
has been suggested to be involved in the cel l ular response to hypoxia [Kenneth et al., 
2009]. 
The identification of inactivating mutations in PBRM 1 in primary ccRCC tumors and 
ccRCC-derived cell lines confirms the recent findings of Varela et a l, who sequenced 
the whole exome of seven primary ccRCC tumors and corresponding normal tissue, 
and identified somatic truncating mutations in PBRM 1 in four of them [Varela et al . ,  
2011]. Mutational screening of PBRM 1 using capillary-based sequencing in a total of 
227 primary ccRCC tumors revealed inactivating mutations in 91 (41 %) of them. The 
frequency and nature of the mutations in PBRM 1 in ccRCC tumors suggest that it is 
a major ccRCC tumor suppressor gene. This points to an important role for aberrant 
chromatin regulation in the development of ccRCC and proves the longstanding 
hypothesis that 3p21 is the location of a major tumor suppressor gene. 
We identified truncating mutations in two additional genes: ZNF1 97 and BAP1  
(Table 1 ,  Supp.Table S1). BAP 1 ,  located at  3p21.31 and coding for BRCA 1 associated 
protein-1, is especial ly interesting with respect to ccRCC pathogenesis. BAP1 mediates 
deubiquitination of histone H2A and HCHC1, and is involved in the transcriptional 
control of genes reg ulating cell growth and proliferation [Yu et al., 201 0]. Frequent 
mutations in BAP7  have been identified in metastizing uveal melanomas and 
malignant pleural mesothelioma [Harbour et al., 2010; Bott et al., 2011 ]. A role for 
BAP1  inactivation in a subset of ccRCC tumors would be consistent with the emerg ing 
role of aberrant chromatin regu lation in ccRCC. BAP1  was not included in the screen 
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by Dalgliesh et al, and no inactivating mutations were identified in the seven ccRCC 
tumors sequenced by Varela et al [Dalg liesh et al., 201 O; Varela et al., 2011 ]. Mutational 
screening of BAP1 in a larger panel of ccRCC tumors should therefore give a better 
estimate of the frequency of inactivation in ccRCC. 
ZNF197 belongs to the zinc finger protein superfamily, members of which are 
regulatory proteins characterized by nucleic acid-binding zinc finger domains. 
Alternative isoform 2 of ZNF197 lacks these zinc finger motifs and codes for a protein 
that has been shown to bind to pVHL and negatively regulate HIF-1-a transactivation [Li 
et al. ,  2003]. Inactivation of ZNF197 might therefore be redundant to VHL inactivation. 
The mutation in ZNF197 was identified in a sample in which no VHL mutation was 
identified (Table 1 ). 
ccRCC genetics 
ccRCC genetics appears to be dominated by inactivation of two tumor suppressor 
genes, VHL and PBRM1, as the majority of primary ccRCC tumors and ccRCC derived 
cell lines have inactivating mutations in VHL and/or PBRM1. Other genes, including 
SETD2, JAR/D1C and UTX, appear to play a role in a smaller subset of ccRCC tumors 
[Dalgliesh et al., 2010]. We did not identify inactivating mutations in these genes 
in our panel of primary ccRCC tumors, nor did we detect any mutations in several 
other (candidate) tumor suppressor genes. Several of our ccRCC derived cell lines 
show concomitant inactivating mutations in VHL, PBRM1 and SETD2, suggesting that 
inactivation of these genes is functionally nonredundant. Further research is needed 
to define the specific roles of VHL, PBRM1 and SETD2 in ccRCC tumorigenesis. Our 
ccRCC-derived cell lines, with their known mutational status for these 3 genes, are 
ideal tools for performing further research. 
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Supplementary Figure 1 .  3p copy number loss in primary ccRCC tumors assessed by SNP 
arrays. Red l ines: regions showing chromosomal loss. B lue horizonta l l ines: regions showing 
chromosomal ga in .  Purple l i ne: regions showing imba lance. 
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Supplementary Figure 2. Confirmation mutations identified by exome sequencing in PBRM1 
(a-g), VHL (h-1), BAP1 (m) and ZNF1 97 (n) by capillary Sanger sequencing. A. Sequence ana lysis 
of part of PBRM 1 .  ( 1 )  Wild type. (2) Tumor T-a ,  showing an intronic mutation affecting a spl ice site 
(NM_01 8 1 65.4:c.3082-1 G>A) (*). B. Sequence ana lysis of part of PBRM 1 .  ( 1 )  Wild type. (2) Tumor 
T-d,  showing a 1 bp insertion introducing a framesh ift resu lting in  a premature term ination codon 
(NM_0 1 8 1 65.4:c3664dup, p . l l e 1 222AsnfsX5) (*) C. Sequence ana lysis of part of PBRM 1 .  ( 1 ) Wi ld 
type. (2) Tumor T-e,  showing a 1 bp deletion introducing a framesh ift resu lting in a prematu re 
term ination codon (NM_0 1 8 1 65.4 :c1 846del, p .Ser6 1 6LeufsX8) (*) D. Sequence ana lysis of 
part of PBRM 1 .  ( 1 )  Wi ld type. (2) Tumor T-f, showing a 1 bp insertion introducing a framesh ift 
resu lting in a premature term ination codon (NM_0 1 8 1 65.4 :  c. 1 491  dup, p .Va l498CysfsX3) (*). E. 
Sequence ana lysis of part of PBRM 1 .  (1 )  Wi ld type. (2) Tumor T-g ,  showing a 1 bp deletion 
introducing a frameshift resu lt ing in  a premature termination codon (NM_01 8 1 65.4 :c3302del ,  
p.Asp1 1 0 1 ValfsX26) (*). F. Sequence ana lysis of part of PBRM 1 .  ( 1 ) Wi ld type. (2)  Tumor T-h ,  
showing a m issense mutation (NM_01 8 1 65 .4 :  c.724T>C, pTyr242His) (*). G.  Sequence ana lysis 
of part of PBRM 1 .  ( 1 )  Wild type. (2) Tumor T-j , showing a 1 bp deletion introducing a framesh ift 
resu lting in a premature termination codon (NM_0 1 8 1 65.4:c .446del ,  p .Asn 1 49MetfsX25) 
(*). The observed additiona l  upstream framesh ift is the resu lt of an intronic 1 bp deletion .  H. 
Sequence ana lysis of part of VHL. ( 1 ) Wild type. (2) Tumor T-a,  showing a m issense mutation 
(N M_00055 1 .2:c.349T>G,p.Trp1 1 7G ly) (*). I. Sequence ana lysis of part of VHL. ( 1 ) Wild type. (2) 
Tumor T-b ,  showing a 2 bp deletion introducing a framesh ift resu lting in a premature term ination 
codon (NM_00055 1 .2:c .49 1 -492del , p .G l n 1 64ArgfsX9) (*) .  Additiona l  mutation : c.493G>C. 
J. Sequence ana lysis of part of VHL. ( 1 )  Wi ld type. (2)  Tumor T-e,  showing a 1 bp insertion 
introducing a frameshift resu lting in a premature term ination codon (N M_00055 1 .2 :c .346dup, 
p . Leu 1 1 6ProfsX1 6) (*). K. Sequence ana lysis of part of VHL. ( 1 ) Wi ld type. (2) Tumor T-g ,  
showing a 4 bp deletion i ntroducing a frameshift resu lting in  a prematu re term ination codon 
(N M_000551 .2 :c401 -404del ,  p.G l u 1 34AspfsX24) (*) . L. Sequence ana lysis of part of VHL. ( 1 ) Wild 
type. (2) Tumor T-j ,  showing a 1 bp deletion affecting a spl ice site (N M_00055 1 .2 :c.463+ 1  del) 
(*) M.  Sequence ana lysis of part of BAP1 .  ( 1 )  Wi ld type. (2) Tumor T-b, showing a 1 bp insertion 
introducing a framesh ift resu lting in a premature term ination codon (NM_0004656.2 :c870del, 
p.Asn290LysfsX45) (*) N. Sequence ana lysis of part of ZNF1 97. ( 1 ) Wi ld type. (2) Tumor T-f, 
showing a 4 bp deletion i ntroducing a frameshift resu lting in a premature termination codon 
(N M_00699 1 .3 :c . 1 339- 1 342del ,  p . l le447Th rfsX22) (*) . 
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Supplementary Figure 3. Mutations in PBRM1 (a-e) and VHL (f-k) in ccRCC derived cel l l ines 
identified by capil lary Sanger sequencing. A. Sequence ana lysis of PBRM 1. ( 1 ) Wild type. (2) . 
RCC-4, showing a 1 bp insertion introducing a framesh ift result ing in a premature term ination 
codon (NM_01 8 1 65.4:c2592dup, p .H is865Th rfsX4) (*). B. Sequence ana lysis of PBRM 1 .  ( 1 )  Wi ld 
type . (2) .  RCC-ER, showing  a 4 bp deletion introducing a frameshift resulting in  a premature 
term ination codon (N M_01 8 1 65.4:c753-756del ,  p.Asp25 1 G lufsX3 1 )  (*). C. Sequence ana lysis  of 
PBRM 1.  ( 1 ) Wi ld type. (2) RCC-FG2, showing  a nonsense mutation (NM_0 1 8 1 65.4:c1 333C>T, 
pG ln445X) (*). D.  Sequence ana lysis of PBRM 1 .  ( 1 ) Wi ld type. (2) RCC-HS, showing a missense 
mutation (NM_0 1 8 1 65 .4: c.3386G> T, pGly1 1 29Val) (*) . E. Sequence ana lysis of PBRM 1.  
( 1 ) Wi ld  type. (2) RCC-MF, showing a 1 bp deletion introducing a framesh ift resulting  i n  a 
premature term ination codon (N M_0 1 8 1 65.4 :c1 487del ,  p .Asn496MetfsX4)(*). F. Sequence 
analysis of VHL. ( 1 ) Wi ld type. (2) RCC- 1 , showing a 37 bp i nsertion i ntroducing a frameshift 
resu lt ing in a premature term ination codon (N M_00055 1  .2 :c458-459ins37, p . Pro 1 54CysfsX2) 
(*) G. Sequence ana lysis of VHL. ( 1 ) Wi ld type. (2) RCC-4, showing a m issense mutation 
(N M_00055 1 .2 :  c . 1 94C>G, pSer65Trp) H. Sequence ana lysis of VHL. ( 1 ) Wild type . (2) RCC-ER,  
showing a 1 bp deletion i ntroducing a frameshift resulti ng i n  a premature term ination codon 
(N M_000551 .2 :c482del ,  p.Asp1 43AlafsX1 6) (*) . I .  Sequence ana lysis of VHL. ( 1 )  Wild type. (2) 
RCC-FG2, showing a 1 bp deletion introducing a framesh ift resu lt ing in a premature term ination 
codon (N M_000551 .2 :c .444del ,  p .Phe 1 48LeufsX1 1 )  (*). J. Sequence ana lysis of VHL. ( 1 )  Wi ld 
type. (2)  RCC-JW, showing an i nframe 6 bp insertion (N M_00055 1 .2 :c .328-444insGCATCA, 
p .H is 1 1 0del insArg l l eAsn) (*) . K. Sequence ana lysis of VHL. ( 1 ) Wi ld type. (2) RCC-MF, showing  a 
missense mutation (NM_000551 .2 :c .236C> T, p . Pro86Ser) (*) . 
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Refseq Tumor 
NM_01 6006 T-a 
NM_01 6006 T-c 
NM_1 82920 T-c 
NM_001640 T-a 
NM_01 2096 T-b 
NM_001 1 42733 T-b 
NM_001 1 2861 5 T-g 
NM_01 9555.2 T-i 
NM_006321 T-b 
NM 001 025068 T-g 
N M_01 6300 T-g 
NM_001 1 4491 2. 1  T-e 
NM_000333 T-b 
NM_000333 T-g 
N M_001 1 28 1 49 T-b 
NM 004656.2 T-b 
N M_004656.2 T-j 
NM 003458 T-a 
NM_01 62 1 0  T-b 
NM_00 1 1 45030 T-h 
NM_001 005505 T-c 
NM_001 005505 T-e 
N M_00 1 005505 T-i 
NM_01 8398 T-i 
N M_01 8398 T-h 
N M_1 53 1 84 T-d 
NM_1 53 1 84 T-d 
NM_01 4296 T-i 
NM_001 234 T-i 
NM 033337.2 T-h 
N M_1 781 73.3 T-h 
NM_001 01 2506 T-j 
NM_00101 2506.4 T-g 
NM_001 837 T-a 
Mutation 
Sanger seq type genomic location 
not performed missense 4374391 4 
not performed missense 43743774 
not performed 3'UTR 64501 7 1 9  
not performed intronic 497 1 5 1 23 
not performed 3'UTR 57303851 
not performed intronic 57303851 
not performed intronic 567791 70 
not performed missense 56787540 
not performed intronic 49004749 
not performed 3'UTR 357268 1 7  
not performed intronic 3572681 7  
not performed missense 1 1 383650 
not performed 3'UTR 639851 57 
not performed 3'UTR 6398651 4 
not performed missense 639851 57 
Confirmed Frameshift 52439842 
not performed intronic 52436770 
not performed missense 49691 434 
not performed 3'UTR 5059637 1 
not performed synonymous 44328924 
not performed 3'UTR 50401 376 
not performed 3'UTR 50400737 
not performed 3'UTR 50401 336 
not performed intronic 54354624 
not performed synonymous 5 5 1 07571 
not performed 3'UTR 861 1 76 1 8  
not performed synonymous 859354 1 3  
n o t  performed missense 1 5259048 
not performed 5'UTR 8775526 
not performed missense 8787347 
Not confirmed missense 4929381 9  
not performed intronic 56651 698 
not performed missense 56653900 
not performed 5'UTR 46283902 
cDNA level 
N M_01 6006.4 
(ABHD5) :c.341 G> T 
N M_01 6006.4 
(AB HD5):c.201 G>C 
N M_01 9555.2 
(ARHGEF3):c.430G> T 
N M_001 1 4491 2. 1  
(ATG7):c.905G>T 
N M_001 1 77387. 1 
(ATXN7):c.2760C>A 
NM_004656.2 
(BAP1 ) :c.870del 
N M_003458.3 
(BSN):c.4445C> T 
N M_01 4296.2 
(CAPN7): c.328A>G 
N M_033337 .2 
(CAV3): c.250C>G 
N M_1 781 73.3 
(CCDC36): c889T>G 
N M_001 01 2506.4 
(CCDC66): c.2629A>G 
protein level Coverage 
p.Arg 1 1 4Leu 787 
Lys67Asn 348 
X 1 65 
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Variant WT Variant/WT 
T G 34.9/65 . 1  
C G 24.7/75.3 
T C 44.2/55.8 
A G 62.4/37.6 
T A 32.0/68.0 
T A 68.0/32.0 
A C 75.3/24.7 
A C 62.0/38.0 
A G 70.4/29.6 
G A 78.8/2 1 .2 
G A 78.8/2 1 .2 
T G 44.8/55.2 
A C 22.6/77.4 
C A 31 .8/68.2 
A C 77.4/22.6 
G 36.5/63.5 
A T 34.3/65.7 
T C 54.5/45.5 
T C 25.2/74.8 
C A 67.3/32.7 
T C 7 1 .3/28.7 
A G 43.8/56.2 
C G 29.8/70.2 
T C 32.8/67.2 -----
T C 63.7/36.3 
T C 1 9.9/8 1 . 1  
T C 7 1 .5/28.5 --- -
G A 6 1 . 1 /38.9 
------
A G 28. 1 /7 1 .9 
G C 63.0/37.0 
G T 73. 1 /26.9 
A G 41 .4/58.6 
G A 73.7/26.3 
T C 37.7/62.3 
Predictions 
AGVGD SIFT Polyphen 
co Tolerated Probably 
damaging 
co Tolerated Benign 
X X X 
X X X 
X X X 
X X X 
X X X 
C65 Affect protein Possibly 
function damaging 
X X X 
X X X 
X X X 
co Tolerated Possibly 
damaging 
---- --
X X X 
X X X 
co Tolerated Possibly 
damaging 
X X X 
X X X 
C65 Affect protein Probably 
function damaging 
X X X 
X X X 
X X X 
X X X 
X X X 
X X X 
X X X 
X X X 
X X X 
co Tolerated Benign 
X X X 
co Tolerated Benign 
co Tolerated Probably 
damaging 
X X X 
co Tolerated Probably 
damaging 
X X X 
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NM 001 008390 
NM_001008390 
NM 01 8397 
N M_01 8397 
N M_01 5097 
N M_1 78868.3 
N M_020872 
N M_1 7561 2 
NM_1 75607 
NM_1 75607 
NM 0 1 4461 
N M_000094 
N M_005677 
NM_ 1 53635 









NM 0 1 55 1 2  
N M_0 1 55 1 2  




Tumor Sanger seq 
T-d not performed 
T-g not performed 
T-c not performed 
T-g not performed 
T-e not performed 
T-g not performed 
T-j not performed 
T-g not performed 
T-f not performed 
T-g not performed 
T-6 not performed 
T-d not performed 
T-i not performed 
T-g not performed 
T-i not performed 
T-a not performed 
T-d not performed 
T-j not performed 
T-f not performed 
T-6 not performed 
T-b not performed 
T-d not performed 
T-g not performed 
T-f not performed 
T-6 not performed 
T-i not performed 
T-i not performed 
T-b not performed 
T-d not performed 
T-6 not performed 
T-e not performed 
T-6 not performed 
T-e not performed 
Mutation 
type genomic location cDNA level 
3'UTR 4641 7340 
3'UTR 4641 7266 
missense 451 30627 NM 022842.3 
(CDCP1) :  c.2000C>G 
3'UTR 48675391 
3 'UTR 88 10 1 730 
3'UTR 88101 339 
3'UTR 53851 505 
intronic 53852920 
intronic 33653588 
missense 32398997 N M_1 78868.3 
(CMTM8): c.280A>G 
missense 7441 3659 NM_020872 . 1  
(CNTN3): c. 1 1 72A> T 
5'UTR 308 1 5 1 9  
intronic 3097734 
synonymous 3081 933 
synonymous 1 33737 1 
intronic 48620392 
3'UTR 1 5491 8 1 8  
missense 97566 1 8  NM_ 1 53635.2 
(CPN E9): c.67 1 A>G 
intronic 4 1 268866 
missense 4 1 266697 NM_001 904.3 
(CTNN B 1 ) : c.494A>G 
3'UTR 49572438 
3'UTR 49572260 
missense 53378932 N M_01 8403 .5 
(DCP 1 A): c . 1 73G>A 
missense 93780283 NM_001 1 95643. 1  
(DHFRL1 ): c.73A>T 
in  frame del 3 8 1 6407 1 NM_007337.2 
(DLEC1) :  c.531 2-531 4del 
missense 381 63900 NM_007337.2 
(DLEC1 ): c.5 1 4 1 C> T 
synonymous 381 63900 
missense 524041 78 N M_01 551 2.4 
(DNA H 1 ): c.6 1 9 1 A>G 
missense 5242031 5  N M_01 551 2.4 
(DNAH 1 ) :  c.8765C>T 
synonymous 523866 1 5  
intronic 5 1 1 1 2909 
synonymous 5 1 399347 
missense 40442421 N M_001 248.2 
(ENTPD3): c.205A>G 
- - -- -
� - ---
Frequency Predictions 
protein level Coverage Variant WT Variant/WT AGVGD S IFT Polyphen 
X 670 T A 32.2/67 .8 X X 
X 630 T G 22.4/77.6 X X 
Thr667Ser 237 C G 39.7/60.3 co Tolerated Benign 
X 328 C G 72.0/28.0 X X X 
7 1 4  A C 40.2/59.8 X X 
X 553 C T 49.9/50.1 X X X 
X 307 T C 64.2/35.8 X X X 
1 70 A G 60.0/40.0 X X X 
284 C T 64.8/35.2 X X 
Met94Val 363 G A 70.5/29.5 co Tolerated Benign 
Lys39 1 lle 370 A T 43.0/57.0 co Affect protein Benign 
function 
X 481 G A 25.8/74.2 X X X 
1 84 T G 63.0/37.0 X X 
367 A G 21 .0/79.0 X X X 
X 597 C T 27.0/73.0 X X X 
1 7 1  A C 55.0/45.0 X X X 
4 1 2  A G 30. 1 /69.9 X X X 
Tyr224Cys 283 G A 1 8.7/8 1 .3 C65 Affect protein Probably 
function damaging 
1 62 G A 60.5/38.9 X X 
Gln1 65Arg 4 1 7  G A 64.7/35.3 co Tolerated Possibly 
damaging 
21 1 A G 26. 1 /73.9 X X X 
X 665 C G 62.9/37.1  X X X 
Arg58Gln 293 T C 47 . 1 /52.9 co Tolerated Probably 
damaging 
Arg25Trp 921 A T 40.7/59.3 co Tolerated Benign 
p.Asp1 772del 253 ATG 58. 1 /4 1 .9 X X 
Pro1 7 1 4Leu 246 T C 64.6/35.4 co Tolerated Benign 
X 246 C T 35.4/65.6 X X X 
Asn2064Ser 61 0 G A 67.7/32.3 co Affect protein Benign 
function 
Ala2922Val 1 95 T C 64. 1 /35.9 co Affect protein Benign 
function 
X 295 T C 28.5/7 1 .5 X X X 
306 T C 75.2/24.8 X X 
X 646 A G 31 .0/68.9 X X X 
Thr69Ala 2 1 0  G A 21 .4/78.6 co Affect protein Probably 
function damaging 
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Gene name 
EPHA3 
EPM2AI P 1  
EPM2AI P 1  
ERC2 















IL1 7 RB 
IL1 7 RC 
IL1 7RE  
IQCF2 
IQ5EC1 
ITI H 1  





KIF 1 5  
LMOD3 
LOC 1 00 1 32526 
LOC401 052 
LRI G 1  
LRIG 1  





N M_01 5576 
NM_1 52678 
NM_001 004019  
N M_1 52536 
N M_1 52536 
N M_1 52536 
NM_032682 
NM_01 5 1 23 
NM_0245 1 3  
NM_207359 
N M_0001 58 
N M_01 5 1 41 
XM_002342357 
N M_01 2260 








NM_00221 7  
N M_001 099952 
N M_003884 
NM_032505 
N M_1 44633 
NM_020242 
NM_1 9827 1 .3 
XM_001 721 2 1 2  
N M_001 008737 
NM_01 5541 
N M_01 5541 
Tumor Sanger seq 
T-6 not performed 
T-i not performed 
T-h not performed 
T-g not performed 
T-6 not performed 
T-g not performed 
T-e not performed 
T-g not performed 
T-6 not performed 
T-i not performed 
T-f not performed 
T-e not performed 
T-j not performed 
T-d not performed 
T-6 not performed 
T-6 not performed 
T-d not performed 
T-i not performed 
T-i not performed 
T-e not performed 
T-i not performed 
T-h not performed 
T-e not performed 
T-d not performed 
T-6 not performed 
T-a not performed 
T-a not performed 
T-c not performed 
T-a not performed 
T-e not performed 
T-a not performed 
T-6 not performed 
T-a not performed 
T-h not performed 
T-d not performed 
T-d not performed 
Mutation 
type genomic location cDNA level 
intronic 894451 94 
3'UTR 37030382 
missense 37033820 NM_01 4805.3 
(EPM2AIP 1 ): c.749T>C 
intronic 56041371  
missense 5761 4059 NM 1 52678.2 
(FAM1 1 5A): c. 1 709G>C 
synonymous 1 3672866 
3'UTR 1 49749 1 0  
3'UTR 1 4862732 ----
intronic 1 4941 867 
intronic 7 1 1 6 1 8 1 7  
3'UTR 69220061 
missense 46008983 NM_0245 1 3.2 
(FYCO 1 ): c . 1  843C> T 
intronic 30898466 
3'UTR 8 1 539250 
3'UTR 32207534 
5 'UTR 5 1 74341 1 
synonymous 1 5609395 
5'UTR 5034051 7  
missense 50327685 NM_006764.4 
(IFRD2): c.496G>A 
intronic 5389 1 058 
intronic 9972688 
missense 9948480 NM_001 1 93380. 1 
( IL1 7RE): c.457A>G 
missense 5 1 897361 NM_203424.1 
(IQCF2): c.470T>C 
intronic 1 2941 9 1 7  
synonymous 528 1 70 1 4  
intronic 52842507 
intronic 4738980 
missense 201 89472 NM_003884.4 
(KAT2B): c.21 37C>A 
3'UTR 67060743 
intronic 1 9559422 
intronic 44869851 
in frame del 69 1 7 1 497 NM_1 9827 1 .3 
(LMOD3): c.41 -43del 
3 'UTR 1 3977985 




















































1 77 --- - -- - -----
235 




p .Leu 1 4_ 358 
Asp1 5delinsHis 
X 235 














































































Variant/WT AGVGD SIFT Polyphen 
21 .8/78.2 X X X 
35.5/64.5 X X X 
73.8/26.2 X X Benign 
32.4/67 .6 X X X 
64.2/35.8 co Tolerated Possibly 
damaging 
30.6/69.4 X X ----
29.5/70.5 X X X 
21 .9/78 . 1  X X X 
57.6/42.2 X X X 
54. 1 /45.9 X X X 
62.5/37.5 X X 
79.4/20.6 co Affect protein Probably 
function damaging 
6 1 .4/38.6 X X 
22.7177.3 X X X 
1 7  .0/83.0 X X X 
25.8/74.2 X X X 
27 . 1 /72.9 X X X 
63.3/36.7 X X X 
68.8/31 .2  co Tolerated Probably 
damaging 
77.3/22.7 X X X --- -
29.6/70.1 X X X 
30.0170.0 co Affect protein Probably 
function damaging 
1 7.3/82.5 C65 Affect protein Probably 
function damaging 
77.3/22.7 X X X 
68.3/3 1 .7  X X X 
70.1 /29.9 X X X 
44.7/55.3 X X X 
20.8179.2 C35 Affect protein Probably 
function damaging 
34.9/65. 1  X X X 
6 1 .0/39.0  X X X 
63.3/37.7 X X 
27.4/72.6 X X 
57.9/42.1 X X X 
67.0/33.0 X X X 
30. 1 /69.9 X 
30.1 /69.9 X X X 
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Gene name Refseq 
LRRC3B N M_052953 
LTF N M_002343 - ---
MAG l 1  
MAG l 1  
MAG I 1  
MAG l 1  
MAG I 1  
MAG l 1  
MAG l 1  















NUP2 1 0  









1 02 CHAPTER 5 
N M_004742 
N M_001 033057 
NM_004742 
N M_001 033057 
N M_001 033057 
N M_001 033057 
N M_001 033057 
N M_002343 
N M_00601 0 
N M_00l 1 34364 
N M_000248 
N M_1 99347 
N M  1 99347 
N M_0071 84 
N M_007 1 84 
N M_020345 








N M_1 38381 
N M_1 77938 
N M_01 8 1 65 
N M_0 1 8 1 65.4 
N M_0 1 8 1 65.4 
N M_01 8 1 65.4 
NM 01 8 1 65.4 






































Sanger seq type genomic location cDNA level 
not performed 3'UTR 26751 986 
not performed synonymous 4649691 0  
not performed 3'UTR 6534641 1 
not performed 3'UTR 65341 301 
not performed 3'UTR 65345591 
not performed intronic 653451 34 
not performed intronic 6534641 1 
not performed intronic 65345591 
not performed missense 654561 35 NM_01 5520.1 
(MAG I 1 ): c.782A>G 
not performed synonymous 65345 1 34 
not performed intronic 5 1 425141  
not  performed 3'UTR 47892855 
not performed 5'UTR 69985764 
not performed intronic 27387564 
not performed missense 27338698 NM 1 99347.2 
(NEK1 0): c . 1 202A>G 
not performed intronic S2504963 
not performed synonymous 52504895 
not performed 3'UTR 23934322 
not performed missense 24003660 NM_0051 26.4 
(NR1 D2): c.71 0A>G 
not performed 3'UTR 1 5086206 
not performed 3'UTR 1 5085906 
not performed 3'UTR 1 5089098 
not performed 3'UTR 1 5088874 
not performed intronic 1 5065790 
not performed 3'UTR 1 3357935 
not performed missense 1 3383322 NM_024923.2 
(NUP2 1 0) :  c .31 54G>A 
not performed synonymous 1 63 1 2495 
not performed missense 49039984 NM_ 1 77939.2 
(P4HTM): c.679A>G 
not performed 3'UTR 52581 406 
Confirmed Frameshift 52598 1 8 1  N M_0 1 8 1 65.4 
(PBRM 1 ): c.3664dup 
Confirmed Frameshift 52643954 NM_01 8 1 65.4 
(PBRM 1 ) :  c . 1 846del 
Confirmed Frameshift 52651 509 NM_01 8 1 65.4 
(PBRM 1 ) :  c . 1 491 dup 
Confirmed Frameshift 5261 3205 NM_0 1 8 1 65.4 
(PBRM1 ): c.3302del 
Confirmed Frameshift 52696231 N M_0 1 8 1 65.4 



























p. l le227Val 
-- -
X ----
p. l le1 222AsnfsX5 
p.Ser61 6LeufsX8 
p.Val498CysfsX3 
p.Asp1 1 01 ValfsX26 
p.Asn 1 49MetfsX25 
Coverage Variant WT 
5 1 6  T C 
302 A G 
362 G C 
689 A G 
861 A G 
334 C T 
362 G C 
861 A G 
583 C T 
334 C T 
1 76 A G 
237 T C 
200 A G 
264 T C 
229 C T 
237 G G 
395 A G 
303 C A 
435 G A 
436 T G 
449 A G 
553 T C 
403 G C 
208 G A 
3 1 9  T C 
521 T C 
1 63 A G 
255 G A 
47 1 T A 







Variant/WT AGVGD SIFT Polyphen 
26.4/73.6 X X X 
34. 1 /65.9 X X 
80.9/1 9.1  X X X 
62.3/37.7 X X X 
63.6/36.4 X X X - -- --
60.5/39.5 X X X 
80.9/1 9.1  X X X 
63.6/36.4 X X X 
53.3/46.7 co Affect protein X 
function 
60.5/39.5 X X X 
67.6/32.4 X X X 
22.8/77.2 X X X 
29.5/70.5 X X X 
32.6/67.4 X X X 
32.8/66.8 co Tolerated Benign 
25.3/74.7 X X X 
28.4/7 1 .6 X X X 
64.4/35.6 X X X 
29.7/70.3 co Tolerated Benign 
38. 1 /61 .9 X X X 
32.3/67.7 X X X 
43.8/56.2 X X X 
33.3/66.7 X X X 
24.0/76.0 X X X 
28.5/7 1 .5 X X X --- ---
23.6/76.4 co Affect protein Probably 
function damaging 
60.7/39.3 X X X 
23.5/76.1 C1 5 Tolerated Benign 
39.9/60.1 X X X 
37.9/61 .6 X X 
· --- --
41 .3/58.7 X X X 
26.0/73.6 X X X 
42.5/57.5 X X X 
1 9. 1 /80.4 X X 
TARG ETED EXO M E  SEQU ENC ING I N  CLEAR CELL RENAL CELL CARC I N OMA 1 03 




















SACM 1 L  
SATB1 
SCN 1 0A 
SCN 1 0A 
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Refseq 
N M_0 1 8 1 65.4 
NM_0 1 8 1 65.4 
N M_1 77966 
NM_000306 
NM 1 98859 
NM_0041 57 
NM_001 1 26 1 28 
NM_00031 3  
N M_00031 3  
NM_01 5466 
NM_002841 




NM_01 5 1 50 
NM_01 2234 
NM_01 2234 
NM_01 401 6 
NM_001 1 3 1 0 1 0  
NM_00651 4  
N M_00651 4  
NM_001 1 36232 
NM_004206 
NM_004 1 86 
NM_004 1 86 
NM_004 1 86 
N M_0 1 4 1 59.6 
NM_004803.3 
NM_003074 
NM_001 1 00594 
NM_001 1 00594 
NM_001 0331 1 7 . 1  
NM 1 82760 
NM_01 5551 
Tumor Sanger seq 
T-h Confirmed 
T-a Confirmed 
T-b not performed 
T-g not performed 
T-a not performed 
T-d not performed 
T-h not performed 
T-h not performed 
T-e not performed 
T-a not performed 
T-j not performed 
T-g not performed 
T-e not performed 
T-i not performed 
T-c not performed 
T-e not performed 
T-d not performed 
T-i not performed 
T-c not performed 
T-b not performed 
T-e Not confirmed 
T-f Not confirmed 
T-d not performed 
T-g not performed 
T-e not performed 
T-e not performed 
T-a not performed 
T-g not performed 
T-h Not confirmed 
T-b not performed 
T-b not performed 
T-g not performed 
T-b not performed 
T-i not performed 
T-e not performed 
Mutation 
type genomic location cDNA level 
missense 52682449 N M_01 8 1 65.4 
{PBRM 1 ): c.724T>C 
Splice 52620705 N M_01 8 1 65.4 
{PBRM 1 ) : c.3028-1 G>A 
missense 57545301 N M_1 77966.5 
{PDE1 2): c . 1 400G>A 
intronic 8732543 1 - -- -
intronic 641 32479 
missense 4881 0437 N M_0041 57.2 
{PRKAR2A): c.647C>T 
3'UTR 7 1 821 252 
3'UTR 93592396 
missense 93629525 N M_0003 1 3.3 
(PROS 1 ): c.284G>A 
3'UTR 47454928 
synonymous 621 1 83 1 4  
intronic 49084697 
synonymous 1 2626 1 30 
synonymous 1 2650270 
intronic 501 5 1 0 1 0  
3'UTR 1 6357592 
3'UTR 72424763 
3'UTR 72424633 
synonymous 45751 040 
intronic 1 8466 1 5 1  
missense 387701 98 N M_00651 4.2 
{SCN1 0A): c2475A>C 
intronic 38752461 
intronic 1 0356992 
intronic 42597410  
3'UTR 50225794 
intronic 50221 027 
missense 641 32479 N M_0041 86.3 
(SEMA3F): c.980C>T 
synonymous 47 1 62229 
Frameshift 383491 47 N M_004803.3 
(SLC22A1 4): c7 1 1 -7 1 4del 
intronic 477 1 22 1 0  
3'UTR 433901 02 
3'UTR 43391 630 
missense 9034594 N M_001 0331 1 7 . 1  
{SRGAP3): c.2482G>A 
intronic 4459590 
missense 331 95202 N M_01 5551 . 1  
(SUSD5): c.922A>G 
Frequency Predictions 
protein level Coverage Variant WT Variant/WT AGVGD SIFT Polyphen 
p.Tyr242His 1 94 G A 35.1 /64.9 co Affect protein Probably 
function damaging ---- --- ------
Splice 381 T C 1 3.9/86. 1  X X X 
Arg467His 263 A G 66.5/33.5 C25 Affect protein Probably 
function damaging 
498 G T 3 1 .5/68.5 X X 
1 99 A T 35.2/64.8 X X 
Pro21 6Leu 306 A G 62.7/37.3 C65 Affect protein Probably 
function damaging 
X 350 T C 69. 1 /30.9 X X 
X 397 T C 50. 1 /49.9 X X X --- --
Gly95Glu 208 T C 38.0/62.0 co Affect protein Probably 
function damaging 
X 3 1 4  T C 26.8/73.2 X X X 
X 469 T C 60. 1 /39.9 X 
263 C T 67.7/32.3 X X X 
X 1 64 C T 75.6/24.4 X X 
X 293 C T 63. 1 /36.9 X X X 
1 98 T G 25.3/74.7 X X X -- ---
X 8 1 4  A G 1 6.7/84.3 X X X 
X 434 C G 22.8/77.2 X X 





343 A G 67. 1 /32.9 X X X 
2 1 9  G C 2 1 .0/78.1 X X X 
p.Glu825Asp 377 G T 1 5.6/84.4 co Tolerated Benign 
1 65 A G 69. 1 /30.9 X X 
226 T C 23.5/76.5 X X X 
274 T C 64.2/35.4 X X X 
21 1 A G 27.5/72.5 X X X 
1 54 T C 20. 1 /79.9 X X X 
p.Pro327Leu 1 53 T C 58.2/41 .8 C1 5 Affect protein Possibly 
function damaging 
X 667 A G 63.3/36.7 X X 
p.Leu238SerfsX25 257 TTTG 54.5/44.7 X X 
203 G A 64.5/35.5 X X X 
X 351 A G 1 5.4/84.6 X X 
X 474 T A 66.7/33.3 X X X 
Gly828Ser 394 T C 64.0/36.0 C55 Affect protein Possibly 
function damaging 
-- - --
1 5 1 A G 57.0/43.0 X X X 
Lys308Glu 356 C T 3 1 .5/68.5 co Affect protein Possibly 
function damaging 
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ZNF 1 67 
ZNF1 67 
ZNF 1 97 
ZNF385D 
ZNF445 
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Refseq 
N M_1 33625 
NM_0031 78 
N M_01 4760 
N M_003241 
N M_000461 




NM_001 042646. 1  
NM_01 4831 .2 
NM_001 1 055 1 3  
NM_01 6206 
NM_01 6206 
NM_001 1 28220 






N M_000551 .2 
N M_001 024644 
NM_005 1 08 
N M_005 1 08 
NM 001 1 35 1 79 
NM_001 1 35 1 80 
N M_022340 
NM_022340 




N M_1 8 1 489 
Tumor Sanger seq 
T-a not performed 
T-h not performed 
T-h not performed 
T-c not performed 
T-g not performed 
T-f not performed 
T-g not performed 
T-g not performed 
T-g not performed 
T-f not performed 
T-b not performed 
T-c not performed 
T-a not performed 
T-i not performed 
T-a not performed 






T-i not performed 
T-d not performed 
T-d not performed 
T-h not performed 
T-h not performed 
T-j not performed 
T-d not performed 
T-a not performed 
T-a not performed 
T-f Confirmed 
T-a not performed 
T-b not performed 
M utation 
type genomic location cDNA level 
3'UTR 1 223251 8  
3'UTR 1 2226293 
3'UTR 1 0321 578 
3'UTR 44955493 
3'UTR 241 6401 4 
synonymous 1 00 1 6 1 59 
intronic 25640770 
intronic 49885642 
synonymous 49881 339 
In frame ins 42251 578 N M_001 042646. 1  
(TRAK1 ) :  c . 1 963+ 1 28_ 1 963+ 1 30del --- --
missense 36871 1 24 NM_0 1 4831 .2  
(TRANK 1 ) : c.8608A>G 
intronic 391 50543 
3'UTR 86994861 
3'UTR 86994499 
5'UTR 1 1 6238 1 9  
intronic 1 1 6238 1 9  
Frameshift 1 01 91 498 NM_000551 .2 
(VHL): c.491_492del 
Frameshift 1 01 88202 NM_000551 .2 
(VHL): c.346dup 
Frameshift 1 0 1 88258 NM_000551 .2 
(VHL): c.401_404del 
missense 1 0 1 88206 NM_000551 .2 
(VHL): c.349T>G 
Splice 1 01 88320 NM_000551 .2 
(VHL): c.463+1 del 
missense 46062889 NM_00S283.2 
(XCR1) :  c.551 T>C 
missense 38401 83 1  N M_005 1 08.3 
(XYLB): c. 1 42A>G 
synonymous 3841 6748 -- --- --
3'UTR 44962767 
intronic 44962767 
3'UTR 1 51 1 2960 
intronic 1 5 1 26593 
3 'UTR 4461 291 9  
intronic 446129 1 9  
Frameshift 44683961 NM_006991 .3 
(ZN F1 97): c. 1 339 _ 1 342del 
intronic 2 1 462942 NM_024697.2 
(ZNF385D): c.955-3C>A 
missense 44488293 N M_1 8 1 489.5 
(ZNF445): c.2870A>G 
protein level 
X ---- -- - -� --
X -- - ---














p.Leu1 1 6ProfsX1 6  
p.Glu 1 34AspfsX24 













p. l le447ThrfsX22 
--- -- - -
Glu957Gly 
Coverage Variant WT 
802 T C 
21 6 T C 
262 G A 
-- --· 
304 A T 
628 T C 
236 T C 
1 64 G A 
442 C A 
591 T C 
GGA 26.2/73.3 
-- --- ---
1 65 C T 
3 1 5  A T 
330 T A 
348 A C 
237 A C 
237 A C 
1 67 AG 
395 C 
43 1 AATT 
540 G T 
253 G 
577 G A 
343 G A 
373 A G 
292 T C 
292 T C 
266 G T 
1 65 T G 
545 G A 
545 G A 
532 ATCC 
2 1 8  T G 
463 C T 
Frequency Predictions 
Variant/WT AGVGD S IFT Polyphen 
40.4/59.6 X X 
27.3/72.7 X X X 
54.6/45.4 X X 
72.0/28.0 X 
20.7/79.3 X X X 
28.4/81 .6 X X X 
38.4/6 1 . 1  X X X 
3 1 .7/68.3 X X 
30.6/69.4 X X 
X X 
67.3/32 . 1  co Tolerated Benign 
67.3/32.7 X X X 
20.9/79 . 1  X X 
62.6/37.4 X X 
24. 1 /75.9 X X X 
24. 1 /75.9 X X X 
46.7/53.3 X X 
40.0/57.7 X X X 
42.5/56.8 X X X 
1 5 .2/84.4 C65 Affect protein Probably 
function damaging 
22.9/77 . 1  X X 
68.8/31 .2 co Tolerated Probably 
damaging 
20.4/79.6 co Tolerated Probably 
damaging 
27.3/72.7 X X X -- --
69.9/30.1 X X 
69.9/30.1 X X X 
33.5/66.5 X X 
70.9/29. 1 X X X 
63.7/36.3 X X X 
63.7/36.3 X X 
26.3/73.3 X X X 
27.5/72.5 X X X 
33.5/66.5 co Affect protein Benign 
function 
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S u p p l e m e n t a r y  T a b l e  S 2 .  I d e n t i f i e d  m u t a t i o n s  i n  V H L ,  P B R M 1  a n d  S E T D 2  i n  c c R C C - d e r i v e d  c e l l  l i n e s .  
c R C C -
d e r i v e d  
c e l l  l i n e  
R C C - 4  
R C C - E R  
R C C - F G 2  
--
R C C - H S  
R C C - M F  
R C C - A B  
R C C - E R  
R C C - F G 2  
R C C - J F  
-
R C C - J W  
R C C - M F  
R C C - 1  
R C C - 4  
R C C - E R  
R C C - F G 2  
R C C - J W  
R C C - M F  
M u t a t i o n  
G e n e  n a m e  R e f S e q  I D  
t y p e  c D N A  l e v e l  
P B R M 1  
N M _ 0 1 8 1 6 5 . 4  
F r a m e s h i f t  
c . 2 5 9 2 d u p  
- - - ---
P B R M 1  N M _ 0 1 8 1 6 5 . 4  
F r a m e s h i f t  
c . 7 5 3 _ 7 5 6 d e l  
- -
- -
P B R M 1  
N M _ 0 1 8 1 6 5 . 4  N o n s e n s e  
c . 1 3 3 3 C > T  
- - - - - - - - - - -
P B R M 1  
N M _ 0 1 8 1 6 5 . 4  
m i s s e n s e  c . 3 3 8 6 G > T  
- -
P B R M 1  
S E T D 2 *  
-
S E T D 2 *  
S E T D 2 *  
- -
S E T D 2 *  
- - - -
S E T D 2 *  
S E T D 2 *  
V H L  
V H L  
V H L  
V H L  
N M _ 0 1 8 1 6 5 . 4  
F r a m e s h i f t  
N M _ 0 1 4 1 5 9 . 6  F r a m e s h i f t  
- - - - -




N M _ 0 1 4 1 5 9 . 6  
l o s s  o f  l a s t  3  e x o n s  
N M _ 0 1 4 1 5 9 . 6  
s y n o n y m o u s  
- - -
N M _ 0 1 4 1 5 9 . 6  m i s s e n s e  
N M _ 0 1 4 1 5 9 . 6  i n  f r a m e  d e l e t i o n  
N M _ 0 0 0 5 5 1 . 2  
- - - -
N  M _ 0 0 0 5 5 1  . 2  
- -
- - -
N M _ 0 0 0 5 5 1 . 2  
N  M _ 0 0 0 5 5 1 . 2  
F r a m e s h i f t  
M i s s e n s e  
-
F r a m e s h i f t  
F r a m e s h i f t  
- -
V H L  N M _ 0 0 0 5 5 1 . 2  
l n f r a m e  i n s e r t i o n  
V H L  N  M _ 0 0 0 5 5 1 . 2  M i s s e n s e  
c . 1 4 8 7 d e l  
c . 6 4 4 7 d e l C  
c . 2 0 1 7 T > A  
- - - - - - - -
u n k n o w n  
- -
c . 4 1 8 9 T > C  
-




c . 5 3 3 0 _ 5 3 3 8 d e l A A C A C A C A C  
- - -
c . 4 5 8 - 4 5 9 i n s 3 7  
c . 1 9 4 C > G  
-
c . 4 8 2 d e l  
- -
c . 4 4 4 d e l  
c . 3 2 8 _  4 4 4 i n s G C A T C A  
c . 2 5 6 C > T  
- -
*  
A c c o r d i n g  t o  t h e  S I F T  p r e d i c t i o n  p r o g r a m ,  t h e  i d e n t i f i e d  v a r i a n t  i n  P B R M 7  i n  R C C - H S  i s  l i k e l y  t o  a ff e c t  p r o t e i n  f u n c t i o n  
( s c o r e  0 . 0 0 ,  m e d i a n  s e q u e n c e  c o n s e r v a t i o n
=
3 . 1 7 )  
*  A c c o r d i n g  t o  t h e  P o l y p h e n  p r e d i c t i o n  p r o g r a m ,  t h e  i d e n t i f i e d  v a r i a n t  i n  P B R M 1  i n  R C C - H S  i s  p r o b a b l y  d a m a g i n g  
p r o t e i n  l e v e l  
p . H i s 8 6 5 T h r f s X 4  
p . A s p 2 5 1  G  l u f s X 3 1  
p . G l n 4 4 5 X  
p . G l y 1 1 2 9 V a l  
p . A s n 4 9 6 M e t f s X 4 1  
R 2 1 3 2 f s X 1 3  
- -
L 6 5 5 X  
u n k n o w n  
- - -
n o n e  
G 1 2 5 9 V  
1 7 6 0 - 1 7 6 2 d e l N T H  
p . P r o 1 5 4 C y s f s X 2  
p . S e r 6 5 T r p  
p . A s p 1 4 3 A l a f s X 1 6  
p . P h e 1 4 8 L e u f s X 1 1  
p . H i s 1 1  0 d e l i n s A r g l l e A s n  
p . P r o 8 6 S e r  
*  A c c o r d i n g  t o  t h e  A G V G D  p r e d i c t i o n  p r o g r a m ,  t h e  i d e n t i f i e d  v a r i a n t  i n  P B R M 7  i n  R C C - H S  i s  l e s s  l i k e l y  t o  i n t e r f e r e  w i t h  p r o t e i n  f u n c t i o n  ( s c o r e  C 1 5 ) .  
*  A c c o r d i n g  t o  t h e  S I F T  p r e d i c t i o n  p r o g r a m ,  t h e  i d e n t i f i e d  v a r i a n t  i n  V H L  i n  R C C - H S  i s  l i k e l y  t o  a ff e c t  p r o t e i n  f u n c t i o n  
( s c o r e  0 . 0 0 ,  m e d i a n  s e q u e n c e  c o n s e r v a t i o n
=
3 . 4 7 )  
*  A c c o r d i n g  t o  t h e  P o l y p h e n  p r e d i c t i o n  p r o g r a m ,  t h e  i d e n t i f i e d  v a r i a n t  i n  V H L  i n  R C C - H S  i s  p r o b a b l y  d a m a g i n g  
*  A c c o r d i n g  t o  t h e  A G V G D  p r e d i c t i o n  p r o g r a m ,  t h e  i d e n t i f i e d  v a r i a n t  i n  V H L  i n  R C C - H S  l i k e l y  t o  i n t e r f e r e  w i t h  p r o t e i n  f u n c t i o n  ( s c o r e  C 6 5 ) .  
*  A c c o r d i n g  t o  t h e  S I F T  p r e d i c t i o n  p r o g r a m ,  t h e  i d e n t i f i e d  v a r i a n t  i n  V H L  i n  R C C - M F  i s  t o l e r a t e d  ( s c o r e  0 . 2 3 ,  m e d i a n  s e q u e n c e  c o n s e r v a t i o n
=
3 . 4 7 )  
*  A c c o r d i n g  t o  t h e  A G V G D  p r e d i c t i o n  p r o g r a m ,  t h e  i d e n t i f i e d  v a r i a n t  i n  V H L  i n  R C C - M F  l e s s  l i k e l y  t o  i n t e rf e r e  w i t h  p r o t e i n  f u n c t i o n  ( s c o r e  C 1 5 ) .  
*  T h e  m u t a t i o n s  i n  S E T D 2  w e r e  i d e n t i f i e d  i n  a n  e a r l i e r  s c r e e n  ( D u n s ,  C a n c e r  R e s e a r c h  2 0 1 1 )  
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ABSTRACT 
Despite numerous studies reporting deregulated microRNA (miRNA) and gene 
expression patterns in clear cell renal cell carcinoma (ccRCC), no direct comparisons 
have been made to its presumed normal counterpart; the renal proximal epithelial 
tubular cells (PTEC). The aim of this study was to determine the miRNA expression 
profiles of ten clear cell renal cell carcinoma-derived cell lines and short-term cultures 
of PTEC, and to correlate these with their gene expression, and copy-number profiles. 
Using microarray-based methods, a significantly altered expression level in ccRCC cel l  
lines was observed for 23 miRNAs and 1 630 genes. The set of miRNAs with significantly 
decreased expression levels include al l  members of the miR-200 family known to be 
involved in the epithelial to mesenchymal transition (EMT) process. Expression levels 
of 13 of the 47 validated target genes for the down regulated miRNAs were increased 
more than two-fold. Our data reinforce the importance of the EMT process in the 
development of ccRCC. 
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I NTRODUCTION 
Clear cell renal cell carcinoma (ccRCC) is  the most prevalent subtype of  kidney cancer 
and accounts for 3% of human malignancies (Jemal et al., 2009). ccRCC is characterized 
by the frequent loss of 3p (van den Berg et al., 1997) and several genes have been 
postulated to be involved in its pathogenesis. Based on the current literature, it can 
be hypothesized that, in addition to protein coding genes, microRNAs (miRNAs) will 
also be involved in the pathogenesis of ccRCC. Several miRNAs have been shown to 
exert tumor suppressive or oncogenic functions in a tissue-specific manner (Chen, 
2005; Garzon et al., 2006; Kent and Mendell, 2006). Aberrant expression of these 
miRNAs results in differential translational control of numerous target genes. This 
can result in the deregulation of cellular processes like proliferation, differentiation, 
programmed cell death, and morphogenesis, thereby contributing to the process 
of tumor development (Chen, 2005; Garzon et al., 2006; Kent and Mendell, 2006). 
Several groups have published up- and downregulated miRNAs in primary ccRCC 
tumors compared to normal kidney tissue (Gottardo et al., 2007; Nakada et al. ,  2008; 
Huang et al., 2009; Petillo et al., 2009; Chow et al. , 2010; Juan et al. , 201 O; Slaby et 
al., 201 O; Weng et al., 2010). However, a disadvantage of examining tumor tissue is 
the admixture of normal cells and intra-tumoral heterogeneity. The same holds true 
for the renal tissue used as the normal counterpart, as kidneys are complex organs 
consisting of many different cel l types. This, and the fact that ccRCC is thought to 
arise specifically from the epithelial cells of the proximal tubuli of the kidney ( PTEC), 
makes the outcome of most studies less reliable (Thoenes et al., 1986). These proximal 
tubular cells can be isolated from kidney tissue and cultured for a limited number of 
passages, allowing isolation of RNA for profiling studies from pure cells (Clifford et 
al., 1998). In the case of ccRCC we postulated that the best strategy would be to 
compare cancer cell lines with short term cultures of these PTEC cells. We adopted 
this strategy and analyzed gene and miRNA expression profiles of ccRCC-derived cell 
lines in comparison to short-term cultures of their precursor cells, i.e. PTECs of the 
kidney. We further correlated the expression profiles with DNA copy numbers. 
MATERIALS AND M ETHODS 
Cel l  l ines 
The ccRCC cell lines RCC-AB, RCC-ER, RCC-FG2, RCC-HS, RCCJ F, RCC-JW, RCC-MF, 
and RCC-WK were obtained from Cell Line Services (Eppenheim, Germany). The 
cells, which tested negative for Mycoplasma, bacteria and fungi, were cultured as 
recommended. Experiments were performed on cells that had undergone six to eight 
additional passages. The ccRCC cell lines RCC-1, RCC-4, and RCC-5 were established 
by Dr. C. D. Gerharz (Institute of Pathology, University Hospital, Dusseldorf, Germany). 
To ensure their authenticity, they were re-karyotyped. All cRCC cell lines were 
maintained in RPMI 1640 (Sigma). MN 160 and PTEC are primary cultures der ived from 
proximal tubular epithelial cells. 
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miRNA expression 
Cells were grown to 70% confluence. Total RNA fractions were isolated using the Trizol 
reagent (lnvitrogen, Carlsbad, CA, USA). RNA qua l ity was assessed using the Agilent 
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) . mi RNA transcript 
abundance was measured using Human m iRNA m icroarrays (V2) (Agilent) fo l lowing 
the manufacturer's protocols . The array contained probes for a total of 542 human 
miRNAs. S lides were scanned using the G25052C DNA microarray scanner (Agilent). 
Array images were analyzed using Agilent feature extraction software (v10.5.1 .1) and 
GeneSpring GX (Agilent) . Data were normalized using a 75% percentile shift (Gibcus 
et al . ,  2009) . Significantly up- and downregulated miRNAs in the ccRCC derived cel l  
lines compared to the PTEC samples were identified using an unpaired t-test followed 
by Benjamini-Hochberg correction (false discovery rate FDR: 0.05 and a fold change 
of at least 2 (FC > 2.0)) . Validated targets of indiv idual mi RNAs were obtained from 
M I  RECORDS (http://mirecords.biolead.org/). 
ArrayCG H 
DNA was isolated from ccRCC-derived ce ll lines using standard protocols . ArrayCGH 
was carr ied out using Agilent Human Genome CGH M icroarray 244a slides (pin 
G4411 B) fo llowing the manufacturer's protocols .  Slides were scanned using the 
G25052C DNA microarray scanner (Agilent Technologies) . Array images were analyzed 
using Agilent feature extraction software (v10.5.1 .1) and NEXU S  copy number software 
(V6 .0, Biodiscovery, Inc. , El Segundo, CA, USA).  In NEXU S,  chromosomes with an 
apparent diplo id copy number were used for re-centering. We then used these data 
to determine the integer copy number of the genomic loci of all mi RNA. 
Gene expression profi l ing 
RNA from ccRCC-derived ce ll lines and normal renal samples was isolated using the 
RNeasy Mini Kit (Oiagen, Venlo, Netherlands) Transcript abundance was measured 
using Human HT-12_ V4_Beadchips (lllumina, San Diego, CA, USA) .  The Lumi package 
implemented in R (Du et a l . ,  2008; Lin et al . ,  2008) was used for variance stabi lizing 
transformation followed by robust spline norma lization of the microarray data (GEO 
Series accession number GSE20491 ). GeneSpring GX 10.0  (Agi lent) was used to 
calculate fold changes between normal renal samples and ccRCC-derived cell lines. 
Significantly up- and downregulated genes were identified following the same criteria 
as given for the mi RNA expression arrays, i .e .  FC > 2.0, FDR < 0.05. Genes were 
omitted from further analysis if the average expression level in the ccRCC cell lines 
and in the PTEC ce ll lines was below a normalized va lue of 7, which is close to the 
background. Pathway-enrichment analyses were done using GeneGo (http://www. 
genego.com/) . 
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RESULTS 
Characterization of the ccRCC cel l  l i nes 
ArrayCGH analysis revealed multiple chromosomal gains and losses in most of the cell 
lines (Figure 1, Supplementary Table 1). All cell lines showed a reduced copy number 
for a large part of the short arm of chromosome 3, with a common region of overlap 
extending 70 Mb from pter. Other recurrently lost regions included segments on 1 p, 
4q, 9, 11 q and 149. Eight out of ten cell lines carried a homozygous deletion on 9p21, 
wh ich varied in s ize from 50 kb to 600 kb and included the CDKN2A and CDKN2B 
gene loci. 
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Figure 1 .  Graphical representation of the chromosomal aberrations 
in the ccRCC cell lines detected by arrayCGH .  The top of the 
panel, indicated as aggregate, shows the frequency with which the 
aberrations are seen. For a summary of the recurrently lost and gained 
regions, see Supplementary Table 1 .  




mRNA profiling revealed a total 11,604 genes (14714 probes) that passed the selection 
filters. Of these, 767 genes were expressed at significantly h igher levels in the ccRCC 
cell lines compared to PTEC, whereas 869 genes were expressed at significantly 
lower levels in ccRCC cell lines. Th is set of 1636 differentially expressed genes was 
significantly enriched for a number of pathways, several of wh ich were cell cycle­
related (supplementary Table 2). Three of the enriched pathways were related to the 
epithelial-to-mesenchymal transition (EMT). Of the downregulated genes (including 
the known tumor suppressors VHL and SETD2, but not FHIT) 65 were located at 3p, 
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the genomic segment most commonly deleted. This equa l s  22% of a ll 3p genes that 
are expressed at a detectable level in PTECs and indicates that genes from 3p are 
significantly overrepresented in the group of genes that have a decreased abundance 
in ccRCC (P-va lue < 0.001 ). 
miRNA expression profiling 
Out of 542 human miRNAs that were present on the array, 239 (44%) miRNAs passed 
the qua lity filter (f lags: present or marginal) in at least four samples. Eight miRNAs 
showed a significantly increased abunda nce in ccRCC compared to PTEC and 1 5  
miRNAs showed a significantly decreased abundance (Figure 2a, b, Table 1 ). 
The l atter set included a ll five members of the miR-200 family. Although ccRCC is 
characterized by recurrent deletions of the short arm of chromosome 3, none of the 
eight miRNAs that were located at 3p and  had detectable levels in PTEC showed a 
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Figure 2. miRNAs showing statistically different levels in ccRCC cell lines compared to 
normal renal epithelium (FC>2.0, p<0.05). A. Vo lcano plot, showing average fo ld changes 
and corresponding p-val ues for the ind ividua l  m i RNAs. Dotted l i nes ind icate the thresholds. B. 
M icroarray heat map showing the re lative abundance of the s ignificantly down- and upregu lated 
m iRNAs in the individua l  cel l  l ines .  C. Corre l ation  between USP4 transcript levels and m iR- 1 97 
abundance (Pearson- correlation :  -0.85) .  D.  Transcript levels of epithe l ia l  marker E-cadherin  in 
normal proxima l  tubu lar  epithe l ia l  cel ls  (MN 1 60 and PTEC), and the ccRCC-derived ce l l  l ines. 
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Table 1 .  mi RNAs sign ificantly up- and downregulated in ccRCC samples. Fold change: average 
expression level in  ccRCC-derived cel l  l ines (n = 1 0) versus average expression level in proxima l  
tubular epithel ia l  cel ls  (n =2). Boxed m iRNAs are located at genomic regions frequently showing 
copy number loss. 
Upregulated in ccRCC Downregu lated in ccRCC 
miRNA Locus Fold change p-value m iRNA Locus Fold  change p-va lue 
miR-892b Xp27.3 2 1 .8 0.001 0 m iR- 1 4 1  1 2p1 3.3 1 73 .8 0.000 1 
-----
miR-43 1 *  1 4932. 3 1  
m iR-324-3p 1 7p 1 3. 1  
m iR-500 Xp1 1 .32 
m iR-423-5p 1 7q 1 1 .2 
m iR-338-5p 1 7q25.3 
m iR-1 49 
m iR-1 97 
2q27.3 
1 p 1 3.3 







0.0280 miR-200c 1 2p1 3.3 1 
0.00 1 0  m iR-205 1 q32.2 
0.3360 m iR-200a 1 p36.33 
0.0069 m iR-429 1 p36.33 
0.0320 miR-1 46a 5q33.3 
0.0041 m iR-200a* 1 p36.33 
0.0083 m iR-200b 1 p36.33 
miR-1 0b 2q3 1 .3 
m iR- 1 0a 1 7921 . 3 1  -- -
miR- 1 35b 1 q32. 1 
m iR-625 1 4q32.3 
m iR- 1 0a* 1 7921 . 3 1  
m iR-200b�36.33 
miR-222* Xp 1 1 .3 
40.4 0.0001 
----
35.3 0.0001 - --
1 0.2 0.0069 
9.3 0.2800 
8.3 0.0090 













Fold change: average expression level in ccRCC-derived cel l  l ines (n = 1 0) vs average expression 
level in proximal tubu lar  epithe l ia l  cel ls (n =2). Boxed miRNAs are located at genomic regions 
frequently showing  copy n umber loss. 
significant decrease in abundance across the entire panel of ccRCC cell lines. Let-7g 
and miR-138, both reported to be suppressed in some cancer types, exhibited a more 
than two-fold decrease in abundance in 6/10 and 8/10 ccRCC cell lines, respectively 
(Supplementary Table 3) .  One pathway, development of microRNAs-dependent 
inhibition of EMT (p-value : 4 .6E-19), appeared to be significantly enriched for the set 
of 23 microRNAs that showed consistent aberrant expression in ccRCC. 
Coupling of miRNA expression to copy number aberrations and gene 
expression levels 
An altered level of miRNA expression in the ccRCC cell lines compared to the PTEC 
cells can be a consequence of an altered copy number for the miRNA locus. To 
address this question we analyzed if there was a correlation between the integer copy 
number and levels of expression of the miRNAs. For 73 miRNA loci, copy number 
aberrations were detected in at least two cell lines. The correlation was > 0.5 for seven 
miRNAs, while the highest correlation was detected for miR-574 located at 4p14, with 
a correlation coefficient of 0. 7 4. 
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To determine the pathogenic consequences of the significantly altered m iRNA 
levels, we correlated their expression levels to those of the protein coding genes. 
We focused on the proven target genes of the 23 m iRNAs we had identified as 
being significantly deregulated .  In total 64 validated targets were reported in 
the miRNA database, of which 47 passed the quality filters set for the microarray 
analysis. Interestingly, this set included only one gene, i.e. FUS1/TUSC2, for the set of 
upregulated m iRNAs. The other 46 genes were targets of the down regulated m iRNAs. 
Thirteen of these genes had a significantly higher mRNA level in the ccRCC cel l  lines, 
with an absolute fold change > 4 (Supplementary Table 4), supporting their interaction 
with the respective m iRNAs. 
miRNAs can exert oncogenic functions by targeting tu mor suppressor genes. We 
focused on 3p, a region of the genome that is deleted in most, if not all, ccRCC 
(van den Berg et al. , 1997). The expression profi ling data revealed 65 significantly 
downregulated transcripts that were located on 3p. Eight of these are predicted 
by TargetScan to contain a conserved target sequence for one of the significantly 
upregu lated miRNAs (Supplementary Table 5). Of these predicted m iRNA/mRNA 
combinations, miR-197 and ubiquitin specific peptidase 4 (USP4) showed the most 
significant inversed correlation {P-value = -0.85) (Figure 2c). 
DISCUSSION 
The kidney is a complex organ comprising many different cel l  types. Based on the 
variety of functions, each cel l type in the kidney will have its own specific m iRNA 
profile. Thus the miRNA profile of a kidney specimen is, to a large part, a reflection of 
the composition of that particular sample. ccRCC is considered to be derived from a 
specific type of cell, the epithelial cells of the proximal tubu l us. Tumor speci mens wi ll 
also contain variable amounts of d ifferent normal cell types, which wi ll al l contribute 
to the mi RNA profile of that specimen. As an example, we used an exome sequencing 
approach on ten pri mary ccRCCs, all microscopically se lected to have at least 80% 
tumor cells. The resulting data ind icated that the fraction of tu mor cells was often 
much lower, in some cases even less than 50%, d ue to unrecognized infiltrating 
lymphocytes. In the current study we circumvented these disadvantages by analyzing 
ccRCC-derived cel l  l ines and comparing their m iRNA profi les with short-term cultures 
of epithelial cells of the proximal tubu lus of the kidney. 
Fifteen miRNAs were significantly downregulated in all ten ccRCC cell lines 
compared to PTEC. We are the first to show such decreased levels for all the miRNA-200 
family members and miR-205. In reported studies on primary ccRCC tu mor specimens 
in comparison to the total renal tissue, only individual members of this m i  RNA family 
were identified (Nakada et al. , 2008; Chow et al. , 2010; Slaby et al., 2010; Weng et 
al . ,  2010), ind icating the strength of our approach using ccRCC-derived cell lines in 
combination with short-term cu ltures of PTEC. 
A decreased miR-205 level has not been reported before in ccRCC tu mors, but 
has been observed in several other tu mor types (Volinia et al., 2006). miR-205 shares 
some i mportant target genes with the miR-200 fam i ly that suppress the epithelial- to 
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mesenchymal transition (EMT) process (Gregory et al., 2008; review by Mongroo and 
Rustgi , 2010). miR-200 family members regulate the processes of EMT mainly by 
regulating ZEB 1 and ZEB2 translation through binding to their 3'UTR sequences. ZEB 1 
and ZEB2 are part of a complex network of transcriptional repressors that regulate 
the expression of E-cadherin and a number of master regulators of epithelial polarity. 
Thus, a decreased abundance of the miR-200 family will result in an increased activity 
of ZEB 1 and ZEB2, amongst others resulting in a repression of E-cadherin. Indeed, 
the transcript level of E-cadherin is strongly decreased in 9/10 of our ccRCC-derived 
cell lines (Figure 2d). Three EMT-related pathways were significantly enriched for 
the differentially expressed genes (Supplementary Table 2), further supporting the 
importance of this transition in the development of ccRCC. The development of the 
proximal tubuli of the kidney is the product of a complex series of events during 
embryogenesis that include a transition from mesenchyme to epithelium (Davies et al., 
1999). The development of ccRCC from these progenitor cells thus appears to include 
the reciprocal process. The acquisition of a mesenchymal phenotype gives tumor cells 
the capacity to infiltrate surrounding tissues, leading to increased cell motility and 
invasion. As such, the process appears to be linked to tumor progression rather than 
to initiating steps. 
Among the other significantly decreased miRNAs are miR-146, loss of which results 
in leukemia in a mouse model (Starczynowski et al., 201 1), and miR-10a and miR- 1 Ob, 
which are involved in the transcriptional regulation of HOX genes and are deregulated 
in several cancer types (Lund, 2010). In studies on primary tumor specimens, miR-
200a* and the primary transcripts of miR- 1 0a and miR- 1 Ob correlated with a good 
prognosis (Petillo et al., 2009). miR-1 0a and 106 have also been associated with 
non-metastatic ccRCC (Heinzelmann et al., 2011). miR-324, miR-423-Sp and miR-149, 
which showed significantly decreased levels in our ccRCC-derived cell lines, have 
been reported to discriminate between ccRCC and papillary RCC (Petillo et al., 2009). 
Three other miRNAs, i.e. miR-2006, miR-200c, and miR10b are part of a 65-member 
miRNA-signature that discriminates between different types of kidney tumors (Youssef 
et al., 201 1  ). 
None of the eight miRNAs that showed significantly increased levels in the ccRCC­
derived cell lines compared to PTEC have been reported in ccRCC before. Only 
miR-197 has a proven target: tumor suppressor candidate 2 (TUSC2/FUS1 ), located at 
the 3p21.3 region that is frequently lost (Du et al., 2008). The TUSC2 transcript levels 
seem to be unaltered in ccRCC. However, this interaction may well be important in 
the pathogenesis of ccRCC, as, in general, miRNA targeting leads to inhibition of 
translation and not degradation of its target genes. 
According to Knudson's classical model, recurrent loss of specific chromosomal 
segments in tumors suggests the presence of tumor-suppressive genes in these 
regions. Such a model could well apply to miRNAs. The clustering of miRNAs in 
regions of the chromosome that are frequently unstable in cancer indeed suggests that 
genomic alterations might be one of the mechanisms that control miRNA expression 
in cancer (Calin and Croce, 2006). Of the miRNAs that showed a decreased transcript 
abundance in the ccRCC-derived cell lines, six were located in genomic loci that are 
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frequently lost in ccRCC, i .e. miR-200a, miR-200a*, miR-200b, miR-200b* and miR-429 
located at 1 p36.33, and miR-625 located at 14923.3. This suggests that the loss of 
the chromosomal region that contains a miRNA locus is an important factor in the 
functional loss of these miRNAs. 
None of the 15 miRNAs that were consistently down regulated map to the short arm 
of chromosome 3, although let-7g and miR-138 did have a decreased level in 6/10 and 
8/10 of the analyzed cell lines, respectively. Thus, loss of function of one of the known 
miRNAs from 3p does not appear to be the driving force for the frequently observed 
loss of this chromosomal segment. As reduced expression of miRNAs by chromosomal 
losses explains only a subset of cases, other mechanisms such as epigenetic changes, 
or mutations within the mi RNA, may play a role in the inactivation of these miRNAs. 
In conclusion, we have used an alternative approach to identify miRNAs whose 
expression is consistently altered in ccRCC compared to their normal counterpart, the 
epithelial cells of the proximal tubulus, and pinpointed the epithelial- to mesenchymal 
transition as an important event in the development of ccRCC. The data presented 
here will help to interpret and understand the findings in primary RCC specimens, 
and may help to elucidate some of the processes that lead to the development and 
progression of ccRCC. With the availability of detailed expression-, miRNA- and CGH 
profi les, these cell lines should prove valuable in further studies. 
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SUPPLEMENTARY FIG U RES AND TABLES 
Supplementary Table 1 .  Recurrent copy number alterations i n  the ccRCC-derived cell lines 
Copy number losses Copy number gains 
Region of overlap Region of overlap 
Location (Mb from pter) Frequency Location (Mb from pter) Frequency 
1p pter-28,099 7 /10 Sq 129,266-qter 6/10 
3p pter-64,696 10/10 7p (1) 3,934-11,673 5/10 
4q 84,724-qter 5/10 7p (2) 27, 174-cen 6/10 
9p 22,022-31,998 8/10 7q cen-qter 5/10 
9q cen-qter 5/10 
11 q 112,852-qter 5/10 
14q 49, 977-qter 7 /10 
Supplementary Table 2. Pathways significantly represented in the group of up- and down­
regulated genes. 
Rank Pathway Maps 
1 Cell cycle_Chromosome condensation in prometaphase 
2 Cell cycle_ The meta phase checkpoint 
3 Cell cycle_Role of APC in cell cycle regulation 
4 Cell cycle_lnitiation of mitosis 
5 Cell cycle_Spindle assembly and chromosome separation 
6 DNA damage_ATM/ATR regulation of G1/S checkpoint 
7 Cell adhesion_Chemokines and adhesion 
8 Cytoskeleton remodeling_Cytoskeleton remodeling 
9 _ _  DNA damage_ATM / ATR regulation of G2 / M checkpo� 
10 Cell cycle_Start of DNA replication in early S phase 
11 Cytoskeleton remodeling_ TG F, WNT and cytoskeletal 
remodeling 
12 Cell cycle_ Transition and termination of DNA replication 
13 Cell cycle_Sister chromatid cohesion 
1 4  Cell cycle_Regulation of G 1 /S transition (part 1) 
15 Cel l  adhesion_ECM remodeling 
1 6  Reproduction_Progesterone-mediated oocyte maturation 
17 Immune response_Histamine H1 receptor signaling in immune 
response 
1 8  Cell cycle_Cell cycle (generic schema) 
19 Cell cycle_Role of Nek in cell cycle regulation 
20 Cell cycle_ESR1 regulation of G1/S transition 
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pValue Ratio 
1.057E-13 15/21 
1.609E-13 1 9/36 
2.734E-12 17/32 
4.919E-12 15/25 
7.444E-11 1 6/33 
5.419E-10 15/32 
1.730E-09 26/100 
1.323E-08 25/1 02 
3.769E-08 1 2/26 
6.580E-08 1 3/32 
8.085E-08 25/111 
1.045E-07 1 2/28 
6.392E-07 10/22 
6.991 E-07 1 3/38 




4 .836E-06 11/32 
·-- ·---
6.811 E-06 11/33 

































dCTP/dUTP metabol ism 
Apoptosis and surviva l_p53-dependent apoptosis 
Cell cycle_Nucleocytoplasmic transport of CDK/Cycl ins 
S igna l  tra nsduction_AKT signal ing 
Immune response_Oncostatin M signa l ing via MAPK i n  human 
ce l l s  
S igna l  tra nsduction_cAMP signa l ing 
-- ---
Cel l  adhesion_Endothe l ia l  cel l  contacts by junctiona l  
mechanisms 
Cel l  cycle_Role of 1 4-3-3 proteins in ce l l  cycle regu lation 
I mmune response_M I F-mediated g lucocorticoid regu lation 
Cel l adhesion_lntegrin-mediated cel l  adhesion and migration 
Immune response_Oncostatin M signa l i ng via MAPK in  mouse 
cel ls 
Cel l  cycle_Role of SCF complex in ce l l  cycle regu lation 
Cell adhesion_ Tight junctions 
Apoptosis and surviva l_G ranzyme A signa l i ng  
---- --
DNA damage_Brca 1 as a transcription regu lator 
DNA damage_Role of Brea 1 and Brca2 in DNA repair 
DNA damage_DNA-damage-induced responses 
Immune response_l L-1 7 s igna l ing pathways 



















1 .647 E-04 
1 .881 E-04 
Development_ TG F-beta-dependent induction of EMT via RhoA, 2 .073E-04 
P l3K and I LK. -- --
Cel l  adhes ion_Cadherin-mediated cel l  adhesion 2.383E-04 
Development_ TGF-beta-dependent induction of E MT via MAPK 2.543E-04 
Immune response_CD40 s igna l ing 
Development_Regu lation of epithel ia l-to-mesenchymal 
transition (EMT) 
Apoptosis and surviva l_HTR 1 A  signa l ing 
-- --- --- --
Regu lation of C FTR activity (norm and CF) 
Development_Beta-adrenergic receptors transactivation of 
EG FR  
ATP/ITP metabol ism 
Regu lation of l ipid metabol ism_Regu lation of l ip id metabo l ism 
by n iacin and isoprena l ine 
-- -- --
Cel l  adhesion_H istamine H 1 receptor s igna l ing in the 
interruption of cell barrier i ntegrity 
3 .251  E-04 
3 .25 1 E-04 
4.520E-04 
4.590E-04 
6 .821  E-04 
7 .224E-04 
7 .501  E-04 




7/1 4  
1 2/43 
1 1 /37 














1 1 /46 
8/26 
1 1 /47 
1 3/64 
1 3/64 
1 1 /50 
1 2/58 
9/37 
1 9/1 24 
1 0/45 
1 0/45 
Ratio: number of genes with a s ign ificantly a ltered level of expression versus the tota l number of 
genes in  th is pathway as indicated in  the GeneGo package 
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Supplementary Table 3. m iRNAs located in recurrently lost regions that show an average 
decrease in transcript abundance of two-fo ld or more in a subset of the ccRCC-derived ce l l  l i nes. 
miRNA Locus RCC-1 RCC-4 RCC-5 RCC-AB 
hsa-m i R-200b 1 p36.33 7 .6  ,!, 27 .0 ,!, 4.0 ,!, 4.3 ,!, 
hsa-m i R-200b* 1 p36.33 2.6 ,!, 4.8 ,!, 1 . 1  t 9.2 ,!, 
hsa-mi R-200a* 1 p36.33 5.0 ,!, 4.9 ,!, 1 0 .7 ,!, 7 .4  ,!, 
hsa-m iR-200a 1 p36.33 40.3 ,!, 1 6 .4 ,!, 4. 1 ,!, 5.8 ,!, 
hsa-m iR-429 1 p36.33 78 .2  ,!, 8.3 ,!, 2 .8  ,!, 5.2 ,!, 
hsa-m i R-34a 1 p36.22 2 .7  ,!, 4.5 ,!, 1 . 1 ,!, 3.2 ,!, 
hsa-let-7g 3p2 1 . 1  5 .4 ,!, 45 .3  ,!, 1 . 7 ,!, 2.5 ,!, 
hsa-mi R- 1 38 3p2 1 .32 & 1 6q 1 3  1 8 .5  ,!, 3 . 2  ,!, 4.7 ,!, 5.9 ,!, 
hsa-let-7f 9922 .32 & Xp1 1 . 22 6.0 ,!, 60. 1  ,!, 3 . 1  ,!, 1 .6 ,!, 
hsa-let-7d 9922.32 3 .0 ,!, 23 .7  ,!, 1 . 8 ,!, 1 .4 ,!, 
hsa-m i R-23b 9q22 .32 4.6 ,!, 1 0 .2 ,!, 1 . 3 ,!, 1 . 3 t 
hsa-m iR-27b 9922.32 8 .7 ,!, 9 .3  ,!, 1 .6 ,!, 1 .0 -- --
hsa-m iR-2 1 993 1 .3 6.0 ,!, 1 1 .3 ,!, 1 .2 ,!, 1 . 5 ,!, 
hsa-let-7a 9922.32 & 1 1  q24 . 1  & 229 1 3 .3 1  4 .8  ,!, 33 .7  ,!, 3 .7  ,!, 1 .4 ,!, 
hsa-m i R-625 1 4923 .3  3 .0  ,!, 7 . 9  ,!, 1 1 .9 ,!, 8 . 1  ,!, 
hsa-mi R-1 34 1 4q23.3 4 .6 ,!, 3.4 ,!, 2 . 1 ,!, 2.3 ,!, 
Numbers ind icate the absolute fo ld change for the ccRCC-derived ce l l  l i ne re lative to PTEC. (t) 
positive FC, (-!-) negative FC. Tota l# ind icates number of ce l l  l ines with a fo ld change > 2.  
Supplementary Table 4. Va l idated target genes with a 






H MG B 1  





TI M ELESS 
UH RF1 
USF2 
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Fold Change microRNA 
3.2 m iR-1 46a 
2 . 1  m iR-1 46a 
4.7 m iR-1 46a 
3 .4  m iR-1 46a 
2 .9  m iR- 1 41  
5 .7  m iR-1 46a 
2.5 m iR- 1 46a 
3 .2 m iR- 1 46a 
2.4 m iR- 1 46a 
2 .9 m iR- 1 46a 
2 .5  m iR- 1 46a 
5.0 m iR- 1 46a 
2 . 1  m iR- 1  0a 
RCC-ER RCC-FG2 RCC-HS RCC-JF RCC-JW RCC-MF Tota l # 
1 8 .7  ,J, 3 . 1  ,J, 7 .4 ,J, 4.2 ,J, 6 .6 ,J, 6 .9 ,J, 1 0  -- - -- -- - -- --
1 . 8 ,J, 3 .6  ,J, 5.8 ,J, 4.6 ,J, 2 .7 ,J, 9.0 ,J, 9 
3.5 ,J, 6 .8 ,J, 1 1 .3 ,J, 9 .6 ,J, 5 .3  ,J, 1 7.5 ,J, 1 0  - --- ---- -- --·-
74.8 ,J, 4.4 ,J, 8 .5 ,J, 7.1 -1, 9.2 ,J, 6.4 -1, 1 0  ---- --
68.5 -1, 4.0 ,J, 4.5 ,J, 6 .7  ,J, 1 0 .5 ,J, 7 .6 -1, 1 0  
1 9.4 ,J, 2 .2  -1, 2 .7  -1, 1 .8 -1, 2 .9  ,J, 1 .6 -1, 7 -- --- - --
1 2 .5 ,J, 1 .6 ,J, 1 6 .8  -1, 1 . 5 -1, 1 6 .4 ,J, 1 .5 -1, 6 -- -- --- -- -- - -- --
----
1 3 . 1  ,J, 7 .6  -1, 2.0 t 2.8 -1, 1 .0 - 1 0.5  ,J, 8 -- --
6.0 ,J, 1 .0 - 23.6 -1, 1 . 1 t 28.4 ,J, 1 .3 -1, 6 -
4.0 ,J, 1 .0 - 1 1 .3 -1, 1 . 1 t 1 3 . 1  -1, 1 . 1 - 5 
4.5 ,J, 1 .0 - 2 .6 -1, 1 .1 t 2 1 .0 ,J, 1 .3 -1, 5 -- -- � -- ---
6.1 -1, 1 .2 ,J, 2 .8  ,J, 1 . 3 ,J, 1 3 .9  -1, 1 .5 -1, 5 -- --
4.2 ,J, 1 .6 -1, 1 3 .7  ,J, 2 .4 -1, 6 .5 ,J, 1 . 1 -1, 6 --- --- --- -- --
3.6 -1, 1 .2 t 1 7 .0 -1, 1 .2 t 34.7 ,J, 1 .5 -1, 6 -- -- -- -- --
3.0 ,J, 1 .5 ,J, 9.6 -1, 8.2 -1, 4.5 -1, 6.0 -1, 9 
4.0 ,J, 7 .6  -1, 2.3 t 1 . 7 -1, 3.2 ,J, 4.0 -1, 9 





p-va lue Symbol FC p-va lue 
Pearson 
correlation 
hsa-m i R- 1 49 2927 .3  3.0 t 0.0041 ARPC4 4. 9 -1- 6 .51  E-09 -0.63 ---




1 p 1 3.3 2 .8  t 
1 7p 1 3 ._1 _
8.3 t 
1 7925.3 
OXSR1  2 .9  ,J, 6 .60E-09 -0.57 
0.0083 USP4 2.2 -1-----
0.001 0 G NAl2 3 .0 -1-
SUMF1 2 .6  -1-
2 .25E-07 




9 . 1 3E-1 1 -0.8 1 
0 .0320 VG LL4 2 .6  -1- 9 .37 E-06 -0.75 ---- ------ ------
G NAl2 3 .0  ,J, 1 . 1 5E-09 -0.57 ------ ---- ---
Xp27.3 2 1 .8 t 0.00 1 0  UBP 1  2.0 -1- 2 .97E-09 -0.72 
FC: Fold change (ccRCC versus PTEC). {t) positive FC, (-1-) negative FC 




In th is thesis, we describe different approaches used to identify novel ccRCC tumor 
suppressor genes. Here, I summarize our findings, put them in a broader perspective, 
and speculate on future perspectives. 
Chromosomal aberrations and VHL mutations in ccRCC 
To facilitate our search for ccRCC tumor suppressor genes, we obtained a panel 
of ccRCC-derived cell lines. During the course of this project, these cel l  lines were 
characterized in detail  with respect to their chromosoma l  copy number, miRNA 
expression, and gene expression profiles. Moreover, these cell lines were screened for 
inactivating mutations in the Von Hippe/ Lindau (VHL) gene, which is a known ccRCC 
tumor suppressor gene. 
We assessed chromosoma l copy number aberrations for a total of eleven ccRCC­
derived cell l ines, and 22 primary ccRCC tumors. We observed, amongst various 
other aberrations, a complete loss of 3p in seven cel l lines and 14 primary tumors. 
Three cell lines and five tumors had a large terminal deletion, the sma llest being 64 
Mb. One primary tumor showed retainment of the terminal pa rt (pter to 24 Mb from 
pter), which included the 3p25 region. The two tumors that did not show 3p loss did 
not show a loss or gain for any other locus, indicating that these samples may not 
have conta ined sufficient tumor cel ls to detect copy number aberrations. Our findings 
underscore those of recent papers that show that the vast majority of ccRCC tumors 
have large termina l deletions of 3p that comprise almost the entire p-arm (Toma et 
a l . ,2008; Sukosd et al., 2003). In contrast to what others h ave observed (Van den Berg 
et al., 1997; Chudek et al., 1997; Braga et al. , 2002), none of the ccRCC samples that 
we ana lyzed showed interstitia l 3p deletions. One cell line that did not show 3p loss 
was excluded from subsequent experiments, as this cel l line may not hold cl ues for a 
3p-located tumor suppressor gene. Other recurrently lost regions include segments 
on 1 p, 4q, 9, 11 q, and 14q. Eight out of ten cel l lines carried a homozygous deletion 
on 9p21 varying in size from 50 to 600 kb, which inc luded the CDKN2A and CDKN2B 
gene loci, encoding the P16 and P15 proteins, respectively. This suggests a possible 
role for p15 and/or p16 inactivation in ccRCC development. 
We identified inactivating mutations in VHL, located at 3p25, in five out of ten 
ccRCC-derived cell lines and in six out of ten primary ccRCC tumors that were screened 
for VHL mutations. This is in agreement with previous reports of the inactivation of VHL 
in about 50 % of ccRCC tumor samples (Gnarra et al., 1994; Nickerson et a l . ,2008). The 
function of VHL and its role in ccRCC tumorigenesis have been well studied during 
the past decade. VHL is part of a ubiquitin ligase complex that targets transcription 
factor HI Fa for proteosomal degradation. Inactivation of V HL results in consistently 
high HIFa levels, triggering the upregu lation of HI Fa targets, which include vascular 
endothelial growth factor (VEGF) and platelet derived growth factor (PDGF). These 
targets in turn activate pathways such as the RAF-MEK-ERK and Phosphatidylinositol-3 
kinase-AKT-m TOR pathways, triggering angiogenesis and proliferation (Clark et a l . ,  
2009; Baldewijn et al . ,  2010; reviewed by Kaelin, 2008) . Recent reports show that VHL 
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is involved in several other processes, including tight junction formation, suggesting 
a role in epithelial-to-mesenchymal transition (Harten et al., 2009). Although VHL is 
a major player in ccRCC tumorigenesis, VHL is not inactivated in all ccRCC tumors, 
and VHL loss alone is not sufficient for ccRCC development, suggesting the need for 
additional genetic events (Mandriota et al., 2002; Young et al., 2008). For a long time 
the search for (ccRCC) tumor suppressor genes has been focused on protein coding 
genes. Recent findings, however, indicate that noncoding genes, including miRNAs, 
can exert tumor suppressive or oncogenic functions in a tissue-specific manner (reviews 
by Kent et al., 2006; Garzon et al., 2006; Chen et al., 2005). 
miRNAs and ccRCC 
In Chapter 6, we compared the genome-wide microRNA expression profiles in the 
ccRCC-derived samples with those in proximal tubular epithelial cells (PTECs), which 
are the cells from which ccRCC tumors are thought to be derived (Thoenes et al., 
1985). We showed a significant downregulation of all members of the miR-200 family 
and miR-205. These miRNAs control cellular morphogenesis by translational regulation 
of targets that include the transcription factors ZEB 1 and ZEB2, which in their turn 
regulate the expression of E-cadherin and a number of master regulators of epithelial 
polarity (Gregory et al., 2008). As a result of loss of the miR-200 family, epithelial 
cells undergo an epithelial-to-mesenchymal transition (EMT), which, in a tumorigenic 
context, confers a metastatic potential to the cells (Gibbons et al., 2009). Thus, our 
data suggest a role for miRNAs in ccRCC progression. None of the known miRNAs 
that are located on the short arm of 3p were consistently downregulated in the ccRCC 
samples, suggesting that loss-of-function of these miRNAs is not the driving force for 
the frequently observed loss in this chromosomal segment. 
A new gene for ccRCC, SETD2 
In Chapter 2, we applied Gene Identification of nonsense-mediated m RNA-decay 
Inhibition (GIN/) on the ccRCC-derived cell lines that showed 3p loss, and identified 
SETD2 as a new candidate ccRCC tumor suppressor gene. SETD2 is located at 
3p21, and encodes a histone methyltransferase that is nonredundantly responsible 
for trimethylation of lysine 36 of histone 3 (H3K36me3). We identified inactivating 
mutations in five out of ten ccRCC-derived cell lines. These five cell lines, and two 
other cell lines, showed loss or significant decrease of global H3K36me3 modification 
levels. Sequencing of SETD2 in a total of 20 primary ccRCC tumors revealed missense 
mutations in two of them. A huge exome-sequencing project revealed inactivating 
mutations in SETD2 in 12 out of 407 (3%) primary ccRCC tumors, providing in vivo 
evidence for the relevance of our findings (Dalgliesh et al., 2010). 
Dalgliesh et al. (2010) did not identify mutations in SETD2 in other tumor types, 
and suggested that inactivation of SETD2 might be specific for ccRCC tumors. We 
performed a mutational screening of SETD2 in nine small-cell lung carcinoma-derived 
cell lines, a type of carcinoma also characterized by loss of 3p21, but also did not 
find any mutations. However, the number of investigated non-ccRCC tumors might 
not have been sufficient to give a good estimate of the mutation rate in other tumor 
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types. M o reover, decreased SETD2 tra nscri pt leve ls  have been observed in m a l ignant 
breast ca ncer (Al Sarakbi et a l ., 2009), and  a tra nsposon-based genetic screen i n  m ice 
suggested a ro le  for SETD2 i nactivation in the deve lopment of pancreatic cancer (Sta rr 
et a l . ,  2009) . Da lg l i esh et a l .  (20 1 0) reported the identification of inactivati ng m utations 
in  other  h i stone-modifying enzymes in  a su bset of ccRCC tu mors; th is  suggests a 
broader  ro l e  for aberra nt h iston e  3 methylation in ccRCC development. Therefore, 
i nactivat ing m utations in these d ifferent h istone H 3-modifying enzymes might 
contribute to tumorigenic devel opment by affecting the same pathways. Aberra nt 
activity of h i stone- mod ifyi ng enzym es cou l d  resu lt i n  a ltered ch romati n configuration 
and d isru ption of norma l transcri ptiona l  progra ms, push ing  the ce l l  towa rds ca ncerous 
deve lopment (Mori n  et a l . , 20 1 1 ;  reviewed by Fu l l g rabe et a l ., 20 1 1 ) .  
The function  of SETD2 
Th e m echan isms th rough wh ich i nactivation of SETD2 contributes to ccRCC 
deve lopment a re not yet fu l l y  known . However, one cou l d  specu late that l oss of 
H 3 K36me3,  wh ich is the resu lt of SETD2 i nactivatio n ,  resu lts in dereg u lated tra nscri ption 
an d/or transcri ption-re l ated process ing of a set of genes that p lay a ro l e  i n  ccRCC 
tu m origenesis. Trimethylat ion of H 3 K36me3 is i nt imate ly  l i n ked with transcriptiona l  
e longation ,  as  S ETD2 is recru ited to nucl eosomes by hyperphosphorylated RNA 
po lymerase d u ring  tra nscriptiona l  e longation (Yoh et a l ., 2008) . Furthermore,  the 
prefere ntia l l ocation  of H3K36me3 on exons  re lative to intronic reg ions suggests a 
ro le  for H K36me3 in exon defi n ition  and ,  therefore , in reg u l at ing sp l ic ing (Kolas i nska­
Zwierz et a l ., 2009; Spies et a l ., 2009, Andersson et a l ., 2009, Huff et a l ., 201 0). H istone 
modifications  have previous ly been suggested to be able to modu late the outcome 
of a lternative sp l ic ing by infl uenc ing th e e longat ion rate of RNAPOL I I  (Schor et a l ., 
2009). S lowing of the e longation rate cou ld  resu l t  i n  recogn ition of "wea k" sp l ice sites, 
resu ltin g  in i nc lusion of a lternative exons (De la M ata et a l ., 2003). I ndeed, recently, 
Luco et a l .  (20 1 0) showed that H 3 K36me3 can d i rectly affect sp l ic ing by recruit ing 
polypyri m i d i n e  tract-b ind ing protei n  (PTB) v ia  the ch romati n bind ing protein M RG 1 5 , 
wh ich specifica l l y  recogn izes trimethylated H 3 K36.  PTB b inds to exon-specific s i lenc ing 
e lements, resu lti ng  in  the repression  of these exons (Luco et a l .,20 1 0). They suggested 
the existence of severa l of these " ad a ptor com plexes " ,  wh ich consist of a combination 
of ( 1 ) a mod ified h i  stone ta i l ,  (2)  a ch romatin b ind ing  protein that recogn izes th is 
specifi c  h istone  modification ,  a n d  (3) a sp l ice reg u lator that is recru ited to the h istone 
mark via the ch romatin-bind ing  protein  (reviewed by Luco et a l ., 201 1 ) .  Recent 
find ings suggest that a lternative sp l ic ing a n d  trimethylated H3K36 can bi-d i rectiona l ly 
infl uence each other. Co-tra nscri ptiona l  sp l iceosome assembly and  sp l ic ing enhances 
the recru itment of SETD2, lead ing  to enrichment of H3 K36me3 (De A lmeida et a l ., 
20 1 1 ;  K im et a l . ,  201 1 ). Al l these find ings  suggest that S ETD2 inactivation  resu lts i n  
aberrant spl ici n g ,  wh ich is com mon i n  cancers a n d  p lays a ro le i n  tu morigenesis and  
m a i ntenance (Venab les et  a l ., 2009) . 
To assess the effect of SETD2 i nactivation on transcri pt level s  a n d  a l ternative 
spl ice s ite cho ice in p roxim a l  tu b u l a r  epith e l i a l  ce l ls ,  we trans iently knocked down 
SETD2 i n  these ce l l s, resu lti n g  i n  s ign ificant ly decreased g loba l H 3 K36me3 levels. 
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By RNAseq, we assessed the effect of this knockdown on transcript levels and exon 
usage genome-wide. As expected from the literature (Edmunds et al., 2008; Yoh et al. ,  
2008), there was a positive correlation between the presence of H3K36me3 and gene 
expression in the wild-type PTEC sample. A limited set of genes showed a significant 
change in transcript levels as a result of SETD2 knockdown. Gene set enrichment 
analysis of the set of 55 downregulated genes showed a significant enrichment for 
angiogenesis-related processes, and the ErbB- and P53 signaling pathways. The 
enrichment for angiogenesis-related genes is in concordance with the crucial role 
for SETD2 in embryonic vascular remodeling in mice (Hu et al., 2010). SETD2 was 
previously suggested to play a role in the transcriptional control of a subset of P53 
target genes by direct interaction with P53 (Xie et al., 2008). It remains to be explored 
which of the observed changes in transcript levels are a direct consequence of SETD2 
knockdown, and what mechanisms link SETD2 function and/or H3K36me3 with the 
regulation of transcript levels. 
Considering alternative splicing, our preliminary data analysis indeed revealed an 
apparent change in alternative splicing as a resu lt  of SETD2 knockdown for a set of 
genes, which corroborated the suggested role of SETD2 via H3K36me3 in alternative 
splice site choice for a subset of target genes (Luco et al., 2010). Several of the 
genes that show a change in alternative exon usage encode proteins that function 
in processes that are relevant to tumorigenesis, such as WNT signaling (Axin), TGF-13 
signaling (LTBP3}, cell cycle entry control (PUM2), and DNA repair (RAD 7) .  Besides 
genes that show a change in alternative splice site choice, some genes appeared to be 
transcribed from a different transcriptional start site as a result of SETD2 knockdown. It 
was recently shown that KDM5B, a H3K4me3 demethylase, is recruited to H3K36me3 
via interaction with the chromodomain protein MRG 15. This resu lts in a decrease of 
intragenic H3K4me3, thereby suppressing cryptic intragenic transcription (Xie et al. ,  
2011 ) .  Thus, loss of H3K36me3 could indeed resu lt  in alternative transcriptional start 
site choice. The exact mechanisms and proteins that underlie the observed changes 
in alternative splicing or transcriptional start site, and the effect of these changes 
on the function of the encoded proteins, as wel l  as their potential role in ccRCC 
tumorigenesis, require further functional study. 
PBRM1 
The observed frequency of inactivating mutations in  SETD2 in  ccRCC tumors suggested 
that there were probably other potential ccRCC tumor suppressor genes located at 
3p21 to be discovered. As our GINI analysis did not reveal any other candidates, we 
decided to make use of the recently developed next-generation sequencing (NGS) 
technology to look for additional inactivated genes (Chapter 5). This resulted in the 
identification of inactivating mutations in PBRM1 in seven out of ten ccRCC tumors 
and inactivating mutations in BAP1 and ZNF197 in one tumor. Moreover, we identified 
inactivating mutations in PBRM1 in five out of ten ccRCC-derived cell lines. PBRM1 
is located at 3p21, and encodes BAF180, which is the chromatin targeting subunit 
of the SWI/SNF nucleosome remodeling complex (Thompson et al., 2009). SWI/SNF 
complexes are large ATP-dependent chromatin-remodeling machines that change 
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the accessibility of DNA by control l ing the dynamics of nucleosome occupancy. The 
frequent inactivation of PBRM 1 in ccRCC has also been reported by Varela et al. 
(2011), who identified inactivating mutations in PBRM 7 in 92 out 227 (41%) primary 
ccRCC tumors. This strongly suggests that PBRM 7 is an important ccRCC tumor 
suppressor gene that plays a role in tumorigenic development in a large fraction of 
ccRCC samples. Severa l  other components of the SWI/SNF remodeling complex are 
involved in the development of different cancer types (Schneppenheim et a l .,  2010; 
Rodriguez-Nieto et al. ,  2011; Jones et a l., 201 O; reviewed by Reisman et a l., 2009). 
The identification of inactivating mutations in PBRM 1 in four breast cancer samples 
(Xia et al., 2008), a pancreatic cancer sample (Jones et a l., 2008), and several cell lines 
derived from different tumor types (Varela et al., 2011 ) provide additional support for 
PBRM 1 being a true tumor suppressor gene. Furthermore, Varela et al. (2011) showed 
that siRNA-mediated knockdown of PBRM 1 in ccRCC-derived cell lines with wild-type 
PBRM 1 results in a significant increase in proliferation, increased colony formation in 
soft agar, and increased cell migration. However, more in vivo evidence is needed to 
prove the tumor suppressive role of PBRM 1 in ccRCC. 
The frequent inactivation of BAP1  in other tumor types (Bott et al., 201 1; Harbour et 
al., 2010), and the role of the encoded protein in chromatin regulation, make BAP1  an 
interesting candidate ccRCC cancer gene. The truncating mutation in ZNF1 97, which 
was identified in a ccRCC sample in which no VHL mutation was found, is interesting, 
given the fact that an alternative isoform of ZNF197 encodes a protein that is possibly 
involved in VHL-mediated HIF-1-a transactivation (Li et al., 2003). Inactivation of 
ZNF1 97 might therefore be redundant to VHL inactivation. Mutational screening of 
a larger panel of ccRCC tumors is however needed to give a better estimate of the 
mutational frequency in ccRCC for these genes. 
ccRCC genetics 
Inactivation of individual ccRCC tumor suppressor genes such as VHL, PBRM 1 ,  or 
SETD2 could confer growth advantage upon the proximal tubular epithelia l  cel l. 
However, the observed concomitant mutations in PBRM 7, VHL, and SETD2 in a subset 
of ccRCC samples suggest that at least three mutations are required for a proxima l 
tubular  epithelial cell to develop into a ccRCC tumor. As shown by Young et a l .  (2008) 
in a Cre/loxP mouse model, VHL inactivation a lone is indeed not sufficient to lead to 
ccRCC tumors in mice. Generation of single-, double-, as well as triple-conditional 
knockout mice that represent the possible "combinations" of inactivation of VHL, 
PBRM 1 ,  and SETD2 might therefore be necessary to confirm the tumorigenic effect of 
inactivation of these genes in proxima l  tubular epithelial cells. These knockout mice 
could a lso provide clues about the possible mechanisms through which inactivation of 
the individua l genes contributes to ccRCC development, as well as the probable order 
in which the mutational events take place during ccRCC development. One possibility 
is that inactivation of these genes contributes to ccRCC development by affecting 
different pathways. Alternatively, the functions of the proteins which are encoded by 
these genes might converge on the same pathways, and inactivation of these genes 
might therefore mutua l ly  strengthen their effects. PBRM1 plays a role in coordinating 
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senescence by regulating the transcriptional activity of a subset of p53 target genes 
(Burrows et al., 2010), and has been suggested to be involved in the cellular response 
to hypoxia (Kenneth et al., 2009), suggesting a functional overlap with VHL function. 
Indeed, Varela et al. (2011) showed that nearly all primary ccRCC tumors that harbor 
inactivating mutations in PBRM 1 have a "hypoxia signature" ,  including those in which 
no VHL mutations were identified. 
An extensive cross-talk has been shown to exist between different histone 
modifications and the enzymes that are responsible for these modifications (Kouzarides 
et al., 2007). Interestingly, the H3K27me3 demethylase UTX travels with the elongating 
RNAPOLII complex (Smith et al., 2007). It is therefore tempting to speculate that the 
inactivation of the different histone methylation enzymes observed in ccRCC tumors 
affects the same set of target genes. Recently, VHL has been shown to regulate gene 
expression and tumor growth through the regulation of histone demethylases (Beyer 
et al., 2008; Niu et al., 2011; Yang et al., 2009). We therefore propose that inactivation 
of VHL has a tumorigenic effect in PTECs partially as a result of deregulation of histone 
demethylases. Inactivating mutations in histone methylation enzymes such as SETD2 
irreversibly alter histone modification patterns, resulting in a loss of cellular identity, 
and contributing to ccRCC development (Figure 1 ) .  
In conclusion, our data indicate that the short arm of chromosome 3 harbors several 
genes that could contribute to ccRCC development when inactivated (Figure 2). 
The frequently observed 3p loss in ccRCC tumors could be driven by the inactivation 
of different ccRCC tumor suppressor genes located at 3p, or combinations of 3p 
tumor suppressors. In general, it is assumed that a subtle mutation in one allele of a 
tumor suppressor gene provides a "first hit " ,  after which loss of a larger chromosomal 
segment results in loss of the other allele, and therefore in the functional inactivation 
of the tumor suppressor gene. Given the apparent presence of multiple candidate 
ccRCC tumor suppressors on 3p, it is however tempting to speculate that 3p loss 
alone could already confer growth advantage upon the proximal tubular epithelial 
cell, and could therefore provide an early step in tumorigenic development. 
Several of the mutated genes in ccRCC encode proteins that modify histone tails 
or remodel chromatin, suggesting that aberrant chromatin regulation is a core driver 
event in the development of clear cell renal cell carcinoma. Unraveling the mechanisms 
through which aberrant chromatin regulation contributes to ccRCC development will 
be an important area of future ccRCC research, and may result in the identification of 
novel therapeutic targets. 
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Figure 1 .  Role of VHL in the regulation of histone modifications. (1 ) V H L  forms part of an 
E3-ubiquitin ligase complex that targets the transcription factor Hypoxia inducible factor (H I F)-a 
for degradation. (2) Inactivation of VHL results in the accumulation of H I F-a, which forms a 
heterodimer with H I F-�, and translocates to the nucleus, where it binds to hypoxia-responsive 
elements (H RE) and activates the transcription of target genes. Recently, these target genes 
have been shown to include several histone demethy lases (Beyer et al., 2008; Niu et a l ., 2008). 
Inactivation of VHL therefore results in consistently high histone demethy lase levels, resulting 
in the aberrant regulation of histone modifications, with possibly  tumorigenic consequences. 
Inactivating mutations in histone methyltransferase SETD2 result in tota l loss of H3K36me3, 
irreversibly a ltering histone modification patterns. The tumorigenic effects of VHL inactivation 
and inactivation of SETD2 and other histone modifying enzymes that have been shown to be 
inactivated in a subset of ccRCCs (Dalgliesh et a l., 2010) might therefore converge, at least 
partia l l y, on the same pathways. 
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Figure 2. Schematic picture of the short arm of chromosome 3 (3p), showing the locations 
of "3p genes" in which inactivating mutations were identified during this project. The 
columns represent the ten ccRCC tumor samples that were screened for mutations in 3p genes 
by targeted exome-sequencing (Chapter 5) and the ten ccRCC-derived cell lines. These cell 
lines were screened for VHL, PBRM 1 ,  and SETD2 mutations, but not for mutations in BAP 7  and 
ZNF1 97. The vertical line represents the minimally deleted region among this set of ccRCC 
samples, comprising a large terminal part of 3p. The little squares represent the identified 
mutations. Targeted 3p exome sequencing of ten primary ccRCC did not reveal any inactivating 
mutations in SETD2. However, screening for SETD2 mutations in another set of primary ccRCC 
tumors revealed missense mutations in two out of ten samples (Chapter 2) . 
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Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, and 
accounts for 3% of all new cancers diagnosed in the Western world. Clear cell renal 
cel l  carcinoma (ccRCC) is by far the most prevalent subtype, comprising more than 
70% of adult malignant kidney tumors. ccRCC tumor are thought to be derived from 
the epithelial cel ls  of the proximal tubuli (PTECs). 
In most cases, ccRCC tumors are still localized at the moment they are found. 
Surgical removal is the standard of care for these tumors, and offers long-term 
recurrence-free survival, although for patients who suffer from metastatic disease or 
develop distant relapse, the scenario is worse. Renal cell carcinomas are resistant 
to traditional cytotoxic chemotherapy. lmmunotherapy, which has been the most 
frequently used therapy until recently, has not been satisfactory in most cases either. 
Advances in the understanding of ccRCC biology have led to the development 
of approaches that target pathways that are characteristic and essential for ccRCC 
tumors, and show superior response rates compared to immunotherapy. 
At the genomic level, ccRCC is characterized by a range of copy number alterations, 
of which loss of the short arm of chromosome 3 is by far the most frequent one. 
Genomic regions with a high incidence of al lelic loss are thought to harbor so-called 
tumor suppressor genes (TSGs). The Von Hippe/ Lindau (VHL) gene, located at 3p25, 
is a known TSG and is bi-allelicely inactivated in a large fraction of ccRCC tumors. 
However, VHL is not inactivated in all ccRCC tumors, and inactivation of VHL alone 
does not result in ccRCC development, suggesting that additional and/or alternative 
genes play a role in ccRCC development. 
The identification of novel TSGs was hampered by the omission of methods to 
screen large numbers of genes in parallel for small (point) mutations. This situation 
has changed in the last decade. New methods like Gene Identification by nonsense­
mediated mRNA decay Inhibition (GINI), and, more recently, next-generation 
sequencing-based approaches, have given us new and powerful tools to identify 
tumor suppressor genes. 
This thesis presents the search for novel ccRCC tumor suppressor genes involved 
in the development of ccRCC. 
In Chapter 1, an overview of the current knowledge regarding the epidemiology, 
etiology, and genetics of ccRCC is presented. 
In Chapter 2, we describe the use of GINI in the search for novel ccRCC tumor 
suppressor genes. In this method, the NMD pathway, a pathway that degrades mRNA 
molecules that harbor a premature termination codon (PTC), is pharmacologically 
inhibited in cell lines. This results in the accumulation of transcripts harboring a 
PTC. The increased transcript levels of these mRNAs can be detected using gene 
expression microarrays. The presence of the mutation in this transcript causing the 
PTC still needs to be identified by Sanger sequencing. We applied a GINI strategy 
on a panel of ten ccRCC-derived cell lines and combined several methods and 
criteria to maximize the chances of finding ccRCC tumor suppressor genes and, at 
the same time, minimize the number of false-positive candidates that hampered the 
analysis of GINI strategies described earlier. This led to the identification of mutations 
introducing a premature termination codon in histone methyltransferase gene SETD2, 
located at 3p21, in two cell lines. Sequencing of SETD2 in the other cell lines revealed 
inactivating mutations in three of them. SETD2 is responsible for trimethylation of 
lysine 36 of histone H3 (H3K36me3). Consistent with this function, we observed a loss 
or a decrease of H3K36me3 in seven out of the ten ccRCC cell lines. Identification of 
missense mutations in 2 out of 10 primary ccRCC tumor samples added support to the 
involvement of loss of SETD2 function in the development of ccRCC tumors. 
In Chapter 3, we evaluate the use of GINI in the search for TSGs by using the current 
knowledge on ccRCC genetics. We show that GINI has some intrinsic limitations. TSGs 
that code for relatively small proteins and/or have only a limited number of exons 
appear to have a limited chance on being identified by GINI. Moreover, the succes of 
the method is dependent on the qual i ty of the used gene expression p latform, and 
the availability of tumor-derived cell lines. 
In Chapter 4, we describe the initial steps that should result in the elucidation of the 
mechanisms through which SETD2 inactivation contributes to ccRCC development. 
H3K36me3 has been suggested to have a function in alternative splice site choice. 
Misregulation of splicing is common in cancer and plays a role in tumor development. 
We knocked down SETD2 in proximal tubular epithelial cells and indeed observed 
an apparent change in alternative splicing for a set of genes, several of which are 
interesting with respect to tumorigenic development. Moreover, a set of genes 
showed a significant change in transcript level as a result of SETD2 knockdown. The 
set of downregulated genes showed a significant enrichment for genes that function 
in angiogenesis-related processes and genes that are involved in the p53-pathway. 
This is in concordance with the earlier described role of SETD2 in embryonic vascular 
remodeling and its function in the regulation of a subset of P53 target genes. 
The recently developed next-generation sequencing (NGS) technologies make it 
possible to screen large numbers of genes in parallel for mutations. We continued our 
search for ccRCC tumor suppressor genes by sequencing all coding regions and exon­
intron boundaries from the short arm of chromosome 3 in ten primary ccRCC tumors, 
using targeted exome capturing followed by NGS, as described in chapter 5. This led 
to the identification of inactivating mutations in PBRM 7 in seven out of ten ccRCC 
tumors and inactivating mutations in BAP1 and ZNF197 in one tumor each. Moreover, 
we identified inactivating mutations in PBRM 7 in five out of ten ccRCC-derived cell 
lines. PBRM 1 is located at 3p21, and encodes BAF180, which is the chromatin targeting 
subunit of the SWI/SNF nucleosome remodeling complex. SWI/SNF complexes are 
large ATP-dependent chromatin-remodel ing machines that change the accessibility of 
DNA by controlling the dynamics of nucleosome occupancy. The observed mutational 
frequency of PBRM 1 suggests that this is a major ccRCC tumor suppressor gene. 
Several ccRCC samples show concomitant mutations in VHL and PBRM 1 ,  suggesting 
that inactivation of these genes is functionally nonredundant. 
Besides protein coding genes, non-coding transcripts, including miRNAs, have 
a function in the development of several tumor types. In Chapter 6, we compared 
miRNA transcript levels in ccRCC-derived cell lines with the miRNA levels in normal 
proximal tubular epithelium, and correlated these transcript levels with copy numbers 




miRNAs in the ccRCC cell lines were all miRNA-200 family members and miR-205. 
As a result of loss of the miR-200 family and miR-205, epithelial cells undergo an 
epithelial-to-mesenchymal transition (EMT), which, in a tu morigenic context, confers 
a metastatic potential to the cel ls. Th us, our data suggest a role for these m iRNAs in 
ccRCC progression. 
In Chapter 7, the results described in this thesis are discussed. The short arm 
of chromosome 3 appears to harbor several genes that could contribute to ccRCC 
development when inactivated. Our data give new insights into the mechanisms  that 
are involved in the development of ccRCC. Several of the mutated genes in ccRCC 
encode proteins that modify histone tails or remodel chromatin, suggesting that 
aberrant chromatin regulation is a core driver event in the development of clear cell 




Niercelcarcinoom is het meest voorkomende type nierkanker en neemt zo'n drie 
procent van alle gevallen van kanker bij volwassenen voor zijn rekening. Verreweg 
de meeste niercelcarcinomen (meer dan 70 procent) zijn van het "clear cel l "  subtype. 
Clear cell niercelcarcinomen (ccRCCs) ontstaan uit de epitheelcellen van de 
proximale tubuli en zijn in de meeste gevallen nog niet uitgezaaid op het moment 
dat ze worden gevonden. De standaardbehandeling voor een patient met een ccRCC 
is de chiru rgische verwijdering van de tumor. Voor patienten met een gelokaliseerde 
tumor biedt deze behandeling langdurige overlevingskansen. Voor patienten die te 
maken hebben met uitzaaiingen is het scenario echter veel minder gunstig. ccRCCs zijn 
resistent tegen traditionele chemotherapie. Ook immunotherapie, een behandeling 
die tot voor kort veel werd toegepast, slaat in de meeste gevallen niet aan. De 
toegenomen kennis en inzicht in de biologie van ccRCC hebben recentelijk geleid tot 
de ontwikkeling van behandelingen die aangrijpen op 'pathways' die karakteristiek en 
essentieel zijn voor ccRCC. Vergeleken met immunotherapie hebben deze gerichte 
therapieen een veel hogere ' response rate'. 
ccRCCs worden genetisch gezien gekenmerkt door een aantal chromosomale 
veranderingen, waarbij verlies van de korte arm van chromosoom 3 het meest voorkomt. 
Het veelvu ldige verlies van 3p in ccRCCs is een aanwijz ing voor de aanwezigheid van 
tumorsuppressor- genen in dit genomische segment. Het Von Hippe/ Lindau (VHL) 
gen, gelegen op 3p25, is een bekend ccRCC tumorsuppressor-gen en is bi- allelisch 
ge·,nactiveerd in de meerderheid van ccRCC tumoren. VHL is echter niet in al le ccRCC 
tumoren ge-,-nactiveerd en inactivatie van VHL alleen leidt niet tot de ontwikkeling van 
ccRCC tumoren. Vermoedelijk spelen additionele en/ of alternatieve genen dan ook 
een rol in de ontwikkeling van ccRCC. 
De zoektocht naar nieuwe tumorsuppressor- genen werd lang bemoei lijkt door de 
afwezigheid van methodes waarmee grote aantallen genen tegelijk kunnen worden 
gescreend voor kleine (punt)mutaties. Deze situatie is het in het laatste decenium 
veranderd. Methodes zoals gene identification by nonsense-mediated mRNA decay 
inhibition (GINI) en "next- generation sequencing" technieken hebben ons nieuwe 
krachtige instrumenten gegeven om tumorsuppressor- genen te identificeren. 
In dit proefschrift beschrijven we de zoektocht naar nieuwe tumorsuppressor­
genen die betrokken zijn bij de ontwikkeling van ccRCC. 
In Hoofdstuk 1 wordt een overzicht gegeven van de huidige kennis betreffende de 
epidemiologie, etiologie en genetica van ccRCC. 
In Hoofdstuk 2 beschrijven we het gebruik van GINI in de zoektocht naar nieuwe 
ccRCC tumorsuppressor- genen. In deze methode wordt de nonsense- mediated mRNA 
decay pathway geblokkeerd in cellijnen. Deze pathway ru imt mRNA molecu len die 
ten gevolge van mutaties een prematuu r  stopcodon (PTC) hebben. Uitschakeling van 
deze pathway resulteert in de ophoping van transcripten met een PTC. De ophoping 
van deze transcripten kan warden gedetecteerd met behulp van gen-expressie 
microarrays. Sanger sequencing wordt vervolgens gebruikt om de aanwezigheid van 
een PTC in de betreffende transcripten aan te tonen. 
We hebben een GINI- strategie toegepast op een panel van tien ccRCC- cellijnen. 
Verschi l lende methodes en criteria werden daarbij toegepast om de kans op het 
vinden van nieuwe tumorsuppressor-genen te vergroten en tegelijkertijd het aantal 
vals- positieve kandidaten te beperken. Dit resulteerde in de identificatie van PTC­
introducerende mutaties in het histon- methyltransferase- gen SETD2, gelegen op 
3p21, in twee cellijnen . Sequencing van SETD2 in de overige cellijnen resulteerde in de 
identificatie van inactiverende mutaties in nog drie cellijnen. SETD2 is verantwoordelijk 
voor trimethylering van lysine 36 van histon 3 (H3K36me3). De bevinding dat zeven 
van de tien ccRCC cellijnen een verlies of in ieder geval een significante afname 
van H3 K36me3 laten zien is in lijn met de betrokkenheid van SETD2 functie in de 
ontwikkeling van ccRCC. Extra bewijs voor de betrokkenheid van verlies van SETD2-
functie in de ontwikkeling van ccRCC- tumoren werd geleverd door de identificatie van 
missense mutaties in SETD2 in twee van de tien gescreende primaire ccRCC- tumoren . 
In Hoofdstuk 3 evalueren we het gebruik van GINI in de zoektocht naar 
tumorsuppressor- genen . Hierbij hebben we gebruik gemaakt van de huidige kennis 
over de genetica van ccRCC. We laten zien dat GINI enkele intrinsieke beperkingen 
heeft. Tumorsuppressor- genen d ie coderen voor relatief k leine eiwitten en/ of 
een beperkt aantal exonen hebben blijken slechts een kleine kans te hebben om 
ge·1dentificeerd te warden met behulp van GINI .  Daarnaast is de kans op succes 
afhankelijk van de kwaliteit van het gebruikte expressie- platform. 
In Hoofdstuk 4 beschrijven we de initiele stappen die moeten leiden tot de 
ontrafeling van de mechanismes waardoor inactivatie van SETD2 bijdraagt aan de 
ontwikkeling van ccRCC. H3 K36me3 is betrokken bij de keuze van alternatieve splice 
sites. Misregulatie van splicing komt vaak voor in kanker en speelt een ro l bij tumor­
ontwikke l ing. lnactivitatie van SETD2 draagt daarom mogelijk bij aan de ontwikkeling 
van ccRCC door een verandering in splicing van targetgenen. Met behulp van siRNA 
zorgden wij voor een afname van de hoeveelheid SETD2 in proximale tubulaire 
epitheelcellen en observeerden inderdaad een verandering in alternatieve splicing 
voor een aantal genen . Verschil lende van deze genen zijn goed te koppelen aan 
tumorontwikkeling. Daarnaast laat een aantal genen als gevolg van de afname van 
SETD2 een verandering in transcript- niveau zien . De groep downgereguleerde 
genen is significant verrijkt voor genen die functioneren in angiogenese- gerelateerde 
processen en voor gen en die een rol spelen in de p53 pathway. Dit is in overeenstemming 
met de eerder beschreven rol van SETD2 in embryonale vasculaire modellering, en de 
rol van SETD2 in de regulatie van een subset van P53 targetgenen. 
De recent ontwikkelde "next generation " sequencing (NGS) technieken maken het 
mogelijk een groot aantal genen in parallel te screenen voor mutaties .  In Hoofdstuk 
5 zetten wij onze zoektocht naar nieuwe ccRCC tumorsuppressor- genen voort door 
a lle coderende regio's en exon-intron grenzen van de korte arm van chromosoom 
3 in tien pr imaire ccRCC tumoren te sequencen met behulp van 'targeted exome 
captur ing' gevolgd door NGS. Dit resulteerde in de identificatie van inactiverende 
mutaties in PBRM 1 in zeven van de tien ccRCC tumoren, en inactiverende mutaties 
in BAP1  en ZNF1 97 ieder in een tumor. Daarnaast identificeerden we inactiverende 
mutaties in PBRM 1 in vijf van de tien ccRCC cellijnen. PBRM 1 ligt op 3p21, en codeert 
voor BAF 1 80, een onderdeel van het SWI/SNF complex. SWI/SNF- complexen zijn 
grote AT P- afhankelijke chromatine- modellerende machines d ie de toegankel ijkheid 
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van DNA kunnen be·1nvloeden door de positie van nucleosomen langs het DNA te 
veranderen. De hoge frequentie van mutaties in PBRM 1 in ccRCC tumoren doet 
vermoeden dat dit een belangrijk ccRCC tumorsuppressor- gen is. 
Behalve genen die coderen voor eiwitten spelen ook niet- coderende transcripten 
zoals microRNAs een rol in de ontwikkeling van verschillende tumortypes. In Hoofdstuk 
6 vergelijken we de mi RNA niveaus in ccRCC- cel l ijnen met de mi RNA niveaus in normaal 
proximaal tubu lair epitheel ,  en correleren de hoeveelheid transcripten met het aantal 
genomische kopieen en de transcript- niveaus van voorspelde mRNA targets. Onder 
de significant downgereguleerde microRNAs in de ccRCC-cellijnen bevonden zich al le 
leden van de miR-200 familie en miR-205. Als gevolg van verlies van functie van deze 
microRNAs ondergaan cel len een zogenaamde epitheel- mesenchym transitie (EMT), 
wat in een tumorigene context bijdraagt aan het metastatisch potentieel van de eel .  
De miR-200 familie en miR-205 lijken dus een rol te spelen in de progressie van ccRCC. 
In Hoofdstuk 7 worden de resultaten die zijn beschreven in dit proefschrift 
bediscussieerd. De korte arm van chromosoom 3 blijkt verschillende genen te 
bevatten die mogelijk een rol spelen bij aan de ontwikkeling van ccRCC. Onze data 
geven nieuwe inzichten in de mechanismes die betrokken zijn bij de ontwikkeling van 
ccRCC. Verschi l lende van de gemuteerde genen in ccRCC coderen voor eiwitten die 
een rol spelen in het modificeren van histonen en het modelleren van chromatin. Een 
verstoring van de regulatie van chromatine lijkt dan ook een essentie le gebeurtenis in 
de ontwikkeling van clear cel l  renal cell carcinoma. 
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